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1. Introduction 
This volume contains the research methodology used in the third General 
Population Survey on Drug Prevalence in the Republic of Ireland conducted by 
Ipsos MORI on behalf of the National Advisory Committee on Drugs (NACD) in 
Ireland. 
The extent and pattern of drug use in the general population is one of the five key 
indicators produced by the EMCDDA2, the European Monitoring Centre for Drugs 
and Drug Addiction (www.emcdda.org), and adopted by EU Member States.  In order 
to ensure that reliable and comparable data is obtained in this regard, the 
measurement of the extent and pattern of drug use amongst the general population 
in Ireland is one of the priorities set out by the NACD in its current work programme 
and agreed by Government.   
In 2002/2003, the NACD and the Drug and Alcohol Information and Research Unit 
(DAIRU) worked together in commissioning the first research study into the 
prevalence of drug use in Ireland and Northern Ireland respectively. Ipsos MORI 
(then known as MORI MRC) conducted the 2002/2003 study in both the Republic of 
Ireland and Northern Ireland. A repeat study was commissioned by the NACD in 
2006/2007 and Ipsos MORI conducted this study in the Republic of Ireland only. In 
this latter study all of the fieldwork was moved from a pen and paper methodology to 
Computer Assisted Personal Interviewing (CAPI).  In 2010, the NACD commissioned 
a repeat of the 2006/2007 Drug Prevalence Survey for the Republic of Ireland only 
and Ipsos MORI was commissioned to conduct the fieldwork. Ipsos MORI was 
required to follow the relevant guidelines published by the EMCDDA and to achieve 
an approximate population sample of 5,000 in Ireland, using An Post’s GeoDirectory 
as its Sampling Frame.  The sample size of 5,000 was agreed in order that the 
sample size remained consistent with the previous survey and to enable reporting by 
health board area. 
1.1. Planning and commissioning process 
 
A Research Advisory Group (RAG) was formed to oversee the commissioning 
process and to support the implementation of the survey to the EMCDDA standard.  
                                            
2 EMCDDA Handbook for Surveys on Drug Use Among The General Population (2002), P.80 
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The membership comprised of the Research Advisory Group included the following 
representatives (in alphabetical order by surname): 
 Mr Eddie Arthurs – Office of the Minister of Drugs (until February 2011); 
 Dr Des Corrigan, Chairperson NACD; 
 Ms Caroline Hickey - Public Health Information and Research Branch, 
Department of Health Social Services and Public Safety; 
 Dr Justine Horgan – Senior Researcher NACD; 
 Dr Jean Long – Health Research Board; 
 Mr Kieron Moore – Public Health Information and Research Branch, 
Department of Health Social Services and Public Safety; 
 Dr Deirdre Mongan - PhD, Health Research Board; 
 Ms Dairearca Ni Neill, Drugs Policy Unit, Department of Health; 
 Ms Joan O’Flynn – Director NACD;	  
 Ms Marian Rackard – HSE Social Inclusion; 
 Ms Susan Scally – Director, NACD (until December 2010). 
The tender was advertised in the Official Journal of the European Commission 
(OJEC) firstly as an Expression of Interest in December 2009 and then as a Request 
for Tender in February 2010.  See details in Appendices A and B. 
In April 2010, the NACD formally commissioned Ipsos MORI to conduct the 
2010/2011 national drug prevalence study in the Republic of Ireland.  What followed 
was a detailed project set-up phase, whereby Ipsos MORI and the Research 
Advisory Group worked together from May-September 2010 to plan all aspects of the 
study in order to ensure its success. 
During the working period of the project between May 2010 and November 2011, a 
total of 9 RAG meetings (number TBC by NACD) were held and two of these 
meetings were convened between the RAG and Ipsos MORI.  Members of the RAG 
also participated in five briefing sessions to field workers conducted by Ipsos MORI. 
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1.2. Research objectives 
The core objective of the research was to provide up-to-date, robust data regarding 
the prevalence of (licit and illicit) drug use amongst the general population.  The 
tender brief stated that the survey would be based on the guidelines produced by the 
EMCDDA which states its main aims as follows: 
1) To report prevalence and continuation rates of the most common illicit drugs in 
the general population by gender and age groups; 
2) To allow cross country assessment of relationships between general patterns of 
use of illicit and licit drugs; 
3) To allow the assessment of relationships between particular population attributes 
and the use of illicit drugs. 
As with the previous studies, the survey was also required to: 
 be reliable, in that overall results are statistically reliable estimates of the 
prevalence of drug use in each jurisdiction and on the island as a whole; 
 be comparable with Northern Ireland and as far as possible with similar studies 
being conducted throughout the European Union; 
 allow analysis of results in terms of a variety of demographic factors. 
To meet the objectives of the study, a target of 5,000 interviews was set and a final 
sample size of 5,128 interviews was achieved. 
The survey was carried out using the EMCDDA Model Questionnaire, with some 
modification, and a face-to-face interviewing methodology was undertaken amongst 
15 to 64 year olds.  A standardised questionnaire was used to collect the information 
on drug use, while the sample was selected using probability sampling. 
The data collection methodology of CAPI remained unchanged from the 2006/2007 
study. However, the addition of new questions to measure problematic use, abuse 
and dependence of cannabis, new questions on alcohol dependence and on the 
prevalence of psychoactive substances meant additional challenges and called for a 
comprehensive set-up phase.  This involved close liaison between Ipsos MORI and 
the Research Advisory Group on key tasks: reviewing the new question wording, 
undertaking cognitive interviews to test the new cannabis questions, piloting the 
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survey, checking the CAPI script and sampling.  Furthermore, the interviewers, upon 
whom the ultimate success of the study was dependent, were taken through a 
detailed programme of engagement, briefing and instruction, to ensure they were 
fully prepared to conduct the interviews. 
 
 
2. Survey design
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2. Survey design 
2.1. Target population 
The universe for the survey was defined as a survey of all adults, aged between 15 
and 64, living in private households in the Republic of Ireland, as per EMCDDA 
guidelines.  This report focuses on the Republic of Ireland survey only. 
As the EMCDDA Handbook observes, surveys of this nature are typically conducted 
in the respondent’s home for methodological and practical reasons3.  In addition to 
this, the length of the questionnaire, i.e. approximately 20 minutes interviewing time, 
dictated that the interview needed to be conducted in the respondent’s home and not 
on the street; moreover the sensitive nature of the subject matter lent itself better to 
the more confidential surroundings of the person’s home. 
2.1.1. Language 
It is worth noting at this stage that the survey did not make a specific provision for 
interviews to be conducted in languages other than English.  Households could 
participate in the study, regardless of their language needs, and NACD was willing to 
provide translation if required.  However, from a practical point of view, it was agreed 
at the outset that this issue would be closely monitored on an ongoing basis and, if a 
significant number of respondents requiring translation of the questionnaire or an 
interpreter were encountered, that this would immediately be brought to the attention 
of the Research Advisory Group to allow it to monitor additional costs. 
In fact, interviews were not conducted in any language other than English and not 
one respondent requested the service of an interpreter. 
                                            
3 EMCDDA Handbook for Surveys on Drug Use Among The General Population (2002) p.80 
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2.1.2. Age 
Adults aged 15-64 years were included in the study in line with EMCDDA guidelines 
and as before, there were two sections of the population which were deliberately 
excluded in terms of age.  The first of these were the under 15s, who were excluded 
in line with EMCDDA guidelines.  Under Market Research Society guidelines, it is 
only permissible to interview 15 year olds and under with the written consent of their 
parents or guardian.  Therefore, in order to include 15 year olds in this study, the 
written consent of their parents or guardians was obtained. In the 2010/11 survey, we 
also obtained the parental consent of 16 and 17 year olds, as required by the 
Research Ethics Committee4. It should be noted that the parent/guardian also had 
the right to sit in on the interview, if they so wished. 
The table below outlines the numbers of under 18 year-old respondents, who 
conducted the interview in the presence of a parent/guardian. 
 Total 
Parent present 98 
Parent not present 118 
Not stated 2 
Total 218 
 
The second age group which was excluded were people aged 65 and over.  This 
group was excluded because, as the EMCDDA points out, responses from 
respondents in this group may be less reliable (due to effects of memory), and in any 
case the prevalence of (lifetime) drug use amongst this group is not expected to be 
very high5. 
 
2.1.3. Audiences outside the scope of this study 
Similar to the previous studies, it was decided not to set out to deliberately achieve 
interviews with specific groupings such as the homeless, members of the Traveller 
                                            
4 Research Ethics Committee Proposal Form – ‘The written consent of their parents or 
guardians will be obtained for children under 18 years’  
5 EMCDDA Handbook for Surveys on Drug Use Among The General Population (2002) p.79 
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community or other minority and ethnic groups, nor with those in institutions, such as 
prisons.  
2.2. Mode of interviewing  
Selecting the most appropriate mode of data collection was critical to the success of 
this survey.  The mode selected had to deliver a highly-accurate dataset while 
remaining cost-effective.  It had to be acceptable and viable to both interviewers and 
respondents, while allowing for stringent project management and monitoring of 
fieldwork. 
The research brief specified the use of Computer Assisted Personal Interviewing 
(CAPI) as the mode of interviewing in the 2010/11 study.  The same mode was used 
in the 2006/07 study. 
2.3. CAPI set-up and validation 
SPSS MR’s Quancept software was used for Computer Assisted Personal 
Interviewing (CAPI). Quancept is an integrated suite of software tools for designing 
surveys and conducting CAPI. It has a Microsoft Windows-based graphical user 
interface making it extremely easy to use. Interviewers required minimal training and 
supervisors could efficiently manage complex projects with numerous field 
interviewers.  
We put in place the following procedures to ensure that the data was suitably 
validated, further enhancing the quality of the data. 
1) Range checks: 
Range checks were built into the CAPI script so that, for example, if the range of 
possible answers to a particular question was between 1 and 5, the interviewer could 
not input the number 50 by mistake and continue.  
2) Rigorous checking of routing (skips): 
All routing was rigorously checked by members of the CAPI set-up team and also by 
several members of the Executive team.  
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3) Consistency checks: 
Consistency checks were built into the script and also rigorously checked as part of 
the checking of routing (skips). 
 
Members of the Research Advisory Group took part in the script approval 
process, by viewing the CAPI script on a laptop after it had been scripted. 
2.4. Sampling 
Population surveys on drug use, in common with most other surveys, are usually 
conducted among a sample of the entire target population because it is not practical, 
nor cost or time-efficient to interview every single individual in the population.  A 
survey is only as good as its sample.  This is especially true of a population survey 
such as this, where the key objective was to provide for reliable national estimates of 
the prevalence of drug use in Ireland to feed into public policy making.  
2.4.1. Random Sampling 
The EMCDDA Handbook suggests that “in prevalence studies, as in social studies in 
general, it is usually not possible to make assumptions (about the distribution of 
survey variables in the population) and, as a consequence probability sampling 
should almost be considered mandatory”6.  Given that collecting accurate, up-to-date 
profile data was a key aim of the survey, and this sampling method was used in 
2002/2003 and 2006/2007, the RAG and the Ipsos MORI project team felt that a 
similar approach should be used in 2010/2011. 
2.5. Sample frame 
As a randomly drawn sample, this survey was one in which every member of the 
defined population (in this case, those aged 15-64) had a calculable chance of being 
included in the sample.  Therefore, the first step in drawing a random sample is to 
define the sampling frame, i.e. a list of all the members of the population.  However, 
such a list is not available in Ireland. 
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The survey used the An Post/Ordnance Survey Ireland GeoDirectory as the 
primary sampling frame.  This file is comprehensive, regularly updated, and has a 
high degree of accuracy.  Additionally, this sampling frame was used in the 
2002/2003 and 2006/2007 studies and was the RAG’s preferred sampling frame for 
the 2010/2011 study.  In particular, the GeoDirectory address list was chosen 
because: 
 It contained every address point in Ireland and is designed for use for market 
research and by all kinds of businesses; 
 It is updated on a quarterly basis; 
 It avoids double counting as buildings, which have alternative names (e.g. No.15, 
Any Street and Rose Cottage, Any Street), would be counted only once; 
 GeoDirectory provides separate lists for businesses and residential addresses. 
 It links every address to its electoral division, allowing for the separation of data 
from both large (e.g. Regional Drug Task Force Areas) and small geographic 
areas (e.g. Electoral Divisions(ED)) alike; 
 Demographic data from the CSO can be easily obtained at a ED level and 
incorporated into databases provided by GeoDirectory; 
 The address lists provided by GeoDirectory would also include those who may 
not be on the electoral register for one reason or another. 
Despite these obvious advantages, using the GeoDirectory list still had the same 
potential for limitations (extra dwellings, combined dwellings and addresses without 
dwellings).  Again, interviewers’ contact sheets were used to gather information on 
the addresses that were excluded. 
                                                                                                                             
6 EMCDDA Handbook for Surveys on Drug Use Among The General Population, (2002), p.97 
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2.6. Selection of sample 
A three-stage process was used to construct the sample for this survey: 
2.6.1. Selection of primary sampling units (PSUs) 
Stratification techniques were used to select Primary Sampling Units (PSUs).  In this 
case, Electoral Divisions (EDs) were defined as Primary Sampling Units (PSUs) in 
the sample stages of the study. 
Since January 2005, the health boards in Ireland have undergone restructuring and 
are merged under one authority – the Health Service Executive (HSE).  However, 
when the last survey was carried out in 2006/07, data was weighted and reported by 
eight health board areas including the Eastern Regional Health Authority which 
incorporated 3 local area health boards.  All of these health boards corresponded to 
the Regional Drug Task Force (RDTF) structures set up under the National Drug 
Strategy, therefore it was agreed that the sampling process would continue to apply 
according to the Health Boards/RDTFs. 
In the first stage of stratification, the number of interviews per RDTF/health board 
area was agreed.  The decision on the number of interviews per RDTF/health board 
area was primarily in proportion to the population, with some modifications for the 
smaller RDTF areas such as the Midlands and the North Western regions, where the 
number of interviews were oversampled to around 400 in each region to enable a 
more robust sample size for these regions, as indicated in the table below. 
The table below provides the latest known population figures at the time of 
commencing fieldwork, which were based on 2006 Census figures.  As detailed in 
chapter 6, 2010 population estimates based on the 2006 Census were used for the 
purposes of weighting the results. 
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Health Board Region/RDTF Total % of 
population 
Sample 
size 
ERHA7  1,064,100 36.60% 1,646 
Midland HB/RDTF  167,766 5.77% 454 
Mid Western HB/RDTF  245,399 8.44% 438 
North Eastern HB/RDTF  265,873 9.14% 451 
North Western HB/RDTF  155,033 5.33% 438 
South Eastern HB/RDTF  307,793 10.59% 476 
Southern HB/RDTF  422,749 14.54% 733 
Western HB/RDTF 278,760 9.59% 492 
    
TOTAL 2,907,473 100.00% 5,128 
 
In the second stage of stratification, a decision was made on the number of Primary 
Sampling Units (PSUs) to be selected (385 in total).  The decision on the number of 
PSUs selected was based on practical considerations (an appropriate compromise 
between allowing sufficient range of coverage and the need to be practical from a 
data collection and field management perspective).  
These PSUs were then ranked by socio-demographic indicators, from census data, 
such as population density, male unemployment and social class, to ensure that a 
representative cross-section of areas was included, and the likelihood of selecting an 
individual PSU would be proportional to the population of that PSU. In this way, 
PSUs of all sizes and compositions would have an equal chance of selection.  The 
table below shows the breakdown of PSUs to RDTF/health board regions. 
                                            
7 ERHA in this instance refers to the combined group of RDTFs: Northern Area RDTF, South 
Western RDTF, East Coast RDTF each equivalent to the former local health board areas prior 
to 2005. 
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Health Board Region/RDTF Number of 
Sampling Points 
ERHA  135 
Midland HB/RDTF 31 
Mid Western HB/RDTF 34 
North Eastern HB/RDTF 35 
North Western HB/RDTF 31 
South Eastern HB/RDTF 35 
Southern HB/RDTF 49 
Western HB/ RDTF 35 
Total 385 
 
On average, 31 addresses were chosen at each of the sampling points. No reserve 
sample points were used in this study. 
 
2.6.2. Selection of addresses 
A sample was drawn at random, from each of the randomly selected PSUs, using the 
information provided in An Post/Ordnance Survey’s GeoDirectory. 
Additional addresses were only issued for a given assignment point when an 
interviewer had encountered 10 or more ineligible properties.  These were non-
residential, derelict, and demolished properties, and where no one in a particular 
household was eligible to take part in the survey, for example because of age. 
The use of CAPI meant that the interviewer needed to physically access the inside of 
the respondent’s home, which was likely to cause some concern to some 
respondents.  To alleviate this, a letter, on NACD letter headed paper, was sent in 
advance to the entire selected sample, outlining that a survey was taking place and 
that an interviewer could call to their door. 
To ensure confidentiality and anonymity, no interviewers conducted the research in 
their immediate locality, thus reducing the likelihood of interviewers having to speak 
to an acquaintance, friend or relative.  
2.6.3. Property and household selection 
When an interviewer called at an address, their initial task was to establish whether 
the address was residential and occupied.  If it was, they next had to establish the 
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number of properties or self-contained dwelling units it comprised (typically defined 
as a self-contained dwelling behind its own front door). 
A household is defined as a person, or group of people who normally live at the same 
property, who share a living room or at least one meal a day.  In properties with 
multiple households, one was randomly selected using a selection grid on the contact 
sheet. 
2.6.4. Respondent selection 
Individuals (aged 15-64) within each randomly selected household were randomly 
selected to take part in the survey, using a “last birthday rule” – i.e. the person 
answering the door at any given residential address was asked to list the birthdays of 
all residents in the target age group.  The person with the most recent birthday was 
then selected to participate.  This random selection procedure took place during an 
initial screening interview, with an adult member of the household.  If the individual 
selected was not present at that time an appointment was arranged for a later date. 
 
 
 
3. Questionnaire design
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3. Questionnaire design 
3.1. Questionnaire development 
The questionnaire used on this study followed the EMCDDA model questionnaire 
with modifications appropriate to the Irish context and without prejudice to the 
purpose of the questionnaire. 
The questionnaire was designed with the full involvement of the RAG. The 
2010/2011 survey was broadly similar to the 2006/2007 survey but additional 
questions were included to estimate the prevalence of alcohol and cannabis 
dependence.  New questions were also added to assess the use of psychoactive 
substances sold in ‘head-shops’ and similar outlets. 
3.2. Cognitive study 
 
There was a need to test additional questions to measure the dependence on 
cannabis and cannabis-related harm amongst users as well as psychoactive 
substances sold in ‘head-shops’ and similar outlets. We reviewed a number of ways 
of testing the additional cannabis questions amongst cannabis users and decided on 
a cognitive approach.  Cognitive interviewing is a diagnostic technique that explores 
the processes employed by people when they answer survey questions, such as 
comprehension, recognition, recall and decision-making8. 
The cognitive approach is appropriate if there are concerns associated with accurate 
recall e.g. recalling activity over the past year or if questions are complex or cover 
abstract concepts. In these cases it was important to check that users’ interpretation 
of the meaning of questions is what is expected/needed. 
Cognitive testing was carried out by members of Ipsos MORI’s executive team who 
had experience of conducting cognitive interviews. 
The one to one interviews were carried out face-to-face. The executive asked the 
questions and followed up with appropriate cognitive questioning techniques.  Ipsos 
MORI employed a flexible mix of ‘think aloud’ whereby respondents were explicitly 
                                            
8 R. Groves, F. Fowler Jr, M. Couper, J. Lepkowski, E. Singer and R. Tourangeau, Survey 
Methodology, (2004), p. 202.   
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instructed to verbalise their thought processes as they answered the survey 
questions and ‘verbal probing’ techniques, which were adapted to suit individual 
respondents.  Ipsos MORI also asked questions in 5-10 minute segments.  This 
represented an approach somewhere between concurrent and retrospective probing.  
Following up in segments rather than after each question allowed the researcher to 
understand better the flow of the questionnaire and how one response impacted on 
answers to subsequent questions. 
Ipsos MORI conducted 19 cognitive interviews with a range of different types of 
cannabis users in terms of age and usage levels.  The NACD RAG Group facilitated 
access to these participants through appropriate contacts and arrangements with 
drug treatment centres in the Dublin area including the Rutland Centre, Soilse and 
drug treatment centres/clinics in Castle Street and Trinity Court on Pearse Street. 
Among the key actions taken as a result of the cognitive study and subsequent 
discussions were: 
 Minor word changes and amendments to specific questions; 
 Adding showcards and interviewer instructions on certain questions to aid 
comprehension; 
 Additional text added at different questions to aid interviewer comprehension. 
In conclusion, the cognitive study proved to be a valuable exercise, as evidenced by 
the issues raised and the corrective actions taken. 
3.3. Pilot study 
 
Ipsos MORI, in line with EMCDDA guidelines, conducted a comprehensive piloting of 
the questionnaire.  The 2010/2011 survey included new questions on the use of 
psychoactive substances as well as additional questions on alcohol and cannabis 
dependence.  Therefore a pilot phase was necessary to highlight any potential 
issues. 
Firstly, the questionnaire was subjected to Ipsos MORI’s internal piloting procedures.  
At this stage, members of the fieldwork team and the core project team tested the 
questionnaire.  This process was primarily designed to ensure all questions were 
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included with the correct wording and in the correct order, and also to check the 
routing. 
Secondly, a series of pilot interviews with members of the general public were 
conducted.  The pilot interviewers were briefed in Ipsos MORI’s offices by members 
of the project team, after which a total of 52 pilot interviews were conducted in June 
2010.  The pilot interviews took place in a range of locations to ensure the survey 
was understood by respondents from a variety of backgrounds.  It was also agreed to 
conduct the pilot study in areas where we would expect to pick up a higher than 
average number of users of drugs, in order to make the pilot as comprehensive as 
possible. 
Once these pilot interviews were completed, interviewers produced detailed 
comment sheets which were reviewed by the Ipsos MORI project team.  In order to 
fully review the pilot study and identify any actions that were required in advance of 
the full study, a pilot debrief meeting was convened in Dublin and included the 
interviewers who worked on the pilot study, members of the Research Advisory 
Group project team and the Ipsos MORI project team.  This meeting took place on 
8th June 2010. 
Among the key actions taken as a result of the pilot study and subsequent 
discussions included grouping together of all cannabis questions, alcohol questions 
and ecstasy questions on the CAPI script.  
3.4.  Questionnaire approval 
The final version of the questionnaire was formally approved by the RAG on 25th 
June 2010. 
A copy of the Final Questionnaire and Showcards is provided in Appendix E/F. 
 
 
4. Fieldwork
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4. Fieldwork 
4.1. Overview 
As noted earlier, there were a variety of possible ways of undertaking this research 
but for this study, fieldwork was conducted by means of face-to-face interviews 
conducted in the respondents’ homes as per EMCDDA guidelines.  There were a 
number of reasons for this decision, as follows:  
 The length of the questionnaire dictated that the interview needed to be 
conducted “in-home” and not “on street”; 
 The sensitive nature of the subject matter lent itself better to the more confidential 
surroundings of the person’s home; 
 Conducting the survey using an “interviewer completion” approach (rather than 
self-completion) was a better means of collecting information from all 
respondents (i.e. including those who had finished education ‘early’ (pre-primary, 
primary), who were illiterate or who had difficulty reading); 
 Any potential bias which may have arisen from the way an interviewer asked a 
question was largely removed through the use of a straightforward questionnaire, 
and the high level of interviewer training and supervision; 
 Face-to-face interviews also generate higher response rates. 
 
It is worth noting that face-to-face interviews are known to result in under-reporting 
particularly when sensitive questions are used. 
4.2. Fieldwork period 
The fieldwork was conducted in two phases, namely from October 2010 to December 
2010 and from January 2011 to June 2011.  This was to allow a spread of interviews 
before and after Christmas 2010.  There were no differences in the questionnaires 
used or in sampling and interviewing techniques used during either period. 
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4.3. Interviewer briefings & instructions 
One of the factors most correlated with high response rates is the experience 
interviewers already have with that particular survey and the extent to which they feel 
an attachment to it. Therefore, a series of interviewer briefings were conducted to 
ensure interviewers were fully prepared to conduct the survey and to allow for 
discussion and dialogue between interviewers, the Ipsos MORI team and the RAG. 
The meetings included opportunities for discussion, practice sessions and role-play 
exercises. Senior members of the study teams led the briefings, and every 
interviewer working on the study attended. 
In addition to verbal briefings, all interviewers received full written instructions on all 
aspects of the survey.  A copy of the full instructions for interviewers is outlined in 
Appendix M. 
A total of eight interviewer briefings were held with interviewers assigned to the 
survey in a number of locations, including Dublin, Limerick and Sligo.  The briefings 
lasted between five and six hours, and provided opportunities for discussion and role-
play, as well as a thorough run-through the survey. 
The details and attendance at the briefings are as follows: 
Briefing date  Location Number of 
Interviewers 
Ipsos MORI 
Regional 
Controller/Regional 
Manager Present 
Members of 
RAG Group 
attended 
23rd September 2010 Dublin 24 x x 
29th September 2010  Limerick 23 x x 
30th September 2010  Sligo 18 x x 
22nd October 2010 Ipsos MORI 
office - Dublin  
4 x  
10th November 2010  Dublin 14 x x 
21st March 2011 Ipsos MORI 
office - Belfast 
6 x  
7th April 2011 Dublin 14 x x 
11th April 2011 Ipsos MORI 
office - 
Manchester 
3 x  
 
Total Interviewers briefed 
 
106 
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All sessions followed the same format and were led by Brenda Boyd, Field Director of 
Ipsos MORI in Ireland. All Field Executives working on the study attended at least 
one briefing session. Orla Deasy, Research Director at Ipsos MORI attended most of 
the briefings. 
Susan Scally, Director of NACD and Dr. Justine Horgan, Senior Researcher with 
NACD, attended briefings in Sligo and Dublin, while Dr. Deirdre Mongan from the 
Research Advisory Group attended briefings in Limerick and Dublin.  Joan O’Flynn, 
Director of NACD from March 2011 attended the Dublin briefing in April 2011. 
4.3.1. Content of interviewer briefings 
All those attending the briefings had copies of the documentation to be used by 
interviewers during fieldwork, including interviewer instructions, show cards, and 
examples of contact sheets.  All briefings followed a similar format, which is 
summarised below: 
 Introductions and the background to the study, with input from representatives 
of the RAG; 
 Discussion about the previous study and its results, enabling interviewers to 
appreciate better how the results might be used; 
 Full explanation of the study design to be employed on the study, with emphasis 
on the importance of random sampling and the need to obtain a high response 
rate; 
 Illustration of the contact sheet.  Advice on averting refusals and how to gain 
cooperation from the initial contact; 
 Discussions around the selection for interview of an individual within a 
household.  Use of Kish grids and how to administer the “last birthday rule”; 
 Working through the survey itself (with the questionnaire projected onto a 
screen), with interviewers given the opportunity to go through the questionnaire 
following different routes, depending on the answers given; 
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 Demonstration of progress reporting using iProgress9, an electronic form onto 
which interviewers can record information from their contact sheets such as 
address outcomes for all addresses and individual respondents within addresses, 
the date and time of calls so that working patterns can be monitored by time of 
day, and separate interim codes to distinguish between telephone and face-to-
face contacts so that both can be logged on the system; 
 Further opportunity for practice interviews as required. 
In summary, the briefing sessions were of real benefit to all the participants. From the 
first briefing, interviewers raised valid questions and concerns which helped Ipsos 
MORI refine the content of subsequent briefing presentations as well as the written 
interviewer instructions.  The interactive discussions and role play, which took place 
at the briefings, fully instructed and engaged the interviewers enabling them to 
appreciate not only the importance of the study, but their crucial role in ensuring its 
success. 
4.3.2. Interviewing team 
All interviewing was carried out by members of the Ipsos MORI Interviewer Panel 
who have been trained and work to the standards of the Interviewer Quality Control 
Scheme (IQCS).  Interviewers working on the study were both male and female, 
across a range of ages but with a higher proportion in the 50+ age category, which is 
reflective of the profile of market research interviewers nationally.  They are recruited 
to the Ipsos MORI panel via a formal process, involving a written application form, a 
personal interview, and checking references. Once references are checked, an 
applicant is invited to attend an Assessment and Training session, (A&T). This 
session lasts two full days and includes modules on interviewer technique and 
approach when involved in the ethical collection of data. It also includes the rules 
pertaining to such collection and the responsibilities of interviewers towards 
respondents. Additionally, the Data Protection Law is explained as well as the rights 
of respondents. The trainer may at any time over the course of the two days decide 
that an applicant is not suited to an interviewer's role.  
                                            
9 iProgress is the electronic system used by interviewers in the field to record their daily 
progress.  This system was introduced in 2010 and this replaced the eProgress system used 
in the 2006/07 population survey.   
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Role play and questionnaire practice in the classroom is followed on the second day 
by some time in the field, accompanied by a supervisor. A further three to four hours 
is devoted at a later date to CAPI training after the successful completion of the 
standard A&T. At the end of the course a written test is administered and the trainee 
interviewer must attain a certain standard otherwise he/she is not accepted onto the 
Ipsos MORI interviewer panel.   
On joining the Ipsos MORI panel, interviewers are accompanied in the field by a 
supervisor when working on each new type of project and thereafter are appraised at 
least twice a year. This usually involves one physical accompaniment and one 
telephone appraisal as well as project reports. 
All Ipsos MORI Interviewers and Recruiters carry Identity Cards issued by the Market 
Research Society (MRS), which bear the photograph and signature of the 
interviewer, and are issued only after the signing of a declaration which states that 
the interviewer has read and agrees to abide by the MRS Code of Conduct.  On the 
population survey this Identity Card was shown to each contact before attempting to 
carry out an interview, to reassure contacts and respondents that the interviewer and 
study was genuine, and that the Company whose name is on the ID card is a bona 
fide member of the MRS.  Furthermore, respondents were given a ‘thank you’ leaflet 
at the end of the interview which stresses the confidentiality of the process, and 
provides the telephone number of Ipsos MORI’s Field department to call if they had 
any further queries.  The telephone number of the MRS is also provided. 
A minimum of 10% of completed interviews are back checked on all quantitative 
surveys carried out by Ipsos MORI using a combination of telephone recall or postal 
check card.  This is applied to ensure that the interviewers conducted the interviews 
professionally and in line with survey specifications.  In general, respondents are 
asked to comment on, among other things, the duration of the interview, their 
recollection of being asked specific questions, being shown interviewer identification 
and their reaction to both the interview and the interviewer.  On random probability 
studies a further personal validation is carried out on a minimum of 10% of addresses 
recorded as ineligible by the interviewer to verify that the property is indeed non-
residential or no-one of eligible age lives in the household at the specified address. 
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4.4. Field management 
Following the sample selection, Ipsos MORI’s Fieldwork Management System was 
used to control and monitor progress on the study.  The process involved was, as 
follows: 
 The sample was loaded into the General Management Survey System 
(GSMS).  This system was designed specifically to control and manage large 
scale pre-selected studies such as this. 
 The allocation of areas was made to interviewers on a rolling basis to ensure 
an even spread of interviews by region by week.  This ensured that any 
seasonal variations in results would be evenly spread out across the country.  
 Interviewers called at the selected addresses and where contact was 
established with a member of the household, the selection of an eligible 
respondent within the household was made, using the last birthday rule. The 
interview was carried out if the selected person was available, or an 
appointment was made to call back and interview the selected household 
member.  Dates and times of all calls made and their outcomes, (successful 
interview taken, appointment made, no contact, refusals etc.,) were entered 
into GSMS by interviewers using iProgress at the end of each interviewing shift.  
iProgress reports on each contact were uploaded to the server at the time of 
uploading completed interviews.  
 Every day, regional field management as well as Ipsos MORI Field Executives 
were able to check individual interviewers’ progress and monitor success rates, 
numbers of refusals, un-worked contacts etc.  
 On the doorstep, interviewers filled in paper contact sheets at the time of each 
call made for each address visited, documenting each attempt to contact or 
interview the selected individual (following the “last birthday rule” methodology 
as detailed in chapter 2 - Survey design). They also established some basic 
details about them (i.e. type of house).  The final outcomes of the attempts to 
interview the selected respondent were noted, as were any reasons for not 
taking part. Information recorded at the time of the call to a household was then 
entered onto the iProgress script, providing a complete call pattern for each 
household.  A copy of the Contact Sheet is provided in Appendix G. 
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 Contact sheets were kept separate from the CAPI script in order to reassure 
respondents about confidentiality.  However, if needed, it was still possible to 
link each contact sheet to each completed interview via serial numbers.  
Contact sheets from each area were returned on an ongoing basis by 
interviewers in the post.  Upon receipt, these contact sheets were edited and 
validated to ensure that the correct person in the household had been selected 
for interview. After this quality control procedure had taken place, they were 
entered into GSMS. 
 As interviews were completed and contact sheets returned, validation 
procedures began.  The Quality team ensured that a minimum of 10% of all 
completed interviews were validated.  There was also a 5% validation of those 
contact sheets stating that no successful interview could take place because of 
age of inhabitants or that the address was for vacant or commercial properties.  
Validation was conducted by telephone or postal check card for successful 
interviews and by means of a personal visit by a supervisor to ineligible 
addresses. 
 Each week an interim field report was compiled for each health board region 
showing addresses issued, successful interviews undertaken, pending 
interviews, refusals etc. 
 At the end of each phase of interviewing, a full fieldwork report was compiled 
showing not only full details of the interviews completed but also the results of 
all quality control procedures. 
 Interviewers had the support of their Region Co-ordinator who was available to 
help them with difficulties in the field or problems of any nature.  Each of the 
Region Co-ordinators attended at least one briefing session as did all local 
supervisors. Regional field management kept in regular communication with 
field staff so that everyone working on the project was informed of 
developments across the whole fieldwork period. 
 In addition to the support from Region Co-ordinators and Supervisors, all 
interviewers had telephone numbers of key field staff and knew that they could 
call on them for help at any time. 
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4.5. Enhancing response rates 
As with any survey of this nature, eliciting a satisfactory response rate presents a 
variety of challenges.  These challenges can include;  
 difficulties in accessing potential respondents at home, due to work etc.;  
 a lack of interest or engagement from respondents;  
 a perceived lack of relevance due to the subject matter;  
 queries regarding the commissioning body;  
 a lack of trust in surveys generally or a lack of credibility in the process;  
 concerns over anonymity and how personal information might be used;  
 lack of time for respondents or an unwillingness to participate due to survey 
length and inclement weather. 
If the interviewer had visited a household, which was occupied, there were a number 
of reasons why an interview may not have been completed at that location.  This may 
have an impact on the accuracy of the sample. During the fieldwork considerable 
effort was taken to avoid such a situation occurring.  Below are some approaches 
used to enhance the response rate for the survey. 
4.5.1. Interviewer calls 
In accordance with EMCDDA guidelines, multiple calls were made to selected 
addresses. Interviewers were instructed to call up to five calls – an initial call, plus 
four call-backs – at each address, at different times (including evenings) and on 
different days (including weekends – Saturdays for initial calls and Sundays by prior 
appointment), to try and ensure they would be able to speak to the potential 
respondent. Where necessary, and as dictated by the response rate in certain health 
board regions, non-contacts and “soft refusals” were re-issued to Senior Interviewers 
and Distance Interviewers10 for further calls. Due to the overall high response rate 
                                            
10 Distance Interviewers are those interviewers who move between the Ipsos MORI regions. 
The Ipsos MORI interviewer panel covers all of Ireland and Great Britain. They are used not 
only because they have a track record in obtaining a high response rate from unused 
addresses in difficult areas such as inner city areas but also because they have the skills to 
convert a substantial proportion of refusals into successful interviews. In addition as Distance 
Interviewers are away from home they tend to work longer days and achieve more than 
average numbers of interviews. On the population survey we used mainly Distance 
Interviewers from Northern Ireland to cover inner city areas in Dublin, Cork and Limerick. 
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for this study, most of the reissues were in the EHRA region where there was a lower 
response rate. 
4.5.2. Trained interviewers 
The effectiveness of interviewers depends, more than anything, on the training they 
receive – and the encouragement they are offered throughout the fieldwork period.  
This is especially true for random pre-selected surveys.  In this regard, only fully 
briefed interviewers worked on the study.  The majority of these interviewers had 
previously had extensive experience of pre-selected survey work.  Some had worked 
on one or both waves of the previous population studies. All interviewers were in 
regular contact with their Region Co-ordinators across the fieldwork period. 
4.5.3. Help-line 
A telephone help-line was set-up for interviewers and respondents to handle queries, 
refusals, and requests for information or appointments from respondents.  This 
helped reassure respondents that this was a genuine survey.  A thoroughly briefed 
member of the support team at the Ipsos MORI office in Dublin handled the calls. 
4.5.4. Naming the client  
Research experience indicates that response rates can be significantly enhanced by 
interviewers being able to name the sponsoring client, and this was especially true 
for a survey which some respondents might find sensitive or intrusive, such as this.  If 
contacts asked about whom the research was for, the interviewers were able to 
name the relevant government department (at the time of fieldwork this was The 
Department of Community, Rural & Gaeltacht Affairs in Ireland) as sponsoring the 
study.  This helped provide reassurance and establish the credibility of the survey for 
the respondent. 
4.5.5. The promise of confidentiality 
Response rates were also enhanced by providing a visual reassurance of 
confidentiality to respondents.  As a matter of course, respondents in all Ipsos MORI 
surveys receive a leaflet reassuring them that the research has been conducted 
within the Code of Conduct of the Market Research Society (MRS). This also 
provides a lo-call telephone contact number for Ipsos MORI in Dublin. 
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4.5.6. Advance letter 
For this particular study, potential respondents were provided with a letter from the 
NACD.  Interviewers also had copies of the letter written by an Ipsos MORI Director 
to the Deputy Commissioner, Garda Síochána informing him that the survey was 
taking place.  These letters provided further reassurance that the survey was a bona 
fide research exercise.  This is standard procedure for all face-to-face surveys 
conducted by reputable research agencies and is designed to prevent undue anxiety 
on the part of the respondent.  Copies of the letters that were presented to 
respondents are provided in Appendices H, I, & J. 
4.5.7. Appointment cards 
Where the selected respondent was not at home, carefully designed appointment 
cards were left with other members of the household.  This card provided brief details 
of the study and a name and telephone number to call to arrange an interview at a 
time most convenient to them.  This was particularly effective in converting some 
interviews with busy young professionals and those in shift work. 
4.5.8. Apartment complexes 
In any apartment complexes where access had to be gained through a gate or entry 
phone, interviewers were encouraged to make arrangements with caretakers and 
other staff to gain access to the block.  In this way, respondents from these locations 
were also included in the survey when access could be made. 
4.5.9. Frequently asked questions 
After discussion at the briefing meetings, it was agreed to prepare a series of 
answers to Frequently Asked Questions (FAQs) in order to provide information to 
those who may be unfamiliar with the study.  A copy of this FAQ document is 
provided in Appendix L. 
4.5.10. Monitoring and supervision 
Significant resources were allocated to monitoring progress in the Field, with weekly 
reports being sent to the dedicated Field Study Manager working on the study.  
 
INTERNAL USE ONLY 
31 
10-000957               December2011 
4.5.11. The “Ipsos MORI” name 
People are more likely to be receptive to an approach from an organisation they are 
familiar with and trust.  As with other studies, interviewers found that the reputation 
and high profile of Ipsos MORI as a trusted and independent research company also 
helped encourage response. 
4.5.12. Incentives 
In households where it was identified that the selected respondent was in the defined 
‘difficult to reach age group category’ i.e. age 15-24, we offered an incentive of an An 
Post One4all Voucher for €15 in order to help boost response from this particular age 
group.  Providing an incentive does not create any bias in random stratified surveys 
as the potential respondent had already been selected through a rigorous sampling 
process and the offer of an incentive will simply helped improve the response rate 
from age group which is frequently ‘under-represented’ in pre-selected surveys 
random surveys. 
A total of 792 interviews were achieved which represented15.4% of the total number 
of interviews. While this is below the overall population percentage of 21.8% it is 
higher than it would have been had the incentive not been introduced. 
 
4.6. Number of contacts 
The process of re-contacting a selected household a number of times in order to 
achieve an interview with the person chosen is critical to the sampling approach, 
since the random selection of the initial list of addresses is maintained.  Inevitably, 
the number of calls, which were necessary to achieve each interview, varied.  The 
following table outlines the number of calls required to achieve interviews in each 
health board region. 
Health Board 
Region /RDTFs 
Number of Calls Average 
 One to 
Three 
Calls (%) 
Four to Five 
Calls (%) 
Six or More 
Calls (%) 
Ireland 81 14 5 2.4 
ERHA  74 21 6 2.7 
Midland HB/RDTF 78 13 9 2.6 
Mid Western 
HB/RDTF 
78 17 6 2.4 
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North Eastern 
HB/RDTF 
80 15 6 2.5 
North Western 
HB/RDTF 
87 9 4 2.0 
South Eastern 
HB/RDTF 
82 15 3 2.3 
Southern HB/RDTF 93 5 1 1.8 
Western HB/RDTF 86 10 4 2.2 
 
On average, interviewers attempted to contact respondents twice before a successful 
interview was conducted. There was variation across the health board regions.  At 
one end of the spectrum, interviewers in the Southern HB had the least difficulty, with 
93% achieving their interviews within three contacts.  In the Midland HB meanwhile, 
9% of all interviews required more than six calls to be completed. 
4.7. Age & gender 
The following table compares the profile of the sample for the survey with the profile 
of the target Republic of Ireland adult population as a whole (aged 15 – 64). 
 Population % population Sample % sample 
Ireland 2,907,473 100.0% 5,128 100.0% 
Gender     
Male 1,471,032 50.6% 2,239 43.7% 
Female 1,436,441 49.4% 2,889 56.3% 
Age     
15-24 632,732 21.8% 792 15.4% 
25-34 722,439 24.8% 1,168 22.8% 
35-44 623,434 21.4% 1,302 25.4% 
45-54 521,813 17.9% 951 18.5% 
55-64 407,055 14.0% 915 17.8% 
Health Board/RDTF     
ERHA  1,064,100 36.6% 1,646 32.1% 
Midland HB/RDTF 167,766 5.8% 438 8.5% 
Mid Western HB/RDTF 245,399 8.4% 454 8.9% 
North Eastern HB/RDTF 265,873 9.1% 451 8.8% 
North Western HB/RDTF 155,033 5.3% 438 8.5% 
South Eastern HB/RDTF 307,793 10.6% 476 9.3% 
Southern HB/RDTF 422,749 14.5% 733 14.3% 
Western HB/RDTF 278,760 9.6% 492 9.6% 
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From this comparison it is clear that there are discrepancies between the profile of 
the sample and that of the population generally. In particular, it seems that the under-
25 year olds, males and those in the Eastern Regional Health Authority (ERHA) 
appear to be under-represented in the survey. 
Given that, as the EMCDDA points out, “no sample frame is perfect and perfect 
probability sampling does not exist”, it is perhaps inevitable that there would be some 
discrepancies.  The weighting procedures followed (as outlined in chapter 6 of this 
report), which were aimed at alleviating the impact of any biases arising from the 
differences between sample and population.  The remainder of this section of the 
report looks at other areas, which might have given rise to bias in the results. 
4.8. Non-Response 
In order to estimate the effects of non-response bias in the achieved sample, the 
contact sheet was used to record the age, gender and ethnicity of the household of 
all those who refuse to take part.  Further, interviewers also coded the external 
features of households where contact had not been possible.  This information was 
compared with characteristics among the achieved sample to help assess its 
representativeness.  
4.8.1. Age & gender 
The table below outlines the gender and age of those who refused to take part in the 
survey. 
Area % of Sample % of Refusals 
Male 44% 52% 
Female 56% 48% 
15-24 years 15% 5% 
25-34 years 23% 20% 
35-44 years 25% 26% 
45-54 years 19% 25% 
55-64 years 18% 25% 
 
In terms of gender, it is clear that a higher proportion of males refused to take part in 
the survey, relative to their proportion of the sample.  There was a higher proportion 
of people in the 45-54 and 55-64 age groups among those who refused to take part.  
At the same time 15-24 year olds made up a smaller proportion of refusals compared 
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to the sample (i.e. 5% vs. 15%).  In terms of the sample, however, these 
discrepancies are greatly reduced after weighting. 
4.8.2. Type of house 
It was also of critical interest to compare the social makeup of those who refused with 
the actual sample.  By the definition, it was not possible to gather data on the social 
classification of those who refused to take part, which could be directly compared 
with the survey results.  As a rough measure of the social composition of the sample 
and of those who refused to take part, the contact sheets also included details on the 
external characteristics of the homes of all those which they attempted to contact.  
The following table compares the property types where completed interviews took 
place and those where potential respondents had refused to take part. 
Type of Property % of 
Successful 
% of 
Refused 
Ireland 
House/bungalow - detached 48.3% 36.1% 
House/bungalow - semi-detached 27.4% 32.5% 
House/bungalow - mid terrace 12.8% 15.9% 
House/bungalow - end terrace 4.8% 5.8% 
Purpose built flat. etc, - building fewer than 6 floors 5.4% 7.4% 
Purpose built flat. etc, - building 6 or more floors 0.4% 1.3% 
Conversion flat/maisonette(s)/shared house 0.4% 0.6% 
Other 0.3% 0.5% 
TOTAL 100.0 100.0 
 
Those who refused to take part were less likely to live in a detached house than the 
sample, with almost half the sample (48.3%) living in detached houses compared to 
36.1% of those who refused to participate.  On the other hand, those who refused 
were more likely to live in semi-detached houses in particular, with 27.4% of the 
sample living in semi-detached houses compared to 32.5% of those who refused to 
participate. 
4.9. Ineligible contacts in sample frame 
Refusals, of course, were not the only reason that an interviewer may not achieve an 
interview at a selected address.  Frame errors, where contacts were ineligible for the 
defined universe (aged 15-64), or where the property was ineligible, vacant, derelict, 
demolished, not found, or a business, also explained why interviews were not 
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conducted at all addresses.  As such, it was important to check that frame errors 
were evenly distributed by region, as an uneven spread of frame errors may point to 
bias in the sample. The following table outlines the extent to which frame errors were 
present in the health board regions.  Besides frame errors, they also show 
breakdowns of the gross sample by:  
 Successful interview - persons belonging to the universe who were part of the 
sampling frame and completed the interview fully; 
 Non-response - households that refused to take part during the initial screening 
interview and respondent selection process, respondents who refused to take 
part once selected, and properties where wardens etc refused on the contact’s 
behalf, or where no contact could be made after multiple calls.   
 
Region Gross 
Sample 
Successful 
interviews 
Non-
Response 
Frame 
Errors 
Capped 
Addresses 
TOTAL n 11935 5128 3490 2592 725 
  % 100% 43% 29% 22% 6% 
ERHA n 4185 1646 1450 1081 8 
  % 100% 39% 35% 26% 0% 
Midland HB/RDTF n 961 454 230 171 106 
  % 100% 47% 24% 18% 11% 
Mid Western 
HB/RDTF 
n 1054 438 347 269 0 
  % 100% 42% 33% 26% 0% 
North Eastern 
HB/RDTF 
n 1085 451 321 168 145 
  % 100% 42% 30% 15% 13% 
North Western 
HB/RDTF 
n 961 438 218 220 85 
  % 100% 46% 23% 23% 9% 
South Eastern 
HB/RDTF 
n 1085 476 309 250 50 
  % 100% 44% 28% 23% 5% 
Southern HB/RDTF  n 1519 733 347 307 132 
  % 100% 48% 23% 20% 9% 
Western HB/RDTF  n 1085 492 268 126 199 
  % 100% 45% 25% 12% 18% 
 
INTERNAL USE ONLY 
36 
10-000957               December2011 
Frame errors accounted for 22% of the gross sample in Ireland.  There was little 
variation on these figures across most health board regions although there was a 
slightly lower level of frame error in Western HB and Northern Eastern HB.   
In order to achieve a balanced sample, whilst optimizing responses within the survey 
period, it was deemed necessary to limit the number of addresses issued within 
certain sampling points.  This is a specific feature of the 2010/11 survey and was 
seen as a far more robust alternative than non-coverage of entire sampling points.  In 
the vast majority of points, 31 addresses were issued, but in others, a certain number 
were removed from this.  Thus in points where fewer addresses were issued (after 
removal / “capping”), those addresses which were interviewed would have had a 
lower chance of being included in the survey than other addresses in the un-capped 
points. Therefore, a weighting component was included to compensate for this 
“capping”. Further details on the weighting involved are in chapter 6.   
4.10. Response rates for population survey 
For the purpose of this study, it was decided that a target of 5,000 interviews should 
be completed.  A response rate of 55% was anticipated; hence in order to achieve 
the desired sample size, approximately 8,600 contacts needed to be made. 
A final response rate of 60% was achieved, with 5,128 responses in total.  Details of 
overall response rates for Ireland, along with rates for the health board regions, are 
shown below. 
Health Board 
Region/RDTF 
Gross 
Sample 
Valid 
Sample* 
Response % 
Response 
Total Ireland 11,935 8,618 5,128 60% 
ERHA 4,185 3,096 1,646 53% 
M HB/RDTF 961 684 454 66% 
MW HB/RDTF 1054 785 438 56% 
NE HB/RDTF  1085 772 451 58% 
NW HB/RDTF 961 656 438 67% 
SE HB/RDTF  1085 785 476 61% 
SH HB/RDTF 1,519 1080 733 68% 
W HB/RDTF  1085 760 492 65% 
*Valid sample = Gross sample – (frame errors + non-valid cases) 
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 Health Board                 
  ERHA MHB MWHB NEHB NWHB SEHB SHB WHB Total 
Outcome description N % valid N 
% 
valid N 
% 
valid N 
% 
valid N 
% 
valid N 
% 
valid N 
% 
valid N 
% 
valid N 
% 
valid 
Successful interview 1646 53% 454 66% 438 56% 451 58% 438 67% 476 61% 733 68% 492 65% 5128 60% 
REFUSED                                     
Refused before Respondent Selection 305 10% 35 5% 82 10% 67 9% 32 5% 77 10% 61 6% 74 10% 733 9% 
Refused after Respondent Selection 228 7% 27 4% 35 4% 29 4% 30 5% 75 10% 54 5% 30 4% 508 6% 
Entry to block/scheme refused by warden 2 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 2 0% 
Withdrawn by head office 51 2% 1 0% 1 0% 3 0% 4 1% 0 0% 5 0% 1 0% 66 1% 
NO CONTACT                                     
Occupied, no contact at address after 5+ calls 364 12% 32 5% 41 5% 58 8% 43 7% 31 4% 28 3% 14 2% 611 7% 
No contact with selected resident, 4+ calls 144 5% 20 3% 24 3% 18 2% 14 2% 27 3% 9 1% 10 1% 266 3% 
Occupier,in but not answering door after 5+calls 58 2% 4 1% 7 1% 3 0% 2 0% 10 1% 4 0% 5 1% 93 1% 
Unsure if occupied,no contact after 5+calls 194 6% 7 1% 28 4% 12 2% 10 2% 6 1% 5 0% 4 1% 266 3% 
Capped Addresses - Non-contact 2 0% 83 12% 110 14% 109 14% 72 11% 35 4% 153 14% 114 15% 678 8% 
No contact other 25 1% 0 0% 0 0% 1 0% 6 1% 0 0% 1 0% 3 0% 36 0% 
PROPERTY INELIGIBLE                                     
Property vacant 173   63  70   47  75   75  109   48  660   
Property derelict 20   4  8   3  6   1  4   0  46   
Property Demolished 7   1  1   0  0   0  0   2  11   
Non-residential property 32   2  12   4  27   14  24   3  118   
Property Not Found 96   10  23   26  19   19  34   4  231   
Unable to access block/scheme/gated apartments 81   6  11   8  1   5  2   1  115   
OTHER                                     
Too ill to participate 18 1% 7 1% 4 1% 3 0% 1 0% 7 1% 7 1% 3 0% 50 1% 
Away during fieldwork 23 1% 5 1% 3 0% 6 1% 0 0% 11 1% 9 1% 1 0% 58 1% 
Household Not Eligible 672   85  144   80  92   136  134   68  1411   
Mother tongue required 18 1% 7 1% 9 1% 9 1% 3 0% 17 2% 6 1% 5 1% 74 1% 
Other 18 1% 2 0% 3 0% 3 0% 1 0% 13 2% 5 0% 4 1% 49 1% 
Capped address - removed from sample 8   106  0   145  85   50  132   199  725   
Total addresses 4185   961   1054   1085   961   1085   1519   1085   11935   
Total valid addresses 3096 100% 684 100% 785 100% 772 100% 656 100% 785 100% 1080 100% 760 100% 8618 100% 
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5. Data processing  
As described earlier in this report, the survey data was captured by the interviewers 
using the Computer Aided Personal Interviewing (CAPI) software package, 
Quancept.  The data from all the interviews was collated together into one database 
with both numerical data and text from the open-ended questions.  The numerical 
data was exported into the statistical software package SPSS (Statistical Package for 
the Social Sciences).  Quancept was able to export both the raw data (numbers) and 
the labels associated with both the question itself and the answer responses (e.g. a 
code ‘1’ could indicate the response ‘yes’ to a particular question, code ‘2’ could 
indicate a response ‘no’). 
Separately, the text from the open-ended questions was exported into Microsoft  
Excel for editing and coding.  Coding involved grouping similar responses and 
assigning a code to these responses.  An appropriate label to describe the code (e.g. 
1 = Drugs purchased in café in Amsterdam) was then applied.  Once coding was 
complete, this data was exported into SPSS as separate variables and checked 
against the other numeric data.  For some questions, a list of pre-defined codes was 
presented to the interviewer on screen with a code to record any ‘other’ response.  
Validation was carried out to ensure that any ‘other’ response did not already appear 
in the list of pre-defined codes. 
Responses were recorded in text or numeric form as appropriate.  When questions 
were not relevant to a respondent’s particular circumstances (i.e. they were routed 
away from them) the cells in the SPSS data file were filled with a “.” which is the 
appropriate ‘system missing’ value for this data analysis software. 
 
 
6. Weighting, design effects  
and confidence intervals
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6. Weighting, design effects and 
confidence intervals 
6.1. Overview 
This chapter aims to describe the technical aspects of the statistical design and 
analysis of the 2010/11 General Population Survey on Drug Prevalence (hereafter 
referred to as the population survey).  These aspects were carried out by the 
Research Methods Centre (RMC) of Ipsos MORI, based in London and they include: 
 Survey weighting; 
 Calculation of Survey Design Effects; 
 Calculation of the Confidence Intervals (CI) around the drug usage point 
estimates; 
 Identification of significant differences in the point estimates between 2006/07 
and 2010/11. 
Each section is described in the following chapter.  The methodology for these 
stages align exactly to what had been carried out in previous waves of the survey 
and described in the technical note surrounding the 2006/07 survey (Muhlau, 2007).  
The only differences in statistical methodology between the 2010/11 wave and 
2006/07 involved possible differences in software used and the existence of an 
additional weighting component in 2010/11. 
Please note that this statistical report is written in respect of the survey which covers 
the Republic of Ireland (ROI) only.  When the results for Northern Ireland are 
included, the analysis will be extended taking account of exactly the same described 
methodology. 
6.2. Overall rationale 
Even with the best-designed surveys, the profile of the achieved sample will not 
exactly align with that of the target population.  This may typically be due to 
unintentional reasons (e.g. differential non-response) or intentional ones (where there 
is a deliberate attempt to over-represent or boost certain sub-groups within the 
population).  Therefore, it is necessary in many surveys, including the population 
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survey to apply weighting to the respondents so that each is scaled up or down to 
represent correctly, its relevant component population. 
It is appropriate, in random probability surveys, to present results with measures of 
the level of precision around them.  This is known as a Confidence Interval (CI).  
For binary (yes / no) survey measures, the width of a standard CI is simplistically 
linked to the sample size (n) and the survey measure (p – eg 0.65 for 65% giving a 
certain result), i.e. the width of a 95% CI is: 
 
n
ppCI )1.(*96.1 −±=  
 
However, the above only applied in the case of a random probability surveys, where 
there is no weighting, clustering or stratification and is based on an infinitely large 
population.  Such an occurrence is very rare in practice and for this reason, actual 
CIs need to be adjusted to allow for these combinations of “design effects” (DE).  
The true 95% CI would thus be: 
n
dppCI ).1.(*96.1 −±=  
 
(where d is the DE). 
In the population survey, three aspects of DEs come into play – i.e. weighting, 
stratification (by Health Board) and clustering (by Electoral District; the Primary 
Sampling Unit).  The details of the calculation of the overall DEs are described later 
in this chapter. 
The actual CIs calculated on the back of this survey will be more sophisticated than 
the standard ones shown above.  This is because the standard (Wald) ones may be 
prone to under-coverage and may thus understate the true level of imprecision of the 
estimates.  This is particularly true where sample sizes are small and / or 
prevalences are close to zero or 100%; the latter situation of very low prevalences 
being of particular relevance to drug usage surveys of the population.  Therefore, the 
usage of alternative, more sophisticated ones are described in this chapter and one 
such method, the “Clopper Pearson” ones are actually calculated and are based on 
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effective sample sizes, so that they are in effect, DE-adjusted.  These give a truer 
measure of the precision levels. 
Finally, for the same reason as the above, when calculating the level of significance 
of differences between results across two time periods, the formula based on the 
standard binomial approximation to the normal distribution is not used.  Instead, we 
apply Newcombe’s Hybrid Score method to calculate these, which allows for 
potential over-dispersion.  Again, these measures are DE-adjusted. 
6.3. Survey weighting  
The population survey involves both pre-weights and post-stratification (PS) weights.  
Pre-weights are used to allow for different selection probabilities of each end 
respondent, whilst the PS weights scale up the responses within each demographic 
cell to represent their respective target populations. 
With the pre-weights (also called “design weights”), there are two components 
involved and these components are multiplied together at the respondent level in 
order to provide an overall pre-weight.  These components are: 
• To allow for different selection probabilities of eligible respondents 
within a household (HH).  As the sample design involves randomly selecting 
HH from the postal address frame, in an EPSEM manner (i.e. with equal 
probability), then a respondent within a HH containing two other eligible 
respondents will have only 1/3 of the probability of appearing in the survey 
compared to another respondent who lives with no other eligible people.  
Therefore, in order to compensate for this, all respondents will be given a HH 
selection pre-weight equivalent to the total number of eligible persons 
(including themselves) within the HH. 
 
• To allow for the capping of addresses issued to certain sampling points.  
In order to achieve a balanced sample, whilst optimizing responses within the 
survey period, it was deemed necessary to limit the number of addresses 
issued within certain sampling points.  This is a specific feature of the 2010/11 
wave of this survey and was seen as a far more robust alternative than non-
coverage of entire sampling points.  In the vast majority of points, 31 
addresses were issued, but in others, a certain number were removed from 
this.  Thus in points where fewer addresses were issued (after removal / 
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“capping”), those addresses which were interviewed would have had a lower 
chance of being included in the survey than other addresses in the un-capped 
points.  The reason for this is that if EDs A and B each contained 200 
addresses in the population eligible for selection and ED A (e.g. Sample point 
#232) was capped in that only 10 addresses were issued and ED B was 
uncapped and the full 31 addresses issued, then a typical address in ED A 
would only have a 10/200 probability of being selected, as compared with 
31/200 for an address in ED B.  Therefore, addresses in ED B will have had 
3.1 (ie 31/10) times the chance of being selected as compared with those in 
ED A.  Therefore, all covered addresses within point #232 were given a pre-
weight component of 31/10 = 3.1 to balance this out.  Hence, a second pre-
weight component was included in order to compensate for this.   
 
Putting this together, the pre-weight (wp) for respondent i in sample point l is given 
by: ⎟⎟
⎠
⎞
⎜⎜
⎝
⎛
=
l
t
lili a
aNwp *  
As an example, a respondent who lives in a selected HH with one other eligible 
person (Nli=2) within a sample point where 10 addresses were capped (and hence 
20 issued – ie al, out of the target of 31 - at), would have an overall pre-weight of 
2*31/20 = 3.10. 
Post-stratification weights were calculated on a cell-by-cell basis (i.e. “cell 
weighting”); a cell being a group of respondents sharing the same combination of 
Regional Authority10 (RA – 8 levels), gender (2) and age group (5).  An appropriate 
scaling-weight was allocated to each of the 80 cells in order to bring up the sum of 
the pre-weights of its respondents to the population it is to represent, according to the 
2010 population estimates based on the 2006 Census.  These weights are based on 
ratio of the population and sample frequencies of age*gender*RA cells. The resulting 
probability (PS) weights corresponds with:  
∑ =
=
ijkn
i li
Census
ijk
ijk
wp
h
wps
1
 
                                            
10 As the weighting is based on the 2010 population estimates, Regional Authority was used 
to define regions instead of Health Board/RDTF.  Regional Authority and the Health 
Board/RDTF equivalent is indicated in Appendix O. 
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where hCensus is the stratum size according to population for a cell, the denominator is 
the sum of the pre-weights within that cell’s in the population survey and i (= 1 to 8) 
refers to the Regional Authority , j (=1 to 2) to gender and k (=1 to 5) to age-group. 
 
The overall weight for each respondent will thus be: 
 
 ijklii wpswpw *=  
 
The wi’s are thus grossing weights in that the sum of these weights equate to the 
exact population they are to cover.  They serve the purpose of both giving each 
respondent the right amount of influence (relative to other respondents) in 
determining the overall survey results at national level and scaling the sample to 
equate to the population.  The second of these “notional” components (i.e. the 
“scaling” component) is a constant for each respondent.  For certain end-purposes, it 
may be useful to exclude this “grossing” component and simply provide an overall 
adjusted weight (wa), such that the mean adjusted weight is exactly 1.00 across the 
entire sample; i.e: 
⎟⎟
⎠
⎞
⎜⎜
⎝
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=
∑
n
w
wwa
i i
i
i
 
 
6.4. Calculation of the survey Design Effects 
6.4.1.  General principles 
The population survey is a complex survey that differs in various aspects from simple 
random sampling.  As with most population surveys that collect data by personal 
interviews, the survey uses a multi-stage design.  In the first stage, electoral 
districts (ED) are selected as primary sampling units.  Within the electoral 
districts, residential addresses (households / HHs) are randomly selected as 
secondary sampling units.  The number of secondary sampling units is roughly 
proportional to the population size of the primary sampling units.  One member of 
each household is selected as final sampling unit following a quasi-random 
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procedure.  In the first stage, stratified random sampling is employed for the 
selection of the primary sampling units.  The strata are formed by health board 
regions and finally, the resulting sample has been weighted in order to calibrate the 
age-gender distribution in the health boards with the population distribution according 
to the 2006 Census. 
The complexity of the sample design influences the point estimates of the prevalence 
rates only by the fact that unequal inclusion probabilities (due to intended unequal 
selection probabilities or differences in response rates) have to been taken into 
account.  Aiming to reduce sampling bias, point estimates derived from the 
population surveys are based on the samples weighted by calibration (or post-
stratification - PS) weights.  However, interval estimates of the prevalence rates 
(confidence intervals) directly depend on the variance of the relevant statistics.  In 
complex surveys such as the population survey, the variance of the estimates is 
usually larger than in simple random samples.  A measure for this variance inflation 
is the design effect (DE).  The design effect is the ratio of the true variance of a 
statistic of a complex sample design to the variance of the statistics for a simple 
random sample with the same number of cases (Kish, 1995).  Three aspects of 
complex designs affect the variance inflation: (1) stratification, (2) clustering, (3) 
weighting.  There is a fourth aspect, namely the finite population multiplier, but this 
only comes into play where samples are large in relation to the population and this is 
not something which applies in the population survey. 
(1) Stratification:  Stratification tends to reduce the sampling variance; the variance 
deflation is stronger the lower the variation on the relevant variables within the strata 
and the higher the variation between the strata.  Disproportional allocation in contrast 
tends to result in higher sampling variance compared with proportional allocation to 
strata.  
(2) Clustering:  The population survey uses a multi-stage design with Electoral 
Districts as primary sampling units.  These electoral districts are ‘clusters’.  Clustering 
almost always leads to inflated sampling variance.  The magnitude of the design 
effect due to clustering is dependent on two aspects, the size of the clusters and the 
homogeneity within the clusters.  Large cluster size and low variation within the 
clusters increase the sampling variance.  
(3) Weighting:  Weighting inflates more often than not, the sampling variance and in 
general, the greater the range of weights across the respondents, the greater the 
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level of variance inflation.  If weights are uncorrelated with the variation of the 
relevant variables, the design effect is larger the more the weights vary.  It is however 
crucial whether groups with higher selection probabilities (smaller weights) exhibit 
larger variation on the survey variables.  If the weights are negatively correlated with 
the variation on the relevant variables, sampling variance is deflated. 
The concept of the “Effective Sample Size”.  This is the sample size under a 
simple random sample design that is equivalent to the actual sample under the 
complex sample design in terms of the actual level of precision on its estimates 
which it yields.  The effective sample size can be determined by dividing the actual 
sample size by the design effect.  For example, an actual sample of 5,000 units and 
a design effect of 2 result in an effective sample size of 2,500 units.  The same 
precision of the estimates could thus have been achieved by a simple random 
sample of half the size.  
6.4.2. Design effect estimation  
For a particular sample with a given design and post-survey adjustment procedure, 
design effects differ for different statistics, survey variables and subgroups. For the 
population survey, the design effects have been estimated using the “Proc 
Surveymeans” procedure in SAS v9.1.3, which uses the Taylor expansion method to 
estimate sampling errors of estimators based on complex sample designs.  The ratio 
of the actual sampling errors to the sampling errors derived through making the 
assumption of there being no clustering, stratification or weighting, yields the DE for 
each measure.  A number of the DEs derived from this have been re-calculated using 
STATA and there was complete agreement between the two methods.  Both SAS 
(Proc Surveymeans) STATA are well-used and recognised methods of calculating 
survey design effects.  
For the estimation of the design effects, the following design parameter have been 
used: 
• Weights:  These are described in Section 6.3 of this chapter; 
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• Strata:  As health-board regions; 
• Clusters:  Electoral districts were used as clusters; 
• Sampling method:  Random sampling without replacement. 
6.4.3. Relative weight of stratification, clustering and weighting 
Table 1 illustrates the relative influence of stratification, clustering and weighting on 
the total design effect for prevalence rates of selected drugs.  DEStrat is the 
estimated design effect if the sample would have been stratified, but neither clustered 
or weighted.  DEClust is the isolated design effect of clustering and DEWeigh 
represents the design effect due to weighting.  DETotal is the combined design effect 
of stratification, clustering and weighting.  Due to interactions between the three 
components, DETotal is not exactly the product of the three isolated design effects.  
The design effects associated with stratification are smaller than one, indicating that 
stratification tends to increase the sampling efficiency.  However, health board strata 
are internally not particularly homogenous as reflected in the fact that the values are 
close to one.  The design effects associated with weighting are more substantial and 
reflect the fact that groups with lower response probabilities (larger weights) such as 
young people and males tend to use drugs more often.  Clustering accounts for the 
largest share of the design effect and its variation and this reflects the fact that area 
of residence (or neighbourhood) affects drug consumption habits to a strong degree 
and that this ‘neighbourhood effect’ differs largely for different drugs. 
Table1:  
Decomposition of total design effect – selected drugs, lifetime, ROI 2010/11 
 
Drug DE_Tot DE_Strat DE_Clust DE_Weigh 
Cannabis 1.904 0.984 1.932 1.337 
Heroin 1.336 0.995 1.242 1.121 
Cocaine (Total) 1.551 0.989 1.381 1.327 
Ecstasy 1.372 0.989 1.319 1.300 
Any illegal drugs 1.961 0.979 2.021 1.329 
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6.4.4. Design effects:  Descriptives 
A complete list, in MS Excel of all calculated DEs in the survey has been prepared 
separately.  It presents the actual sample size, the effective sample size, the rate (i.e. 
the proportion who are users) and the DE for each measure, along with the Clopper 
Pearson Confidence Intervals (whose methodology and rationale are fully described 
in Section 6.5).  Nine such tables have been produced; one for each health board 
and one for the Republic of Ireland overall.  Within each table 660 measures (one on 
each row) are presented – i.e. 
• Prevalence levels (3 – i.e. Lifetime, Last Year and Last Month); 
• Demographic sub-groups (10 – i.e. overall, 2 genders, 2-level and 5-level age 
groups); 
• Drug types (22). 
 
Table 2 summarises the calculated ROI-level design effects for the 2006/07 and 
2010/11 population surveys. The column DE presents the mean design effect and its 
standard deviation for all estimated design effects, the column DE(LIM) refers to the 
sample of design effects larger than one, i.e. the design effects that have been used 
in adjusting the confidence intervals. Design effects for the 2010/11 survey are larger 
than for 2006/07 and for lifetime prevalence larger than for last year and last month 
prevalence.  There is no difference in the DEs between the genders, and the age 
bracket between 35-64 years has the highest DE.  The highest DEs relate to Opiates, 
as followed by Magic Mushrooms, New Psychoactive substances Cannabis and 
Tobacco with relatively small DEs estimated for Crack, LSD and Methadone. 
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Table 2:  Design effect by sample, prevalence type, sub-sample and drug type 
 
  2006/07 2010/11 
  DE DE(LIM) DE DE(LIM) 
  Mean SD Mean SD Mean SD Mean SD 
Total 1.32 0.35 1.34 0.31 1.46 0.77 1.50 0.73 
Prevalence                 
Lifetime 1.38 0.34 1.39 0.32 1.55 0.81 1.57 0.80 
Last Year 1.3 0.34 1.33 0.31 1.51 0.86 1.56 0.82 
Last Month 1.26 0.35 1.29 0.31 1.31 0.59 1.39 0.50 
Subsample                 
All 1.49 0.4 1.51 0.38 1.89 1.32 1.90 1.31 
Males 1.63 0.32 1.63 0.32 1.55 0.62 1.56 0.61 
Females 1.03 0.19 1.09 0.12 1.52 1.00 1.59 0.93 
15-34 1.5 0.31 1.5 0.3 1.38 0.62 1.44 0.56 
35-64 1.2 0.23 1.23 0.18 1.74 0.93 1.76 0.92 
15-24 1.57 0.26 1.57 0.25 1.22 0.47 1.30 0.37 
25-34 1.35 0.24 1.36 0.21 1.28 0.45 1.34 0.38 
35-44 1.06 0.19 1.11 0.13 1.26 0.56 1.33 0.49 
45-54 1.2 0.22 1.21 0.2 1.46 0.46 1.49 0.40 
55-64 0.99 0.17 1.05 0.07 1.30 0.48 1.32 0.45 
Drug type                 
Alcohol 1.26 0.29 1.27 0.27 1.43 0.22 1.43 0.22 
Tobacco 1.39 0.23 1.39 0.23 1.47 0.16 1.47 0.16 
Cannabis 1.64 0.46 1.64 0.46 1.47 0.21 1.47 0.21 
Opiates (Tot) 1.41 0.34 1.42 0.33 3.14 1.32 3.14 1.32 
Heroin 1.01 0.26 1.11 0.16 1.08 0.44 1.23 0.28 
Methadone 1.04 0.23 1.11 0.18 1.00 0.33 1.13 0.18 
Other opiates 1.45 0.36 1.46 0.35 3.16 1.32 3.16 1.32 
Technical Report – General Population Survey on Drug Prevalence 2010/2011 
51 
10-000957               December2011 
Cocaine (Tot) 1.4 0.23 1.4 0.23 1.36 0.33 1.38 0.30 
Crack 1.22 0.24 1.25 0.19 1.00 0.34 1.11 0.24 
Cocaine 1.41 0.24 1.41 0.24 1.37 0.33 1.39 0.30 
Amphetamines 1.26 0.26 1.3 0.2 1.42 0.54 1.47 0.46 
Ecstasy 1.48 0.34 1.48 0.34 1.04 0.28 1.13 0.16 
Hallucinogens 1.36 0.38 1.38 0.34 1.37 0.51 1.43 0.43 
LSD 1.27 0.34 1.31 0.29 1.01 0.33 1.12 0.21 
Magic mushr. 1.4 0.28 1.4 0.28 1.50 0.45 1.50 0.45 
Sed, Tranqu. 1.14 0.17 1.16 0.15 1.29 0.23 1.30 0.22 
Anti-Depress 1.11 0.13 1.12 0.12 1.36 0.13 1.36 0.13 
Solvents 1.09 0.32 1.19 0.21 1.32 0.46 1.36 0.40 
Poppers 1.35 0.29 1.37 0.25 0.97 0.35 1.13 0.20 
Anabolic 
Steroids 
1.21 0.39 1.29 0.28 1.38 0.40 1.39 0.38 
New 
Psychoactive 
Substances 
        1.49 0.32 1.49 0.31 
Any illegal 
drugs 
1.66 0.48 1.66 0.46 1.49 0.23 1.49 0.23 
 
 
6.4.5 Design effects smaller than one 
Confidence intervals and significance levels have been only adjusted for design 
effects if the estimated design effect is larger than one.  In the case of design effects 
that are smaller than one the statistics has been calculated using the unadjusted 
procedures.  This decision follows the practice of the US National Survey on Drug 
Use and Health (see Gordek and Folom, 2006).  In cases where the sampled number 
of positives (drug users) is zero, design effects cannot be calculated and the 
unadjusted procedures were used.  
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6.5. Calculation of Confidence Intervals (on proportions) 
6.5.1. Sampling 
For the population survey, not all persons in the sampling frame were interviewed, 
but only a relatively small selection of about 5,000 persons were interviewed.  Hence, 
the prevalence rates calculated from the sample are only estimates of the 
prevalence rate in the frame population. The same sample design, i.e. the same 
procedure to derive the sample, could have resulted in an almost infinite number of 
different samples.  If prevalence rates would be calculated for these potential 
samples, the estimated prevalence rates would vary somewhat.  This variation is 
called the sampling variance.  The higher the sampling variance the lower the 
precision of an estimate derived from a particular sample.  
6.5.2. Confidence intervals 
For the evaluation of the findings of the population survey it is therefore useful to 
provide not only the sample prevalence rate as an estimate of the population 
prevalence rate, the point estimate, but also an indication of how reliable or precise 
this estimate is.  Such an indication is provided by confidence intervals (CI).  A 
confidence interval is an interval estimate for a population parameter with an 
associated probability, the confidence level.  For studies like the population survey, 
the confidence level is typically 95%.  A 95% confidence interval means that if the 
sampling was repeated numerous times and a confidence interval calculated for each 
sample, 95 percent of the confidence intervals should contain the population 
prevalence rate. 
6.5.3.  Quality of methods to estimate confidence intervals  
There are many different methods to estimate confidence intervals.  Given the variety 
of methods, researchers should select methods to determine confidence intervals 
that are best suited for the purpose of their study.  The main criterion to evaluate the 
quality of a confidence interval method is how likely confidence intervals estimated by 
a specific method cover the population value.  The question of how the actual 
coverage of a confidence interval compares with the nominal coverage is typically 
examined in simulation studies where samples are repeatedly drawn from a 
population with known characteristics.  The percentage of confidence intervals 
containing the population rate is established and this coverage probability is 
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compared with the nominal coverage.  Under-coverage is considered to be 
undesirable, i.e. the percentage of confidence intervals covering the population rate 
should not be systematically smaller than the confidence level.  Given satisfactory 
coverage, the width of the confidence intervals is a second criterion, where more 
narrow confidence intervals are preferred to wider ones.  Finally, consideration 
should be given to computational requirements. 
6.5.4. The ‘conservatism’ issue 
While there is general agreement that under-coverage should be avoided, there is 
some disagreement of what characterises a confidence interval with good coverage 
properties.  Confidence interval methods do not perform uniformly across all possible 
combinations of prevalence rates in the population (p), and samples of different sizes 
(n).  The first position is that a good method to determine confidence intervals should 
guarantee at least a coverage probability that is equal to the nominal coverage.  This 
means that a 95% percent confidence interval should in all possible circumstances 
cover the population parameter in not less than 95 percent of the samples.  This 
position has been criticised as ‘too conservative’ (e.g., Agresti and Coul, 1998; Brown 
et al., 2001).  The alternative position is that a good method is characterised by 
confidence intervals where (across all possible combinations of population 
proportions and sample sizes) the actual coverage on average equals the nominal 
coverage. 
We adopt, in the evaluation of the methods, a differentiated approach: With regard to 
confidence intervals for prevalence rates we choose a more conservative or cautious 
position, arguing for methods that guarantee actual coverage of at least the nominal 
value for the combinations of population proportions and sample sizes that are 
relevant in the drug surveys.  With regard to confidence for differences between 
proportions, i.e. comparisons between the 2006/07 and 2010/11 surveys, we prefer a 
less strict position.  With regard to comparisons, the construction of the confidence 
intervals is directly related to hypotheses testing.  In this context the avoidance of 
‘false negatives’ is important: We wish to know whether the data provide enough 
evidence to reject the null-hypothesis that the prevalence rate has not changed 
between 2006/07 and 2010/11 (and that observed differences in the prevalence rates 
are due to sampling error).  In a hypothesis testing framework, two potential sources 
of error have to be considered: The likelihood that the null-hypothesis is rejected 
although the null-hypothesis is true (false positives) and the likelihood that the null-
hypothesis is not rejected although the alternative hypothesis is true (false 
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negatives).  A more conservative approach to testing has a consequence that the 
likelihood of false negatives increases, i.e. that the null hypothesis that drug use did 
not change between 2006/07 and 2010/11 is not rejected in spite of ‘sufficient 
evidence’ to the contrary.  With regard to the prevalence rates, we adopt a more 
conservative position as there are no meaningful null or alternative hypotheses 
regarding the prevalence rates. 
6.5.5. Sampling distribution of proportions 
In order to calculate confidence intervals, an idea about the sampling distribution of 
the statistic in question is needed.  The sampling distribution of a rate (i.e. a 
proportion) is binomially distributed.  The shape of the sampling distribution depends 
on the ‘true’ prevalence rate in the population (p) and, in the case of simple random 
sampling, the sample size n.  The mean of the sampling distribution is p and the 
variance  2 = p(1- p)/n.  Further, the sampling distribution of a proportion is not 
symmetric (if p is not exactly .5).  The measure for the degree of asymmetry is called 
skewness.  The skewness of the sampling distribution of a rate is a function of the 
population proportion.  The more the mass of the distribution is concentrated on the 
left of the mean and the longer the right tail, the more positively skewed it is, whilst 
the more the mass of the distribution is concentrated on the right of the mean and the 
longer the left tail, the more negatively skewed it is.  
6.5.6. Confidence Intervals for single proportions: Wald 
The standard method to calculate confidence intervals for rates is not based on the 
(binomial) sampling distribution, but on the approximation of the sampling distribution 
by the normal distribution.  The normal approximation method of determining 
confidence intervals is based on the inverted Wald test (Wald procedure) and the 
limits of the confidence is given by:  
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where  
pˆ  is the sample proportion  
n is the sample size 
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2/αz  is the value of the standard normal distribution such that the area to its right is 
equal to alpha/2. 
 
6.5.7. Quality of Wald intervals  
The Wald method has various deficiencies which are mainly related to the fact that 
the normal approximation does not reflect the skewness of the sampling distribution 
of proportions and that the width of the confidence interval converges towards zero 
when sample probability approaches zero.  Various studies showed that the Wald 
method generates confidence intervals that grossly undercover the population 
parameter.  The under-coverage is more severe when samples are small and when 
the population parameter is close to 0 percent (or close to 100 percent).  Whilst the 
former poses no problem for surveys with substantial sample size, the latter is a 
problem in drug prevalence studies.  Prevalence rates for drug use are close to zero 
for many drugs and subpopulations in the population surveys. Therefore, Wald 
confidence intervals should not be used for population surveys on drug use. Wald 
confidence intervals have the additional problem that they provide no meaningful 
confidence intervals for rates that are zero and can generate lower confidence limits 
that are smaller than zero (ie: over-shooting).  
6.5.8. Confidence Intervals for single proportions: Clopper-Pearson 
The Clopper-Pearson procedure to compute two-sided confidence intervals is based 
on the binomial procedure (Clopper and Pearson, 1937). The interval estimator is 
obtained by inverting the test procedure for two one-sided hypotheses, one for the 
lower limit and the other for the upper bound.  Due to the relationship of the 
cumulative binomial and beta distributions, the following formula for the confidence 
interval can be derived as a function of the observed number of drug users k and the 
sample size n (e.g., Krishnamoorthy, 2006: 38): 
[ ]);1;2/1();1;;2/( 11 knkknk −+−ℑ+−ℑ −− αα  for 0 < k < n; 
[ ]);1;2/1(;0 1 knk −+−ℑ− α  for k=0; 
[ ]1);1;;2/(1 +−ℑ− knkα  for k=n. 
 
where );;(1 bap−ℑ  is the inverse function of the beta distribution with quantile p and 
shape parameters a and b. 
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The Clopper-Pearson confidence intervals (95%) for each of the 660 measures 
and for each HB (and overall) are presented separately in MS Excel tables 
described in Section 7.4. 
 
6.5.9. Quality of Clopper-Pearson intervals 
Clopper-Pearson confidence intervals guarantee an actual coverage that is at least 
as high as nominal coverage, i.e. a 95% confidence intervals covers the population 
rate with a probability larger than 95 percent.  Clopper-Pearson intervals can show 
substantially higher coverage than the nominal coverage.  However, the problem of 
over-coverage is less severe for large samples as the actual coverage approximates 
the nominal coverage with increasing n (Agresti, 2003).  The results of one simulation 
study are particularly relevant for drug prevalence surveys because the study 
examines combinations of k and n how they are typically found in the drug 
prevalence surveys (Tobi et al., 2005).  This study recommended the Clopper-
Pearson procedure and showed that they generate confidence intervals that have 
higher coverage but are not wider than the highly-regarded Wilson score method 
(see below; Tobi et al., 2005). 
6.6. Identification of significant differences in the point 
estimates between 2006/07 and 2010/11 
6.6.1. Description of Results 
A separate MS Excel table presents the results for the usage rates of each drug type 
* Demographic sub-group * Prevalence level for each HB and overall of the current 
population survey (2010/11) and the two previous population surveys (2006/07 and 
2002/03) , presenting measures of the extent of the level of significance.  More 
precisely, the measure of the changes over time, along with the 95% CI around this 
are computed and presented.  Where the full extent of the CI falls to one side of the 
“zero difference” point, then one may conclude that there is sufficient evidence for a 
change in usage levels between the surveys and the null hypothesis of thee being no 
difference may be rejected.  Where the CI cuts the zero point, then one may 
conclude there is insufficient evidence to demonstrate a change in usage levels 
amongst the population. 
Technical Report – General Population Survey on Drug Prevalence 2010/2011 
57 
10-000957               December2011 
Note that 2006/07 v 2010/11 and 2002/03 v 2010/11 comparisons have been made 
both at the national (ROI) level and for each Health Board.  The 2006/07 data had 
been presented / tabulated with ERHA split into three sub-areas.  In making the 
comparison for ERHA across the two years, we collapsed the three ERHA sub-areas 
into a single overall one for 2006/07, calculating a weighted (by the actual sample 
size) average of drug usage rates. 
6.6.2. Confidence Intervals for difference between independent proportions: 
Wald 
For the difference between rates, the standard method is again a Wald procedure 
(Wald confidence intervals for differences between proportions of independent 
samples). The limits of the Wald confidence intervals are given by:  
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where p1 hat and p2 hat are the proportions observed in the first and the second 
sample and n1 and n2 the respective sample sizes.  
6.6.3. Quality of Wald intervals for difference between proportions 
For differences between rates, the Wald procedure shows similar coverage and 
overshooting problems as the Wald procedure for single proportions (Newcombe, 
1998; Agresti and Coull, 2001).  The performance of Wald is particularly problematic 
if either p1 or p2 approaches 0, conditions frequently met in the drug surveys. 
6.6.4. Confidence Intervals for difference between independent proportions: 
Newcombe’s hybrid score method 
Exact confidence intervals for the difference between proportions of independent 
samples (analogous to the Clopper-Pearson procedure for single proportions) are 
very difficult to compute.  Therefore, Newcombe (1998) developed a ‘hybrid score 
method’ that is easier to compute than exact methods but avoids the pitfalls of the 
Wald method.  
Newcombe hybrid score method is based on Wilson’s score method (Wilson, 1927) 
for single proportion.  Wilson score method derives a midpoint for the confidence 
intervals as a weighted average of the sample proportion and .5 (with the sample 
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proportion gaining greater weight as the sample size rise).  Further, the weighted 
average of the variance of the observed sample proportion and the variance of a 
proportion of .5 is used instead of the variance of the sample proportion as estimate 
of the sampling variation. 
The Wilson score method derives the following confidence interval for the proportion 
estimate of samples with the following two roots providing the upper and lower 100(1-
α)% confidence limits for π (the population score). 
 
 
 
 
 
  
 
 
 
For two samples 1 and 2 with p1 hat > p2 hat, the Newcombe hybrid score confidence 
interval for the difference between the proportion is derived from the lower and upper 
limits of the Wilson score intervals for single proportions: 
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6.6.5. Quality of Newcombe hybrid score intervals 
In several studies of the coverage qualities of confidence intervals for the difference 
between proportions, Newcombe hybrid score method belonged to the best-
performing methods (while Wald was always the poorest performing method). 
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6.7. Calculation of the Rates, Design Effects and (Effective) 
bases for the All-Island Data 
In this section, we describe the approach used to generate a set of results that cover 
the All-Island Data. 
 
Owing to the fact that differences exist between the sampling methodology for the 
two countries (i.e. Northern Ireland – NI and the Republic of Ireland - ROI), the 
summary results11 were calculated indirectly from the separate summary results from 
each separate country. 
 
A certain amount of preliminary data manipulation work (in SAS) was carried out in 
order to generate identically-structured and formatted files (one file for each separate 
country), which contained their own summary results listed by the three result levels, 
i.e.: 
 
• Prevalence (3); 
• Sub-sample (10). 
• Drug (20 levels common to both surveys); 
 
These two files were merged together as linked by the above common variables and 
an All-Island (All_I) set of summary results calculated.  The calculations were carried 
out as follows: 
 
• The “realistic” effective base for each country was established (this is the 
effective base, which when the individual country DE is less than 1.0, is set as 
being equivalent to the actual base – ie not allowing the effective base to 
exceed the actual base); 
 
• The All_I effective base is the sum of the individual country “realistic” effective 
bases; 
 
• The All_I rate is the average of the individual country rates, weighted 
according to their relative survey populations (i.e. adults aged 15-64).  
                                            
11 Rates, Design Effects and (Effective) bases 
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According to the 2010 Census-based estimates, 28.23% of the All Island 
Survey population are residents of NI, with the remainder residents of ROI. 
 
• The Clopper-Pearson Confidence Intervals for 2010/11 (see sections 6.5.8 
and 6.5.9 for further details) were applied at All Island level based on the 
above calculated effective bases and rates. 
 
• Changes in the rates between 2002 and 2010/11 between 2006/07 and 
2010/11 along with their statistical significances were calculated according to 
the Newcombe method (see section 6.6.4 for further details). 
 
• The overall Design Effect for 2010/11 was calculated by dividing the total of 
the actual bases for both countries by the sum of the effective bases12. 
 
                                            
12 In this particular case, the sum of the effective bases for each country, which was not 
limited to being less than or equal to the separate country actual base was used.  However, a 
second overall ROI DE was calculated, this time ensuring that the overall DE did not fall 
below 1.0. 
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Appendix A OJEC notice re Expression of Interest 
Expressions of Interest sought for Tender 
General Population Survey on Drug Prevalence Use 
 in Republic of Ireland in 2010-2011 
 
 
Background 
The National Advisory Committee on Drugs (NACD) was established in July 2000 to advise the Government 
in relation to the prevalence, prevention, treatment/ rehabilitation and consequences of problem drug use in 
Ireland, based on the analysis of research findings and information. The Committee oversees the delivery of a 
work programme on the extent, nature, causes and effects of drug use in Ireland. The Committee comprises 
representatives nominated from relevant agencies and sectors, both statutory and non-statutory. The 
Committee operates under the aegis of the Department of Community, Rural and Gaeltacht Affairs and 
reports to the Minister of State responsible for the National Drugs Strategy. Further information can be 
obtained from the NACD website www.nacd.ie. 
 
 
Commission 
The NACD commissioned Drug Prevalence Surveys to establish population prevalence of drug use in Ireland 
in 2002/2003 and in 2006/2007.  (Further information on these surveys can be obtained from www.nacd.ie). 
The NACD now wishes to commission a repeat of the 2006/2007 Drug Prevalence Survey.     The survey to 
be carried out in 2010/2011 will be broadly similar to the survey carried out in 2006/2007, but will contain 
additional questions designed to estimate the prevalence of alcohol and cannabis dependence in the general 
population. 
 
It is intended that the Drug Prevalence Study fieldwork will be carried out from September 2010 to April 2011.   
The data will then be cleaned and validated with a view to submission to the NACD by 30th of June 2011. 
Preliminary analysis will be undertaken in the months following, culminating in the publication of the first 
Bulletin on national prevalence figures and trends in December 2011.   
The contractor will be required to follow the relevant guidelines published by the European Monitoring Centre 
for Drugs and Drug Addiction (www.emcdda.org) and to achieve a minimum population sample of 5,000 in the 
Republic of Ireland.  The primary sampling frame will be the An Post/Ordnance Survey Ireland Geo-directory.  
The survey questionnaire will be provided to the successful contractor(s). 
 
Contracts awarded will give complete ownership of all data (including electronic and manual files) to the 
NACD and provide for the return of the data by electronic form in SPSS “.sav” format to the NACD.  
Contractors will be expected to comply with the DATA Protection Act 1988 (as amended) and with the 
European Communities (Data Protection) Regulations 2001.  The contract will be governed by the laws of 
Ireland. Under the terms of appointment, subcontracting of the services will not be permitted. 
 
Expressions of Interest 
In accordance with the EU Directive 2004/18/EC, Article 28 and 29 expressions of interest are invited for the 
undertaking of the Drug Prevalence Study fieldwork (September 2010 to April 2011) and analysis, subject to 
receipt by the NACD of ethical approval for the Study.   Persons wishing to tender for this contract should 
submit an expression of interest to the address below.  
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Potential contractors should demonstrate in their expression of interest that they have: 
 
• Capacity to carry out Computer Assisted Personal Interviewing (CAPI) 
• Capacity to prepare CAPI interview programme immediately on award of contract 
• Ability to prepare, clean and validate very large SPSS data files 
• Sufficient intellectual capacity with adequate and suitably qualified staff to successfully undertake the 
project 
• Have a track record in this field (large scale social CAPI based research projects).   
• Have high level of quality control and quality assurance to research standards, including stringent 
fieldwork management procedures (please enclose a description), and 
• Have adequate financial standing.  
 
Based on short-listing against the above criteria, the NACD intend to invite five to seven contractors to submit 
a tender at the next stage.  
 
Expressions of interest should be sent to the NACD offices together with  2 copies of recent financial 
accounts, example of previous relevant work (2 copies), track record, and evidence of capacity (human and 
technical) to undertake the work, no later than 15.00, Wednesday 20th, January 2010.  
 
 
Please mark your envelope Ten/popsurvey10/11. 
 
Invitations to tender will be dispatched to selected candidates on Wednesday, 27th January 2010.  
 
Note that applicants must provide information regarding the experience, qualifications, capacity etc of all those 
they propose to be involved in the carrying out of the services.  
 
The Secretary 
NACD 
1st Floor 
Dún Aimhirgin 
43-49 Mespil Road 
Dublin 4 
Ireland 
 
Tel: 00 353 1 647 3240;  
Fax 00 353 1 647 3150; 
 
Email: info@nacd.ie; Web: www.nacd.ie  
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Appendix B Tender Brief 
Tender NACD Drug Prevalence Survey 2010-2011 – Ireland.  
 
Background 
 
The National Advisory Committee on Drugs (NACD) was established in July 2000 to advise the 
Government in relation to the prevalence, prevention, treatment/ rehabilitation and consequences of 
problem drug use in Ireland, based on the analysis of research findings and information. The 
Committee oversees the delivery of a work programme on the extent, nature, causes and effects of 
drug use in Ireland. The Committee comprises representatives nominated from relevant agencies 
and sectors, both statutory and non-statutory. The Committee operates under the aegis of the 
Department of Community, Rural and Gaeltacht Affairs and reports to the Minister of State 
responsible for the National Drugs Strategy. Further information can be obtained from the NACD 
website www.nacd.ie. 
 
In Ireland, the measurement of the extent and nature of drug use in the general population is one of 
the priorities in relation to research and information under the National Drugs Strategy (interim) 
2009-2016. See Chapter 5 of the Strategy on 
http://www.pobail.ie/en/OfficeoftheMinisterforDrugs/file,10108,en.pdf.      As the prevalence and 
patterns of drug use in the general population is one of the key five indicators produced by the 
EMCDDA13 (http://www.emcdda.europa.eu  ) and adopted by EU Member States, it is imperative 
that reliable and comparable data is obtained in this regard.   
 
Commission 
The NACD commissioned Drug Prevalence Surveys to establish population prevalence of drug use 
in Ireland in 2002/2003 and in 2006/2007. (Further information on these surveys can be obtained 
from www.nacd.ie). The NACD now wishes to commission a repeat of the 2006/2007 Drug 
Prevalence Survey for Ireland only. The survey to be carried out in 2010/2011 will be broadly similar 
to the survey carried out in 2006/2007, but will contain additional questions designed to estimate the 
prevalence of alcohol and cannabis dependence in the general population. In addition, three new 
questions have been added to obtain information on the use of psychoactive substances sold in 
‘Headshops’ and other outlets.  
 
The Brief 
It is essential that the Drug Prevalence Study fieldwork be carried out from September 2010 to April 
2011.  The data will then be cleaned and validated with a view to submission to the NACD by 30th of 
June 2011. Preliminary analysis will be undertaken in the months following with a view to the 
production of a first report of national prevalence figures and trends by the NACD in December 
2011.  This will enable the NACD to make comparisons with  previous surveys, identify trends in 
drug use nationally, across regions and the EU thus meeting commitments to provide the 
Government and the EMCDDA with the relevant population prevalence information.  The proposed 
survey will be carried out using a pre-prepared questionnaire (draft attached on a confidential basis) 
and computer assisted face-to-face interviews (preferred method under EMCDDA guidelines) 
among those aged 15–64 years.  Information on lifetime use, last year and last month use will be 
just some of the issues explored.   
 
The survey is based on the guidelines produced by the EMCDDA which state as the main aims: 
 
                                            
13 EMCDDA the European Monitoring Centre for Drugs and Drug Addiction 
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(1) To report prevalence and continuation rates of the most common illicit drugs in the 
general population by gender and age groups; 
 
(2) To allow cross country assessment of relationships between general patterns of use of 
illicit and licit drugs; 
 
(3) To allow the assessment of relationships between particular population attributes and the 
use of illicit drugs. 
 
 
Potential bidders should refer to the EMCDDA guidelines (www.emcdda.europa.eu ) on conducting 
population surveys in relation to drug use and to the Technical Report on the 2006-2007 Drug 
Prevalence Survey published on the web 
(http://www.nacd.ie/publications/prevalence_DPS_Tech_Report.html ) for further information on 
how the survey should be conducted. 
 
The contractor will be required to achieve a population sample of 5,000 in Ireland. The preferred 
sampling frame will be using the An Post Geo-directory in Ireland.   
 
Copyright will rest with the NACD. The Contract awarded will give complete ownership of all data 
(including electronic and manual files) to the NACD and provide for the return of the data by 
electronic form in SPSS “.sav” format to the NACD.  Contractors will be expected to comply with the 
Data Protection Act 1988 (as amended) and with the European Communities (Data Protection) 
Regulations 2001.  The contract will be governed by the laws of Ireland. Under the terms of 
appointment, subcontracting of the services will not be permitted. 
 
REQUIREMENTS 
Potential contractors should demonstrate the following in their tender submission: 
 
1. Capacity -  
• Capacity to carry out Computer-assisted Personal Interviewing (CAPI) in Ireland 
• Capacity to prepare CAPI interview programme immediately on award of contract 
• Ability to prepare, clean and validate very large SPSS data files and  demonstrate 
familiarity with SPSS software 
• Sufficient intellectual capacity with adequate and suitably qualified staff to successfully 
undertake the project 
• Have a track record in this field (large scale social CAPI based research projects) 
• Have high level of quality control and quality assurance to research standards, including 
stringent fieldwork management procedures (please enclose a description). 
 
2. Survey mode - 
The population survey will be conducted by face-to-face interview and participants will be 
interviewed on use of all drug types to include alcohol, tobacco, prescribed medicines and illicit 
drugs (see Bulletin 2 from the 2006/2007 Drug Prevalence Survey to see full range of drugs 
reported on in tables one and seven).   
 
The surveys to be carried out in 2010/2011 will be broadly similar to the survey carried out in 
2006/2007, but will contain additional questions designed to estimate the prevalence of alcohol and 
cannabis dependence in the general population. We require a random order approach to the 
administration of the cannabis dependence questions (186-190 SDS questions) versus (191-192 – 
CIDI questions). Three new questions has been added to obtain information on the use of 
psychoactive substances sold in ‘head-shops’ and other outlets.  
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It is anticipated that only 30% of respondents will need to answer the detailed smoking questions, 
80%  the detailed alcohol questions, 20% the detailed cannabis questions, 5% the detailed cocaine 
and ecstasy questions and so on.   Only a very small proportion of respondents will need to answer 
all questions.  The time range would be between 10 to 35 minutes depending on the number of 
questions the respondent will be required to answer.  (See draft questionnaire attached on a 
confidential basis). 
 
3. Sampling frame - 
The sample population to be surveyed will be the 15-64 age group and resident in households.  
Information on lifetime use, last year use and last month use is required. We expect at minimum a 
70% response rate including vacant houses. Non-contacts and refusals must be dealt with as per 
EMCDDA guidelines (see technical report also).  Tenderers are expected to describe the sampling 
design appropriate to this survey and what mechanisms would be used to include interviews with 
difficult to reach age groups in the tender submission.  The sample profile should reflect the 
population profile. 
    
4. Fieldwork Management - 
Tenderers are expected to document how the fieldwork will be managed and supervised.  Any 
variations in how fieldwork is managed, interviewers are recruited and trained should be stated in 
the tender and how this might impact on the study.  In particular, the controls to be put in place for 
data protection; how files will be transferred from CAPI instruments to a central database and what 
procedures are in place to protect the anonymity of the study participants so their responses are not 
known to anyone outside of the study.   
 
Ethical approval has been obtained for the study from the Royal College of Physicians of Ireland 
Faculty of Public Health Medicine and Faculty of Occupational Medicine Research Ethics 
Committee. Therefore, the contractor will be required to adhere to the procedures set out in the 
Study Protocol (see Research Activities on the NACD website 
(http://www.nacd.ie/activities/repeat2010_2011.html ) in relation to securing the informed consent of 
respondents.   
 
5. Data Protection -  
Tenderers must comply with Data Protection legislation.  The successful bidder will be expected to 
demonstrate steps they will take to protect and store the data from corruption, infiltration and 
technical damage. 
 
6. Data Analysis- 
Once the data has been collected a comprehensive analysis must be carried out.  The substantive 
report will include an analysis by drug, by age and by gender in the first instance, then by age, 
gender and by Regional Drug Task Force area.  We expect trends to be presented in the tables 
providing comparisons with the 2002/2003 and 2006/2007 survey.   The previous surveys will be 
provided to the contractor in SPSS format.   Please refer to published Bulletins for further 
information.   
 
The contractor will also be required to: 
- carry out weighting of data by age, gender and Regional Drug Task Force Areas and these 
weights will be required to be detailed in the Technical Report; 
- run the tables for the first bulletin of national prevalence figures and trends and the second 
bulletin on trends by Regional Drug Task Force area; 
- calculate 95% design effect adjusted  confidence intervals for each drug by age, gender, 
region of residence and time period and run the tables for the confidence intervals.  
 
As the survey is being conducted simultaneously in  Ireland and Northern Ireland (on behalf of the 
Public Health Information and Research Branch (PHIRB), at the Department of Health, Social 
Services and Public Safety), careful consultation is required to ensure comparisons can be made 
between both sets of results.    In this context, the contractor will be required to merge data from a 
comparable dataset from Northern Ireland to provide all island and North South comparable figures.  
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Any issues which could impact on this process of merging data should be identified in the tender. 
Please note that this tender refers only to the survey to be conducted in Ireland. 
 
7. Cost 
The tenderer must set out  details of costs and justification for the costs of implementing this study 
in Ireland with regard to the specified requirements outlined in the tender brief.    
 
 
8. Duration of Project 
The successful contractor will be expected to be in a position to commence work no later than 6th 
April 2010 and to complete the project no later than 1st December 2011 to enable the production of 
a first report of national prevalence figures and trends by the NACD in December 2011.    A liaison 
schedule will be agreed as part of the contract. 
 
 
EVALUATION OF THE SUBMISSIONS WILL BE BASED ON THE FOLLOWING CRITERIA: 
 
Research methodology 
Understanding of the project 
Understanding of the work involved 
Feasibility of the approach suggested 
 
Project management 
Ability to deliver key outputs on time 
Clarity in description of milestones 
Qualifications and capacity of personnel 
Track Record 
 
Value for Money 
A full and detailed breakdown of fees and costs (excluding VAT) is required. Tenderers should 
indicate the estimated number of person/days for completing the work.   
 
The NACD reserves the right to reject any or all of the proposals submitted and will not be obliged 
to accept the lowest or any tender. 
 
RESEARCH ADVISORY GROUP  
 
A Research Advisory Group comprising representatives from the NACD and other experts, will be 
appointed to oversee the project and the successful bidder will work closely with the Research 
Advisory Group.  The Research Advisory Group will expect to have some involvement when 
fieldworkers are briefed on their tasks and targets and during the pilot-testing phase.  Progress 
reports will have to be provided to the Research Advisory Group at various stages of the project 
during the early implementation phase pre and post pilot, post interviewer briefings and every four 
weeks of the fieldwork phase confirming that the project is on track.  The successful bidder will be 
expected to flag any potential difficulties or problems early to the Research Advisory Group so that 
a quick resolution can be achieved. 
 
TECHNICAL REPORT 
 
The successful bidder will provide a detailed technical report to the Research Advisory Group on 
completion of the fieldwork and before the analysis begins.   Following completion of analysis, 
technical details must be added to the report such as the number and types of checks controls and 
cross validation of the data in cleaning and preparing it for analysis.  Syntax for check programmes 
should be provided to the Research Advisory Group.  These controls must be applied to the data 
when it is in SPSS and not in some other software database to eliminate the risk of missing errors.  
The Research Advisory Group will also carry out cross checks on the data when it is provided in 
SPSS.  
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FINANCIAL REPORT 
 
A separate complete financial report for the project on completion will be required before final 
payment is made to the contractor.   
 
NACD CONTRACT 
 
A copy of the NACD contract is attached for your information. 
 
 
CLOSING DATE FOR SUBMISSION 
 
Six copies of the tender together with a signed Freedom of Information Declaration (form attached) 
and an up-to-date Tax Clearance Certificate should be sent to the NACD offices together with two 
copies of an example of previous relevant work and include a short CV of those leading and 
managing this study no later than 15.00, 3rd March 2010.  Short listing may take place.  Interviews 
if required will take place on Thursday, 11th March 2010. 
 
 
Tenders will not be accepted by email. 
 
Please mark your envelope Ten-popsurvey10/11.   
 
The Secretary 
NACD 
1st Floor, 
Dún Aimhirgin 
43-49 Mespil Road   
Dublin 4 
Ireland 
 
Tel: 00 353 1 647 3240  
Fax 00 353 1 647 3150 
Email: info@nacd.ie; Web: www.nacd.ie  
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Appendix C About Ipsos MORI 
 
The Ireland operation of Ipsos MORI was founded in 1987. It provides a full range of qualitative and 
quantitative research services, the latter using face-to-face, telephone, self-completion and web-
based methodologies.  
Ipsos MORI embraces both traditional and technologically advanced research methods, which 
means that it can design the research programme that best meets a client's research objectives.  
As part of the Ipsos MORI Group, we have access to a huge amount of specialist expertise and 
technical support, which ensures we can provide the best service possible to our clients. 
Ipsos MORI has an extensive and varied client base, incorporating public sector organisations and 
blue-chip private sector companies.  
As indicated in the next section, Ipsos MORI offers the highest quality research services throughout 
Ireland, and is the only market research agency accredited with ISO 9001 and ISO 20252 and 
providing fieldwork to IQCS standards throughout Ireland in both telephone and face-to-face 
interviewing. 
In addition, Ipsos MORI has its own auditing and quality team, including our own Customer Service 
Monitor which provides feedback from our clients on the standard and quality of service we provide.  
Ipsos MORI directors and executive/field staff are members of the Market Research Society, and 
are therefore subject to the requirements of the Market Research Society (MRS) Code of Conduct. 
This assures all respondents that the information gathered during the course of an interview is 
confidential and that their opinions and views would remain anonymous. 
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Appendix D Quality standards in fieldwork 
Quality is at the heart of the Ipsos MORI business model and we believe it is critical to the accurate 
and successful completion of all our research projects. 
As the population survey was dealt with completely in-house by Ipsos MORI staff, it ensured quality 
and accuracy at all stages of the research process – from CAPI set-up through the interviewing 
process to the reporting stage.  As the survey results come under external scrutiny and feed into 
policy decisions, it was essential that quality assurances were in place to counteract any 
questioning of the data or the research process and to provide the necessary reassurance in terms 
of its validity.   
Detailed below is the Ipsos MORI commitment to quality control and the practical implications it has 
on the work practices in place within the company. 
Commitment to Quality and Quality Control 
 In 2005 we were the first market research company to sign our organisation up to the rigours 
of the Market Research Society (MRS) Code. With the increasing importance of self-
regulation, we wanted to be at the forefront of supporting the ethics and quality of our industry 
by applying the industry's professional Code to our entire organisation including all our 
interviewers. Previous to this, the Code applied solely to individuals who are members. There 
are now over 300 MRS company partners who have followed our lead.  
 Our quality system has been accredited to ISO 9001 for many years. In 2006 we were the first 
company in the world to achieve the new ISO 20252, the new international process standard 
which replaces MRQSA/BS7911. This standard sets out minimum standards for each stage of 
a market research project and is designed to enable accredited companies to provide a 
superior service to their clients. Reflecting this, we upgraded our 'Quality Excellence System' 
in 2007 which has helped us to pass a series of inspections with flying colours. 
 In 2008 we became the first UK agency to be awarded ISO 27001 which is the international 
standard for information security (we were setting up our systems before the series of high 
profile data losses during 2008). 
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Quality: how we are different 
While virtually all agencies are able to show some quality accreditations, five things differentiate us 
from many other agencies: 
• the extent to which our quality systems go beyond the minimum, meaning that we can 
guarantee ‘true’ quality to our clients; 
• the size, know-how and motivation of our field force which means that we can maximise 
response rates and ensure that what we do reflects well on our clients;  
• the experience we have in reaching ‘hard to reach’ groups either within general survey projects 
or as specific projects in their own right, and also in employing sophisticated data collection 
and sampling methods; 
• the way in which we challenge our own data using validation systems, and data trend analysis 
tools; 
• the systems we have in place to ensure that survey data is collected, used and stored 
securely. 
Face-to-face fieldwork quality 
All interviewing on this project was carried out by members of the Ipsos MORI Interviewer Panel.  
Our interviewers work in accordance with the ISO 20252 system which incorporates much of the 
Interviewer Quality Control Scheme (IQCS) and the old MRQSA/BS7911. We regard these 
standards as minimum requirements, not as goals in their own right. This is because our work with 
other research agencies has convinced us that compliance is not a guarantee of quality. In several 
key aspects of fieldwork, we think it necessary to go beyond the minimum as we explain in the table 
below in answers to some key questions we often get asked by clients about face-to-face 
interviewing: 
How many 
interviewers will be 
involved? 
Too many questionnaires allocated to one interviewer can result in 
poor quality data in a high percentage of the fieldwork. For any survey, 
Ipsos MORI restricts interviewers to 10% maximum of the sample. 
There is no ISO 20252 requirement for this. 
What training  
do your interviewers 
have? 
ISO 20252 requires only 6 hours training for new interviewers.  We 
give a minimum of 12-22 hours training (12 in the classroom). This 
ensures that our interviewers are trained to high standards and 
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lessens the chance of interviewer bias affecting results. 
If an interviewer works on more than five jobs a year they will be 
appraised or accompanied at least once a year by an experienced 
Supervisor/Senior interviewer. All work by a new interviewer is 
checked for their first three jobs. 
What back-checking 
takes place? 
Telephone or written validations are made on a minimum of 10% of 
interviews for all of our surveys (i.e. respondents are called back by 
one of our team of Validators). As well as checking the interviewer’s 
conduct, we ask survey-specific questions. Where there is doubt over 
interview(er) quality, validations are carried out in person by an Ipsos 
MORI representative. By contrast, some companies conduct all of 
their validations by post, which yields very low response rates, and 
many do not ask survey-specific questions.  
How is recruitment 
done? 
References are taken up for all interviewers. Criminal Records Bureau 
checks are also taken up where appropriate. All interviewers sign a 
Data Protection Act and confidentiality statement when they join. 
Who do you use for 
interviewing? 
Unlike some agencies, Ipsos MORI does not parachute groups of 
students or others into areas they do not know. We have around 250 
interviewers in Ireland and over half of our field force work for us 
exclusively – unlike smaller research companies whose interviewers 
will work for multiple agencies. 
Our dedicated and large field force puts us in a privileged position and 
means that we have locally based interviewers who have a detailed 
knowledge of the local area and local sensitivities. Because we do not 
sub-contract our fieldwork we can ensure that our quality standards 
are observed consistently at every stage of fieldwork. 
What support do you 
give interviewers? 
Our field force structure in Ireland includes a Region Manager and 
three Region Co-ordinators who are full-time, working solely for us. 
They are supported by a network of Supervisors, and interviewer 
mentors.  
We operate a buddy system for all new interviewers so that they 
receive additional support while they gain experience. This takes the 
form of coaching in the field (so watching other interviewers work) and 
regular telephone calls to check progress and give advice. All 
interviewers are briefed in writing for all surveys. For complex surveys, 
interviewers are briefed face-to-face by a research director. 
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Given the importance of these issues, and to facilitate regular surveillance visits carried out by 
external bodies in connection with ISO, we have our own established auditing and quality teams 
which have board representation. With the help of feedback from our clients, respondents and 
interviewers, the teams continuously monitor the quality of service we provide.  
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Appendix E Questionnaire 
 
 
 
UNIQUE 
ADDRESS CODE 
    SAMPLE POINT 
NUMBER 
     
 
 
 
 
 
 
 
 
Republic of Ireland 
 
POPULATION STUDY 
 
 
2010 
 
10-000957 
 
 
FINAL Version – 04-10-2010 
 
 
INTERNAL USE ONLY 
 
 
Technical Report – General Population Survey on Drug Prevalence 2010/2011 
 
10-000957 December 2011 
POPULATION STUDY 
INTRODUCTION 
Good morning/afternoon/evening. My name is .......... We are conducting a study today about 
lifestyles such as alcohol, tobacco and drugs, and I’d like to ask you some questions. The interview 
will last approximately 25 minutes. 
 
IF ASKED: This study is being conducted on behalf of the Department of Community, 
Equality and Gaeltacht Affairs and the National Advisory Committee on Drugs in the 
Republic of Ireland. 
IF UNSURE/CONCERNED ABOUT CONFIDENTIALITY STATE: 
We would like to stress that all information you give in the questionnaire will be treated 
confidentially.  No information about you as an individual, including your name and address, 
will be passed on to anyone outside this research study.  All the details collected are purely 
for the purpose of research and the information is used purely for statistical purposes. 
Tobacco 
First of all I’m going to ask a few questions about tobacco. 
Q1 Do you smoke tobacco products, such as 
cigarettes, cigars or a pipe? 
Yes 1 GO TO Q.3 
 No 2  
CONTINUE   Don’t know X 
  Refused Y 
 
Q2 Have you ever smoked tobacco products in 
the past? 
Yes 1 CONTINUE 
 No 2 
GO TO Q10   Don’t know X 
  Refused Y 
 
Q3 At what age did you smoke tobacco products 
for the first time? 
 
 
 
  INSERT 
AGE 
 Don’t know X 
  Refused Y  
 
Q4 During the last 12 months have you smoked 
tobacco products? 
Yes 1 CONTINUE 
 No 2  
GO TO Q10   Don’t know X 
  Refused Y 
 
Q5 During the last 30 days have you smoked 
tobacco products? 
Yes 1 CONTINUE 
 No 2  
GO TO Q10   Don’t know X 
  Refused Y 
 
Q6 During the last 30 days on how many days 
have you smoked? 
 
 
  INSERT 
FIGURE 
 Don’t know X 
  Refused Y  
 
Q7 What type of tobacco product do 
you most commonly use? 
READ OUT – CODE ONE ONLY 
Branded cigarettes 1 
CONTINUE 
 Hand rolled cigarettes 2 
 Cigars 3 
GO TO Q10 
 Pipe 4 
  Don’t know X 
  Refused Y 
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Q8 During the last 30 days 
how many cigarettes have 
you smoked on an 
average day?  
READ OUT 
Less than 5 cigarettes per week  1  
 Less than 1 cigarette per day 2  
 1-5 cigarettes per day  3 
  6-10 cigarettes per day 4 
 11-20 cigarettes per day 5 
 More than 20 cigarettes per day  6  
  Don’t know X  
  Refused Y  
 
Alcohol 
Now I’m going to ask a few questions about alcohol. 
 
Question 9 removed 
 
 
Q10 Have you ever drunk alcohol? 
 
Yes 1 CONTINUE 
 No 2 
GO TO Q16   Don’t know X 
  Refused Y 
 
If yes to ‘10’ ask 
 
Q11a At what age did you first drink alcohol ‘beyond 
sips or tastes’? 
 
 
  INSERT 
AGE 
 Don’t know X 
  Refused Y  
 
If yes to ‘10’ ask  
 
Q11b How often have you 
consumed alcohol in the last 
12 months?  
Daily 1 
CONTINUE 
 4/5 times a week 2 
 2/3 times a week 3 
 Once a week 4 
 2-3 times a month 5 
 Once a month 6 
 Less often than once a month 7 
  Never 8 
GO TO Q16   Don’t know X 
  Refused Y 
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SHOW CARD 11c 
   INSERT   
FIGURE  
 
 
A standard drink 
is (SHOW CARD with pictures depicting measures): 
• A half pint or a glass of beer, lager or cider 
• A single measure of spirits, for example, whiskey, vodka, gin 
• A small glass of wine (100ml) 
• A bottle of alcopops (275ml long neck standard bottle) 
• A small can/bottle of beer, lager or cider (330 ml) 
 
 
 
Ask everyone who has consumed alcohol in the past 12 months 
SHOW CARD 11D & 11D2 
Q11d During the last 12 months, how 
often have you consumed (drunk) 
the equivalent of 4 pints of 
beer/cider or more or 7 pub 
measures of spirits or one bottle 
of wine or 6 pre-mixed spirit drinks 
(alcopops) on one drinking 
occasion?   
READ OUT & (SHOW CARD with 
these amounts) 
Daily 1 
 4/5 times a week 2 
 2/3 times a week 3 
 Once a week 4 
 2/3 times a month 5 
 Once a month 6 
 Less often than once a month 7 
 Never 8 
 Don’t know X 
 Refused Y 
 
Questions 12 to 15 removed 
 
 
Now I’m going to ask a few questions about drugs that are sometimes used as medicines. 
 
SHOW CARD 16 
Q16 Have you ever heard of any of these 
…………..? SHOW CARD, IF YES TO ANY 
LISTED ON CARD CODE YES AND 
CONTINUE 
Yes 1 CONTINUE 
 No 2 
GO TO Q25  Don’t know X 
 Refused Y 
    
 
Show card 16 again. 
Interviewer to read out: 
“All of the drugs listed on this card are names for sedatives or tranquilisers”. 
Q17 Do you personally know people who take 
sedatives or tranquillisers? 
Yes 1  
 No 2  
  Don’t know X  
  Refused Y  
 
Q11c During the last 12 months, how many 
standard drinks containing alcohol have you 
drunk on a typical day when you were 
drinking? 
 
 
 Don’t know X 
 Refused Y 
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Q18 Have you ever taken sedatives or 
tranquillisers? 
Yes 1 CONTINUE 
 No 2 
GO TO Q25   Don’t know X 
  Refused Y 
 
Q19 At what age did you first take sedatives or 
tranquillisers? 
 
 
  INSERT 
AGE 
 Don’t know X 
 (Lower age limit set to 0) Refused Y  
 
Q20 During the last 12 months have you taken 
sedatives or tranquillisers? 
Yes 1 CONTINUE 
 No 2 
GO TO Q25   Don’t know X 
  Refused Y 
 
Q21 During the last 30 days have you taken 
sedatives or tranquillisers? 
Yes 1 CONTINUE 
 No 2 
GO TO Q25   Don’t know X 
  Refused Y 
 
Q22 During the last 30 days, on how many days 
have you taken sedatives or tranquillisers? 
 
 
  INSERT 
FIGURE 
 Don’t know X 
  Refused Y  
 
SHOW CARD 23 
Q23 What method do you most commonly use to take 
sedatives or tranquillisers? 
Just call me out the number from the card 
CODE ONE ONLY 
Oral (Tablets or Syrup) 1 
 Injection with a needle 2 
 Other (specify) 
___________________ 
3 
 Don’t know X 
  Refused Y 
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SHOW CARD 24 
Q24 On the last occasion you 
took sedatives or 
tranquillisers how had you 
obtained them? 
Just call me out the 
number from the card 
CODE ONE ONLY 
I got them on a prescription 1 
I got them from someone I know 2 
I bought them without a prescription in a chemist 3 
I bought them over the internet 4 
Other (specify) 
 
5 
 Don’t know X 
 Refused Y 
 
SHOW CARD 25 
Q25 Have you ever heard of any of these 
…………..? SHOW CARD, IF YES TO ANY 
LISTED ON CARD CODE YES AND 
CONTINUE 
Yes 1 CONTINUE 
 No 2 
GO TO Q34  Don’t know X 
 Refused Y 
 
Show card 25 again. 
Interviewer to read out: 
“All of the drugs listed on this card are names for anti-depressants”. 
Q26 Do you personally know people who take anti-
depressants? 
Yes 1  
 No 2  
  Don’t know X  
  Refused Y  
 
Q27 Have you ever taken anti-depressants? Yes 1 CONTINUE 
 No 2 
GO TO Q34   Don’t know X 
  Refused Y 
 
Q28 At what age did you first take anti-
depressants? 
 
 
  INSERT 
AGE 
 Don’t know X 
  Refused Y  
 
Q29 During the last 12 months have you taken 
anti-depressants? 
Yes 1 CONTINUE 
 No 2 
GO TO Q34   Don’t know X 
  Refused Y 
 
Q30 During the last 30 days have you taken anti-
depressants? 
Yes 1 CONTINUE 
 No 2 
GO TO Q34   Don’t know X 
  Refused Y 
 
 
Q31 During the last 30 days, on how many days 
have you taken anti-depressants? 
 
 
  INSERT 
FIGURE 
 Don’t know X 
  Refused Y  
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SHOW CARD 32 
Q32 What method do you most 
commonly use to take anti-
depressants? 
Just call me out the number from 
the card CODE ONE ONLY 
Oral (Tablets or Syrup) 1  
Injection with a needle 2 
 
Other (specify) ___________ 3 
 Don’t know X  
 Refused Y  
 
SHOW CARD 33 
Q33 On the last occasion you 
took anti-depressants how 
had you obtained them? 
Just call me out the number 
from the card 
CODE ONE ONLY 
I got them on a prescription 1  
I got them from someone I know 2 
 I bought them without a prescription in 
a chemist 
3 
I bought them over the internet 4  
Other (specify)  5  
  Don’t know X  
  Refused Y  
 
Now I’m going to ask a few questions about other drugs. 
 
SHOW CARD 34 
Q34 Have you ever heard of any of these 
…………..? SHOW CARD, IF YES TO ANY 
LISTED ON CARD CODE YES AND 
CONTINUE 
Yes 1 CONTINUE 
 No 2 
GO TO Q45  Don’t know X 
 Refused Y 
 
Show card 34 again. 
Interviewer to read out: 
“All of the drugs listed on this card are names for cannabis”. 
Q35 Do you personally know people who take 
cannabis? 
Yes 1  
 No 2  
  Don’t know X  
  Refused Y  
 
Q36 Have you ever taken cannabis? Yes 1 CONTINUE 
 No 2 
GO TO Q38   Don’t know X 
  Refused Y 
 
Q37 At what age did you first take cannabis?  
 
  INSERT 
AGE 
Don’t know X 
  Refused Y  
SHOW CARD 38 
Q38 How many times have you been 
offered cannabis either free of 
charge or to buy in the last 12 
months? Just call me out the 
number from the card - CODE 
ONE ONLY 
Never 1 
ALL WHO 
ANSWERED YES 
AT Q36 GO TO 
Q39.   
 Once or twice 2 
 3 to 5 times  3 
 6 to 9 times  4 
 10 to 19 times  5 
 20 times or more  6 
  Don’t know X 
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  Refused Y 
 
OTHERS GO TO 
Q45 
 
 
 
Q39 During the last 12 months have 
you taken cannabis? 
Yes 1 CONTINUE 
 No 2 
GO TO Q45   Don’t know X 
  Refused Y 
 
Q40 During the last 30 days have you taken 
cannabis? 
Yes 1 CONTINUE 
 No 2 
GO TO Q45   Don’t know X 
  Refused Y 
 
Q41 During the last 30 days, on how many days 
have you taken cannabis? 
 
 
  INSERT 
FIGURE 
 Don’t know X 
  Refused Y  
 
SHOW CARD 42 
Q42 What type of cannabis 
do you most 
commonly use?  
Just call me out the 
number from the 
card  
CODE ONE ONLY 
Grass 1 
CONTINUE Weed 2 
Skunk 3 
Hash Oil 4 GO TO Q44 
Herb 5 CONTINUE 
Hash 6 
GO TO Q44 
Resin  7 
Other (specify)________ 8 
Don’t know X 
  Refused Y 
  
Q43 Is it Irish grown?  
CODE ONE ONLY 
Yes 1  
No 2  
 Don’t know X  
  Refused Y  
 
SHOW CARD 44 
Q44 What method do you most commonly 
use to take cannabis? 
Just call me out the number from 
the card  
CODE ONE ONLY 
Joint 1  
 Pipe 2  
 Bong 3  
 Eat 4  
 Other (specify) 
________________
_ 
5 
 
 Don’t know X  
  Refused Y  
 
SHOW CARD 45 
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Q45 Have you ever heard of any of these 
…………..? SHOW CARD, IF YES TO 
ANY LISTED ON CARD CODE YES AND 
CONTINUE 
Yes 1 CONTINUE 
 No 2 
GO TO Q53  Don’t know X 
 Refused Y 
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Show card 45 again. 
Interviewer to read out: 
“All of the drugs listed on this card are names for ecstasy”. 
Q46 Do you personally know people who take 
ecstasy? 
Yes 1  
 No 2  
  Don’t know X  
  Refused Y  
 
Q47 Have you ever taken ecstasy? Yes 1 CONTINUE 
 No 2 
GO TO Q49   Don’t know X 
  Refused Y 
 
Q48 At what age did you first take ecstasy?  
 
  INSERT 
AGE 
 Don’t know X 
  Refused Y  
SHOW CARD 49 
Q49 How many times have you been 
offered ecstasy either free of 
charge or to buy in the last 12 
months? Just call me out the 
number from the card - CODE 
ONE ONLY 
Never 1 
ALL WHO 
ANSWERED YES 
AT Q47 GO TO 
Q50.  
 
ALL OTHERS GO 
TO Q53 
 
 Once or twice 2 
 3 to 5 times  3 
 6 to 9 times  4 
 10 to 19 times  5 
 20 times or more  6 
  Don’t know X 
  Refused Y 
 
Q50 During the last 12 months have you taken 
ecstasy? 
Yes 1 CONTINUE 
 No 2 
GO TO Q53   Don’t know X 
  Refused Y 
 
Q51 During the last 30 days have you taken 
ecstasy? 
Yes 1 CONTINUE 
 No 2 
GO TO Q53   Don’t know X 
  Refused Y 
 
Q52 During the last 30 days, on how many days 
have you taken ecstasy? 
   INSERT 
FIGURE 
 Don’t know X  
  Refused Y  
 
SHOW CARD 53 
Q53 Have you ever heard of any of these 
…………..? SHOW CARD, IF YES TO 
ANY LISTED ON CARD CODE YES AND 
CONTINUE 
Yes 1 CONTINUE 
 No 2 
GO TO Q62  Don’t know X 
 Refused Y 
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Show card 53 again. 
Interviewer to read out: 
“All of the drugs listed on this card are names for amphetamines”. 
Q54 Do you personally know people who take 
amphetamines? 
Yes 1  
 No 2  
 Don’t know X  
 Refused Y  
 
Q55 Have you ever taken amphetamines? Yes 1 CONTINUE 
 No 2 
GO TO Q57   Don’t know X 
  Refused Y 
 
Q56 At what age did you first take amphetamines?  
 
  INSERT 
AGE 
 Don’t know X 
  Refused Y  
SHOW CARD 57 
Q57 How many times have you been 
offered amphetamines either free 
of charge or to buy in the last 12 
months? Just call me out the 
number from the card - CODE 
ONE ONLY 
Never  1 
ALL WHO 
ANSWERED 
YES AT Q55 GO 
TO Q58. 
 
OTHERS GO TO 
Q62 
 
 Once or twice 2 
 3 to 5 times  3 
 6 to 9 times  4 
 10 to 19 times  5 
 20 times or more  6 
  Don’t know X 
  Refused Y 
 
Q58 During the last 12 months have you taken 
amphetamines? 
Yes 1 CONTINUE 
 No 2 
GO TO Q62   Don’t know X 
  Refused Y 
 
Q59 During the last 30 days have you taken 
amphetamines? 
Yes 1 CONTINUE 
 No 2 
GO TO Q62   Don’t know X 
  Refused Y 
 
Q60 During the last 30 days, on how many days 
have you taken amphetamines? 
 
 
  INSERT 
FIGURE 
 Don’t know X 
  Refused Y  
 
Question 61 removed 
 
SHOW CARD 62 
Q62 Have you ever heard of any of these 
…………..? SHOW CARD, IF YES TO ANY 
LISTED ON CARD CODE YES AND 
CONTINUE 
Yes 1 CONTINUE 
 No 2 
GO TO Q70  Don’t know X 
 Refused Y 
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Show card 62 again. 
Interviewer to read out: 
“All of the drugs listed on this card are names for crack”. 
Q63 Do you personally know people who take 
crack? 
Yes 1  
 No 2  
  Don’t know X  
  Refused Y  
 
Q64 Have you ever taken crack? Yes 1 CONTINUE 
 No 2 
GO TO Q66   Don’t know X 
  Refused Y 
 
Q65 At what age did you first take crack?  
 
  INSERT 
AGE 
 Don’t know X 
  Refused Y  
 
SHOW CARD 66 
Q66 How many times have you been 
offered crack either free of 
charge or to buy in the last 12 
months? Just call me out the 
number from the card - CODE 
ONE ONLY 
Never  1 
ALL WHO 
ANSWERED YES 
AT Q64 GO TO 
Q67. 
 
OTHERS GO TO 
Q70 
 
 Once or twice 2 
 3 to 5 times  3 
 6 to 9 times  4 
 10 to 19 times  5 
 20 times or more  6 
  Don’t know X 
  Refused Y 
 
Q67 During the last 12 months have you taken 
crack? 
Yes 1 CONTINUE 
 No 2 
GO TO Q70   Don’t know X 
  Refused Y 
 
Q68 During the last 30 days have you taken 
crack? 
Yes 1 CONTINUE 
 No 2 
GO TO Q70   Don’t know X 
  Refused Y 
 
Q69 During the last 30 days, on how many days 
have you taken crack? 
 
 
  INSERT 
FIGURE 
 Don’t know X 
  Refused Y  
 
SHOW CARD 70 
Q70 Have you ever heard of any of these 
…………..? SHOW CARD, IF YES TO ANY 
LISTED ON CARD CODE YES AND 
CONTINUE 
Yes 1 CONTINUE 
 No 2 
GO TO Q79  Don’t know X 
 Refused Y 
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Show card 70 again. 
Interviewer to read out: 
“All of the drugs listed on this card are names for cocaine”. 
Q71 Do you personally know people who take 
cocaine? 
Yes 1  
 No 2  
  Don’t know X  
  Refused Y  
 
Q72 Have you ever taken cocaine? Yes 1 CONTINUE 
 No 2 
GO TO Q74   Don’t know X 
  Refused Y 
 
Q73 At what age did you first take cocaine?    INSERT 
AGE 
 Don’t know X  
  Refused Y  
SHOW CARD 74 
Q74 How many times have you been 
offered cocaine either free of 
charge or to buy in the last 12 
months? Just call me out the 
number from the card - CODE 
ONE ONLY  
Never  1 
ALL WHO 
ANSWERED YES 
AT Q72 GO TO 
Q75. 
 
OTHERS GO TO 
Q79 
 
 Once or twice 2 
 3 to 5 times  3 
 6 to 9 times  4 
 10 to 19 times  5 
 20 times or more  6 
  Don’t know X 
  Refused Y 
 
 
Q75 During the last 12 months have you taken 
cocaine? 
Yes 1 CONTINUE 
 No 2 
GO TO Q79   Don’t know X 
  Refused Y 
 
Q76 During the last 30 days have you taken 
cocaine? 
Yes 1 CONTINUE 
 No 2 
GO TO Q79   Don’t know X 
  Refused Y 
 
Q77 During the last 30 days, on how many days 
have you taken cocaine? 
   INSERT 
FIGURE 
 Don’t know X  
  Refused Y  
SHOW CARD 78 
Q78 What method do you most commonly use to take 
cocaine? Just call me out the number from the 
card – CODE ONE ONLY 
Doing a line/Snort 1 
 Injection with a needle 2 
 Smoke 3 
 Other (specify)_________ 4 
 Don’t know X 
  Refused Y 
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SHOW CARD 79 
Q79 Have you ever heard of any of these 
…………..? SHOW CARD, IF YES TO 
ANY LISTED ON CARD CODE YES AND 
CONTINUE  
Yes 1 CONTINUE 
 No 2 
GO TO Q88  Don’t know X 
 Refused Y 
    
 
Show card 79 again. 
Interviewer to read out: 
“All of the drugs listed on this card are names for heroin”. 
Q80 Do you personally know people who take 
heroin? 
Yes 1  
 No 2  
  Don’t know X  
  Refused Y  
 
Q81 Have you ever taken heroin? Yes 1 CONTINUE 
 No 2 
GO TO Q83   Don’t know X 
  Refused Y 
 
Q82 At what age did you first take heroin?  
 
  INSERT 
AGE 
 Don’t know X 
  Refused Y  
SHOW CARD 83 
Q83 How many times have you been 
offered heroin either free of 
charge or to buy in the last 12 
months? Just call me out the 
number from the card - CODE 
ONE ONLY  
Never  1 
ALL WHO 
ANSWERED YES 
AT Q81 GO TO 
Q84. 
 
OTHERS GO TO 
Q88 
 
 Once or twice 2 
 3 to 5 times  3 
 6 to 9 times  4 
 10 to 19 times  5 
 20 times or more  6 
  Don’t know X 
  Refused Y 
 
 
Q84 During the last 12 months have you taken 
heroin? 
Yes 1 CONTINUE 
 No 2 
GO TO Q88   Don’t know X 
  Refused Y 
 
Q85 During the last 30 days have you taken 
heroin? 
Yes 1 CONTINUE 
 No 2 
GO TO Q88   Don’t know X 
  Refused Y 
 
Q86 During the last 30 days, on how many days 
have you taken heroin? 
 
 
  INSERT 
FIGURE 
 Don’t know X 
  Refused Y  
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SHOW CARD 87 
Q87 What method do you most 
commonly use to take heroin? 
Just call me out the number 
from the card – CODE ONE 
ONLY 
Smoke 1  
 Injection with a needle 2  
 ‘Chasing the dragon’ 3  
 Other (specify)_________ 4  
 Don’t know X  
  Refused Y  
 
SHOW CARD 88 
Q88 Have you ever heard of any of these 
…………..? SHOW CARD, IF YES TO ANY 
LISTED ON CARD CODE YES AND 
CONTINUE 
Yes 1 CONTINUE 
 No 2 
GO TO Q96  Don’t know X 
 Refused Y 
    
 
Show card 88 again. 
Interviewer to read out: 
“All of the drugs listed on this card are names for LSD”. 
Q89 Do you personally know people who take 
LSD? 
Yes 1  
 No 2  
  Don’t know X  
  Refused Y  
 
Q90 Have you ever taken LSD? Yes 1 CONTINUE 
 No 2 
GO TO Q92   Don’t know X 
  Refused Y 
 
Q91 At what age did you first take LSD?  
 
  INSERT 
AGE 
 Don’t know X 
  Refused Y  
SHOW CARD 92 
Q92 How many times have you been 
offered LSD either free of charge 
or to buy in the last 12 months? 
Just call me out the number 
from the card - CODE ONE 
ONLY 
Never  1 
ALL WHO 
ANSWERED YES 
AT Q90 GO TO  
Q93. 
 
OTHERS GO TO 
Q96 
 
 Once or twice 2 
 3 to 5 times  3 
 6 to 9 times  4 
 10 to 19 times  5 
 20 times or more  6 
  Don’t know X 
  Refused Y 
 
Q93 During the last 12 months have you taken 
LSD? 
Yes 1 CONTINUE 
 No 2 
GO TO Q96   Don’t know X 
  Refused Y 
 
Q94 During the last 30 days have you taken 
LSD? 
Yes 1 CONTINUE 
 No 2 
GO TO Q96   Don’t know X 
  Refused Y 
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Q95 During the last 30 days, on how many days 
have you taken LSD? 
 
 
  INSERT 
FIGURE 
 Don’t know X 
  Refused Y  
 
SHOW CARD 96 
Q96 Have you ever heard of any of these 
…………..? SHOW CARD, IF YES TO ANY 
LISTED ON CARD CODE YES AND 
CONTINUE 
Yes 1 CONTINUE 
 No 2 
GO TO Q104  Don’t know X 
 Refused Y 
 
Show card 96 again. 
Interviewer to read out: 
“All of the things listed on this card are names for solvents”. 
Q97 Do you personally know people who take 
solvents? 
Yes 1  
 No 2  
  Don’t know X  
  Refused Y  
 
Q98 Have you ever taken solvents? Yes 1 CONTINUE 
 No 2 
GO TO Q100   Don’t know X 
  Refused Y 
 
Q99 At what age did you first take solvents?  
 
  INSERT 
AGE 
 Don’t know X 
  Refused Y  
SHOW CARD 100 
Q100 How many times have you been 
offered solvents either free of 
charge or to buy in the last 12 
months? Just call me out the 
number from the card - CODE 
ONE ONLY 
Never 1 
ALL WHO 
ANSWERED YES 
AT Q98 GO TO 
Q101. 
OTHERS GO TO 
Q104 
 
 Once or twice 2 
 3 to 5 times  3 
 6 to 9 times  4 
 10 to 19 times  5 
 20 times or more  6 
  Don’t know X 
  Refused Y 
 
Q101 
 
 
During the last 12 months have you taken 
solvents? 
Yes 1 CONTINUE 
No 2 
GO TO Q104  Don’t know X 
 Refused Y 
 
Q102 During the last 30 days have you taken 
solvents? 
Yes 1 CONTINUE 
 No 2 
GO TO Q104   Don’t know X 
  Refused Y 
 
Q103 During the last 30 days, on how many days 
have you taken solvents? 
   INSERT 
FIGURE 
 Don’t know X  
  Refused Y  
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SHOW CARD 104 
Q104 Have you ever heard of any of these 
…………..? SHOW CARD, IF YES TO ANY 
LISTED ON CARD CODE YES AND 
CONTINUE 
Yes 1 CONTINUE 
 No 2 
GO TO Q112  Don’t know X 
 Refused Y 
    
 
Show card 104 again. 
Interviewer to read out: 
“All of the drugs listed on this card are names for poppers”. 
Q105 Do you personally know people who take 
poppers? 
Yes 1  
 No 2  
  Don’t know X  
  Refused Y  
 
Q106 Have you ever taken poppers? Yes 1 CONTINUE 
 No 2 
GO TO Q108   Don’t know X 
  Refused Y 
 
Q107 At what age did you first take poppers?    INSERT 
AGE 
 Don’t know X  
  Refused Y  
SHOW CARD 108 
Q108 How many times have you been 
offered poppers either free of 
charge or to buy in the last 12 
months? Just call me out the 
number from the card - CODE 
ONE ONLY 
Never 1 
ALL WHO 
ANSWERED YES 
AT Q106 GO TO 
Q109. 
 
OTHERS GO TO 
Q112 
 
 Once or twice 2 
 3 to 5 times  3 
 6 to 9 times  4 
 10 to 19 times  5 
 20 times or more  6 
  Don’t know X 
  Refused Y 
 
 
Q109 During the last 12 months have you 
taken poppers? 
Yes 1 CONTINUE 
 No 2 
GO TO Q112   Don’t know X 
  Refused Y 
 
Q110 During the last 30 days have you taken 
poppers? 
Yes 1 CONTINUE 
 No 2 
GO TO Q112   Don’t know X 
  Refused Y 
 
Q111 During the last 30 days, on how many days 
have you taken poppers? 
   INSERT 
FIGURE 
 Don’t know X  
  Refused Y  
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SHOW CARD 112 
Q112 Have you ever heard of any of these 
…………..? SHOW CARD, IF YES TO ANY 
LISTED ON CARD CODE YES AND 
CONTINUE 
Yes 1 CONTINUE 
 No 2 
GO TO Q121  Don’t know X 
 Refused Y 
 
Show card 112 again. 
Interviewer to read out: 
“All of the drugs listed on this card are names for magic mushrooms”. 
Q113 Do you personally know people who take 
magic mushrooms? 
Yes 1  
 No 2  
  Don’t know X  
  Refused Y  
 
Q114 Have you ever taken magic mushrooms? Yes 1 CONTINUE 
 No 2 
GO TO Q116   Don’t know X 
  Refused Y 
 
Q115 At what age did you first take magic 
mushrooms? 
 
 
  INSERT 
AGE 
 Don’t know X 
  Refused Y  
SHOW CARD 116 
Q116 How many times have you been 
offered magic mushrooms either 
free of charge or to buy in the 
last 12 months? Just call me 
out the number from the card - 
CODE ONE ONLY 
Never  1 
ALL WHO 
ANSWERED YES 
AT Q114 GO TO 
Q117. 
 
OTHERS GO TO 
Q121 
 
 Once or twice 2 
 3 to 5 times  3 
 6 to 9 times  4 
 10 to 19 times  5 
 20 times or more  6 
  Don’t know X 
  Refused Y 
 
Q117 During the last 12 months have you 
taken magic mushrooms? 
Yes 1 CONTINUE 
 No 2 
GO TO Q121   Don’t know X 
  Refused Y 
 
Q118 During the last 30 days have you taken 
magic mushrooms? 
Yes 1 CONTINUE 
 No 2 
GO TO Q121   Don’t know X 
  Refused Y 
 
Q119 During the last 30 days, on how many days 
have you taken magic mushrooms? 
 
 
  INSERT 
FIGURE 
 Don’t know X 
  Refused Y  
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SHOW CARD 120 
Q120 On the last occasion you 
took magic mushrooms how 
had you obtained them? 
Just call me out the number 
from the card 
CODE ONE ONLY 
I picked them myself 1  
 I got them from someone I know 2 
 
 I bought them off the internet 3 
 I bought them in a shop/market  4  
 Other (specify)___________  5  
  Don’t know X  
  Refused Y  
 
SHOW CARD 121 
Q121 Have you ever heard of any of these 
…………..? SHOW CARD, IF YES TO ANY 
LISTED ON CARD CODE YES AND 
CONTINUE 
Yes 1 CONTINUE 
 No 2 
GO TO Q138  Don’t know X 
 Refused Y 
    
 
Show card 121 again. 
Interviewer to read out: 
“All of the drugs listed on this card are names for methadone”. 
Q122 Do you personally know people who take 
methadone? 
Yes 1  
 No 2  
  Don’t know X  
  Refused Y  
 
Q123 Have you ever taken methadone? Yes 1 CONTINUE 
 No 2 
GO TO Q138   Don’t know X 
  Refused Y 
 
Q124 At what age did you first take methadone?  
 
  INSERT 
AGE 
 Don’t know X 
  Refused Y  
 
Q125 During the last 12 months have you taken 
methadone? 
Yes 1 CONTINUE 
 No 2 
GO TO Q138   Don’t know X 
  Refused Y 
 
Q126 During the last 30 days have you taken 
methadone? 
Yes 1 CONTINUE 
 No 2 
GO TO Q138   Don’t know X 
  Refused Y 
 
Q127 During the last 30 days, on how many days 
have you taken methadone? 
 
 
  INSERT 
FIGURE 
 Don’t know X 
  Refused Y  
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SHOW CARD 128 
Q128 
On the last occasion 
you took methadone 
how had you 
obtained it? Just call 
me out the number 
from the card 
CODE ONE ONLY 
I got it on a prescription 1  
 I got it from someone I know 2 
  I bought it without a prescription in a 
chemist 
3 
 I bought it over the internet 4  
 Other (specify)_________________ 5  
  Don’t know X  
  Refused Y  
 
 
NOTE TO INTERVIEWER: Q129-Q137 NOT APPLICABLE TO ROI QUESTIONNAIRE 
 
I would now like to ask you about other opiates excluding heroin and methadone, which I have 
previously asked about. 
SHOW CARD 138,  SHOW CARD CODEINE PRODUCTS (138) IF CODEINE MENTIONED 
 
Q138 Have you ever heard of any of these 
…………..? SHOW CARD, IF YES TO ANY 
LISTED ON CARD CODE YES AND 
CONTINUE 
Yes 1 CONTINUE 
 No 2 
GO TO Q146  Don’t know X 
 Refused Y 
    
 
Show card 138 again. 
Interviewer to read out: 
“All of the drugs listed on this card are names for other opiates excluding heroin and methadone”. 
Q139 Do you personally know people who take 
other opiates? 
Yes 1  
 No 2  
  Don’t know X  
  Refused Y  
 
Q140 Have you ever taken other opiates? Yes 1 CONTINUE 
 No 2 
GO TO Q146   Don’t know X 
  Refused Y 
 
Q141 At what age did you first take other opiates?    INSERT 
AGE 
 Don’t know X  
  Refused Y  
 
Q142 During the last 12 months have you taken 
other opiates? 
Yes 1 CONTINUE 
 No 2 
GO TO Q146   Don’t know X 
  Refused Y 
 
Q143 During the last 30 days have you taken other 
opiates? 
Yes 1 CONTINUE 
 No 2 
GO TO Q146   Don’t know X 
  Refused Y 
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Q144 During the last 30 days, on how many days 
have you taken other opiates? 
   INSERT 
FIGURE 
 Don’t know X  
  Refused Y  
 
SHOW CARD 145 
Q145 
On the last occasion 
you took other opiates 
how had you obtained 
them? Just call me out 
the number from the card 
CODE ONE ONLY 
I got them on a prescription 1  
 I got them from someone I know 2 
  I bought them without a prescription in 
a chemist 
3 
 I bought them over the internet 4  
 Other (specify)_________ 5  
  Don’t know X  
  Refused Y  
 
SHOW CARD 146 
Q146 Have you ever heard of any of these 
…………..? SHOW CARD, IF YES TO 
ANY LISTED ON CARD CODE YES 
AND CONTINUE 
Yes 1 CONTINUE 
 No 2 
GO TO Q154  Don’t know X 
 Refused Y 
    
 
Show card 146 again. 
Interviewer to read out: 
“All of the drugs listed on this card are names for anabolic steroids”. 
Q147 Do you personally know people who take 
anabolic steroids? 
Yes 1  
 No 2  
  Don’t know X  
  Refused Y  
 
Q148 Have you ever taken anabolic steroids? Yes 1 CONTINUE 
 No 2 
GO TO Q154   Don’t know X 
  Refused Y 
 
Q149 At what age did you first take anabolic 
steroids? 
   INSERT 
AGE 
 Don’t know X  
  Refused Y  
 
Q150 During the last 12 months have you taken 
anabolic steroids? 
Yes 1 CONTINUE 
 No 2 
GO TO Q154   Don’t know X 
  Refused Y 
 
Q151 During the last 30 days have you taken 
anabolic steroids? 
Yes 1 CONTINUE 
 No 2 
GO TO Q154   Don’t know X 
  Refused Y 
 
Q152 During the last 30 days, on how many days 
have you taken anabolic steroids? 
   INSERT 
FIGURE 
 Don’t know X  
  Refused Y  
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SHOW CARD 153 
Q153 
On the last occasion you took anabolic 
steroids how had you obtained them?  
Just call me out the number from the card 
CODE ONE ONLY 
I got them on a prescription 1 
 I got them from someone I know 2 
 I bought them without a prescription 
in a chemist 
3 
 I bought them over the internet 4 
 Other (specify)__________ 5 
 Don’t know X 
 Refused Y 
 
 
I’d like to ask you for your opinions on different matters relating to drugs. 
 
SHOW CARD 154 
Q154 Do you perceive a drug addict more as a criminal 
or more as a patient? 
More as a criminal 1 
 More as a patient 2 
 Neither a criminal nor a patient 3 
 Both a criminal and a patient 4 
 Don’t know, cannot decide X 
  Refused Y 
 
SHOW CARD 155 
Q155 To what extent do you agree with the following statements …. 
READ OUT IN TURN 
  
Fully 
agree 
Largely 
agree 
Neither Largely 
disagre
e 
Fully 
disagre
e 
Don’t 
know 
Refuse
d 
“People should be permitted to 
take cannabis for medical 
reasons” 
1 2 3 4 5 X Y 
“People should be permitted to 
take cannabis for recreational 
reasons” 
1 2 3 4 5 X Y 
”People should be permitted to 
take heroin” 
1 2 3 4 5 X Y 
 
SHOW CARD 156 
Q156 Individuals differ in whether or not they disapprove of people doing certain things. I will 
mention a few things, which some people might do.  Can you tell me if you would not 
disapprove, disapprove or strongly disapprove when people do any of these things? 
READ OUT IN TURN 
  
Do not 
disappro
ve 
Disappro
ve 
Strongly 
disappro
ve 
Don’t 
know Refused 
Trying ecstasy once or twice 1 2 3 X Y 
Trying heroin once or twice 1 2 3 X Y 
Smoking 10 cigarettes a day 1 2 3 X Y 
Smoking cannabis occasionally 1 2 3 X Y 
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SHOW CARD 157 
Q157 Now I would like to know how much do you think that people risk harming themselves, 
physically or in other ways, if they do certain things. I will again mention a few things some 
people might do. Please tell me if you consider it to be no risk, a slight risk, a moderate risk 
or a great risk, if people do such things. 
READ OUT IN TURN 
  
No 
Risk 
Slight 
risk 
Moderat
e risk 
Great 
risk 
Don’t 
know Refused 
(a) Smoke one or more packs of    
cigarettes a day 
1 2 3 4 X Y 
(b) Binge drink 1 2 3 4 X Y 
(c) Smoke cannabis regularly 1 2 3 4 X Y 
(d)Try ecstasy once or twice 1 2 3 4 X Y 
(e) Try cocaine once or twice 1 2 3 4 X Y 
(f) Try crack once or twice 1 2 3 4 X Y 
 
Read out to all who are asked any question from Q160 to Q180. 
“I’d like to ask you a few more questions about some of the substances you said earlier that you had 
used”.  
 
 
Question 158 to 159 removed.  
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ASK ALL WHO HAVE EVER TAKEN CANNABIS AT Q36. OTHERS GO TO Q164 
Q160 Earlier in the study you stated that you have 
taken cannabis, have you ever taken cannabis 
regularly? 
Yes 1 CONTINUE 
 No 2 
GO TO Q172  Don’t know X 
 Refused Y 
 
Q161 Earlier in the study you stated the age when 
you first took cannabis, can you tell us at what 
age did you first take cannabis regularly? 
   INSERT 
AGE 
 Don’t know X  
  Refused Y  
 
SHOW CARD 162 
Q162 Have you ever tried to stop 
taking cannabis?  
Yes – tried to and stopped 1 
CONTINUE  Yes -  tried to but not stopped 2 
 No 3 
GO TO Q172   Don’t know X 
  Refused Y 
 
SHOW CARD 163 
Q163 What was the main reason for stopping/trying to stop taking cannabis? 
Just call me out the number from the card – CODE ONE ONLY 
Cost/could no longer afford it 1 Put on rehabilitation programme  9 
Persuaded by friends/family 2 Did not want to take anymore 10 
Impact on job/friends/family 3 Did not enjoy after effects 11 
No longer part of social life 4 The pros of taking did not outweigh the cons 12 
Concern about health/health reasons 5 Other (specify) _________________ 13 
Pregnancy 6 Don’t know X 
Less available supply 7 Refused Y 
Gave up smoking cigarettes 8   
 
 
ASK ALL WHO HAVE USED CANNABIS (Yes at Q39) IN THE LAST 12 MONTHS.  
OTHERS GO TO Q164 
SHOW CARD 163a Given by family/friend 1 
Q172 How did you get the 
cannabis on the last 
occasion you used it? 
Just call me out the 
number from the 
card 
CODE ONE ONLY 
Given by a contact I did not know personally 2 
 Given by a stranger 3 
 Shared amongst group of friends 4 
 Bought from a friend 5 
 Bought from a contact I did not know personally 6 
 Bought from a stranger 7 
  Other (specify)_______________ 8 
  Don’t know X 
  Refused Y 
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ASK ALL WHO HAVE USED CANNABIS (Yes at Q39) IN LAST 12 MONTHS 
OTHERS GO TO Q164 
SHOW CARD 163b Street/park 1 
Q173 In which of the 
following places did 
you obtain the 
cannabis on the last 
occasion you used it? 
Just call me out the 
number from the 
card 
CODE ONE ONLY 
Disco/bar/club 2 
 Office/workplace 3 
 School/college 4 
 House of a dealer 5 
 House of a friend 6 
 Ordered by phone for collection/delivery  7 
 Internet 8 
 Other (specify)__________________ 9 
 Don’t know X 
  Refused Y 
 
 
ASK ALL WHO HAVE USED CANNABIS (Yes at Q39) IN LAST 12 MONTHS 
OTHERS GO TO Q164 
SHOW CARD 163c 
Q174 How easy or difficult is it to obtain cannabis in 
a 24 hour period? 
Just call me out the number from the card 
Very easy 1 
 Fairly easy 2 
 Neither easy nor difficult 3 
 Fairly difficult 4 
 Very difficult 5 
 Don’t know X 
  Refused Y 
 
 
ASK ALL WHO HAVE USED CANNABIS (YES AT Q39) IN THE LAST 12 MONTHS 
OTHERS GO TO Q164 
 
As a result of your cannabis use in the last 12 months 
 
Q186 Have you thought your use of ‘cannabis’ 
was out of control? 
PROBE TO PRECODE 
Never/almost never 0 
 Sometimes 1 
 Often 2 
 Always/nearly always 3 
  Don’t know X 
  Refused Y 
 
Q187 Has the prospect of missing a dose or joint 
made you anxious, worried or stressed? 
PROBE TO PRECODE 
Never/almost never 0 
 Sometimes 1 
 Often 2 
 Always/nearly always 3 
  Don’t know X 
  Refused Y 
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Q188 Have you worried about your use of 
cannabis? 
PROBE TO PRECODE 
Never/almost never 0 
 Sometimes 1 
 Often 2 
 Always/nearly always 3 
  Don’t know X 
  Refused Y 
 
 
Q189 Have you wished you could stop using 
cannabis? 
PROBE TO PRECODE 
Never/almost never 0 
 Sometimes 1 
 Often 2 
 Always/nearly always 3 
  Don’t know X 
  Refused Y 
 
ASK Q190B TO THOSE WHO HAVE USED CANNABIS IN THE LAST 12 MONTHS (CODE 1 AT 
Q39) AND WHO HAVE NOT STOPPED (CODES 2, 3, X AND Y AT Q162) 
 
 
Q190b How difficult do you find it to go without 
cannabis? 
Not difficult 0 
 Quite difficult 1 
 Very difficult 2 
 Impossible 3 
 Don’t know X 
 Refused Y 
  
         
ASK Q190 TO THOSE WHO HAVE USED CANNABIS IN THE LAST 12 MONTHS (CODE 1 AT 
Q39) AND WHO HAVE STOPPED (CODE 1 AT Q162) 
 
Q190 How difficult did you find it to stop, or go 
without cannabis? 
Not difficult 0 
 Quite difficult 1 
 Very difficult 2 
 Impossible 3 
 Don’t know X 
 Refused Y 
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 ASK ALL WHO HAVE USED CANNABIS (YES AT Q39) IN THE LAST 12 MONTHS. 
 
Interviewer to read out: 
 
“During this part of the survey I am going to ask you more detailed questions about your cannabis 
use and some of the questions will appear to be eliciting the same information. This is because the 
researchers want to compare two ways of asking about cannabis use to determine if the shorter 
method is as good as the longer method. If the shorter method is as good as the longer method, the 
researchers will use these questions in future surveys. We need your help to do this” 
 
Q191 As a result of your cannabis use in the last 12 months,  
SHOW CARD 164a SCALE 
 
 
 
 
No Yes, 
once 
Yes, 
more 
than 
once 
Don’t 
know 
Refused Not  
Applicable 
191.1. Did you experience significant 
problems at work, at school or when 
taking care of the household? 
SHOW CARD (164b) EXAMPLES OF 
SIGNIFICANT PROBLEMS 
Examples of significant problems are:  
Missed days and poor performance at 
work or school/college; 
Suspended or expelled from school; 
Neglected children and or other family 
members 
 
1 
 
2 
 
3 
 
X 
 
Y 
 
191.2. Were you at increased risk of 
injury? 
INTERVIEWER NOTE: ‘Risk of injury’ 
does not include self harming 
 
191.2a. Have you accidently hurt 
yourself? 
 
1 
 
 
 
 
 
1 
 
2 
 
 
 
 
 
2 
 
3 
 
 
 
 
 
3 
 
X 
 
 
 
 
 
X 
 
Y 
 
 
 
 
 
Y 
 
 
191.4. Have you committed an offence? 
SHOW CARD (164c) EXAMPLES OF 
COMMITTING AN OFFENCE 
 
Examples of committing an offence are: 
Possession of cannabis for use, sale or 
supply 
Theft to obtain the substance 
Driving under its influence (SHOW 
CARD) 
 
1 2 3 X Y  
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No Yes, 
once 
Yes, 
more 
than 
once 
Don’t 
know 
Refused Not  
Applicable 
191.5. Have your friends and family 
expressed concern about its use? 
 
1 
 
2 
 
3 X Y  
191.6. Have you experienced a break-
up in your relationship with a partner? 
 
1 2 3 X Y Z 
191.7. Have you had financial troubles? 
 
 
1 
 
2 
 
3 X Y  
191.8. Have you physically attacked 
anybody? 
 
1 
 
2 
 
3 X Y  
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ASK ALL WHO HAVE USED CANNABIS (YES AT Q36)  
 
Q192    As a result of your cannabis use SHOW CARD 165 
 
 No, never Yes, in 
the last 12 
months 
Yes, but 
more than 
12 months 
ago 
Don’t 
know 
Refused 
192.1. Have you needed to take more than 
before to achieve the same effect or have 
you found that the same amount had less 
effect than before? 
1 2 3 X Y 
192.2. When you used less or none at 
all, did you experience any of the 
following:- trouble sleeping; sweating; 
trembling; rapid heartbeat; anxiety; 
irritability or depression? 
SHOW CARD Question & Symptons 
(165a) 
 
192.2a. If so, have you taken cannabis in 
order to ease these symptoms or to 
prevent them recurring? 
1 
 
 
 
 
1 
2 
 
 
 
 
2 
3 
 
 
 
 
3 
 
X 
 
 
 
 
X 
Y 
 
 
 
 
Y 
192.3a. Have you used more on a single 
occasion than you originally intended? 
 
1 2 3 X Y 
192.3b. Have you used more over a longer 
time-period than you originally intended? 
 
1 2 3 X Y 
192.4. Have you wanted to cut down or 
stop using on more than one occasion? 
 
192.4a. On more than one occasion have 
you tried to stop or reduce but did not 
succeed? 
 
Only a single score permitted 
 
1 
 
 
1 
 
2 
 
 
2 
3 
 
 
3 
X 
 
 
X 
Y 
 
 
Y 
 
192.5. Have you found that cannabis has 
taken over your life, by this I mean have 
you spent a lot of time obtaining it, using it 
or recovering from its effect? 
 
1 2 3 X Y 
192.6. Have you restricted or abandoned 
important activities, such as sport, work or 
being with family or friends? 
1 2 3 X Y 
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 No, never Yes, in the 
last 12 
months 
Yes, but 
more than 
12 months 
ago 
Don’t 
know 
Refused 
192.7. Have you experienced any of these 
health problems?  
SHOW CARD HEALTH PROBLEMS 
(165b) 
 
Eye and mouth dryness 
Nausea 
Hoarseness 
Persistent cough 
 
192.7a. If so, have you continued to use it 
despite those health problems? 
 
 
1 
 
 
 
 
 
 
 
 
 
1 
2 
 
 
 
 
 
 
 
 
 
2 
3 
 
 
 
 
 
 
 
 
 
3 
X 
 
 
 
 
 
 
 
 
 
X 
Y 
 
 
 
 
 
 
 
 
 
Y 
192.8. Have you experienced any of these 
emotional or psychological problems? 
SHOW CARD HEALTH PROBLEMS 
(165c) 
 
Apathy (not caring about anything) 
Depression 
Paranoia (suspicion of other people, 
feelings that people are thinking and talking 
about you) 
Thinking and seeing things differently 
Heightened sense of awareness 
 
192.8a. If so, have you continued to use it 
despite those psychological problems? 
1 
 
 
 
 
 
 
 
 
 
 
1 
2 
 
 
 
 
 
 
 
 
 
 
2 
3 
 
 
 
 
 
 
 
 
 
 
3 
X 
 
 
 
 
 
 
 
 
 
 
X 
Y 
 
 
 
 
 
 
 
 
 
 
Y 
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ASK ALL WHO HAVE  EVER TAKEN ECSTASY AT Q47 
OTHERS GO TO Q168 
 
Q164 Earlier in the study you stated that you 
have taken ecstasy, have you ever taken 
ecstasy regularly? 
Yes 1 CONTINUE 
 No 2 
GO TO Q175  Don’t know X 
 Refused Y 
 
Q165 Earlier in the study you stated the age when 
you first took ecstasy, can you tell us at what 
age did you first take ecstasy regularly? 
   INSERT 
AGE 
 Don’t know X  
  Refused Y  
 
SHOW CARD 166 
Q166 Have you ever tried to stop 
taking ecstasy?  
Yes – tried to and stopped 1 
CONTINUE 
 Yes -  tried to but not stopped 2 
 No 3 
GO TO Q175   Don’t know X 
  Refused Y 
 
SHOW CARD 167 
Q167 What was the main reason for stopping/trying to stop taking ecstasy?   
Just call me out the number from the card – CODE ONE ONLY 
Cost/could no longer afford it 1 Put on rehabilitation programme  8 
Persuaded by friends/family 2 Did not want to take anymore 9 
Impact on job/friends/family 3 Did not enjoy after effects 10 
No longer part of social life 4 The pros of taking did not outweigh the cons 11 
Concern about health/health reasons 5 Other (specify) _________________ 12 
Pregnancy 6 Don’t know X 
Less available supply 7 Refused Y 
 
 
ASK ALL WHO HAVE USED ECSTASY (Yes at Q50) IN THE LAST 12 MONTHS 
OTHERS GO TO Q168 
 
SHOW CARD 175 Given by family/friend 1 
Q175 How did you get the 
ecstasy on the last 
occasion you used it? 
Just call me out the 
number from the 
card 
CODE ONE ONLY 
Given by a contact I did not know personally 2 
 Given by a stranger 3 
 Shared amongst group of friends 4 
 Bought from a friend 5 
 Bought from a contact I did not know personally 6 
 Bought from a stranger 7 
 Other (specify)_______________ 8 
  Refused Y 
  Don’t know X 
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ASK ALL WHO HAVE USED ECSTASY (Yes at Q50) IN THE LAST 12 MONTHS 
OTHERS GO TO Q168 
 
SHOW CARD 176 Street/park 1 
Q176 In which of the following 
places did you obtain the 
ecstasy on the last occasion 
you used it? 
Just call me out the 
number from the card 
CODE ONE ONLY 
Disco/bar/club 2 
 Office/workplace 3 
 School/college 4 
 House of a dealer 5 
 House of a friend 6 
 Ordered by phone for collection/delivery  7 
 Internet 8 
 Other(specify)______________ 9 
 Don’t know X 
 Refused Y 
 
ASK ALL WHO HAVE USED ECSTASY (Yes at Q50) IN LAST 12 MONTHS 
OTHERS GO TO Q168 
 
SHOW CARD 177 
Q177 How easy or difficult is it to 
obtain ecstasy in a 24 hour 
period? 
Just call me out the number 
from the card 
Very easy 1 
 Fairly easy 2 
 Neither easy nor difficult 3 
 Fairly difficult 4 
 Very difficult 5 
 Don’t know X 
  Refused Y 
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ASK ALL WHO HAVE EVER TAKEN COCAINE AT Q72 
OTHERS GO TO Q183 
 
Q168 Earlier in the study you stated that you have 
taken cocaine, have you ever taken cocaine 
regularly? 
Yes 1 CONTINUE 
 No 2 
GO TO Q178  Don’t know X 
 Refused Y 
 
Q169 Earlier in the study you stated the age when 
you first took cocaine, can you tell us at what 
age did you first take cocaine regularly? 
   INSERT 
AGE 
 Don’t know X  
  Refused Y  
 
SHOW CARD 177a 
Q170 Have you ever tried to stop 
taking cocaine?  
Yes – tried to and stopped 1 
CONTINUE 
 Yes -  tried to but not stopped 2 
 No 3 
GO TO Q178   Don’t know X 
  Refused Y 
 
SHOW CARD 177b 
Q171 What was the main reason for stopping/trying to stop taking cocaine?  
Just call me out the number from the card – CODE ONE ONLY 
Cost/Could no longer afford it 1 Put on rehabilitation programme  8 
Persuaded by friends/family 2 Did not want to take anymore 9 
Impact on job/friends/family 3 Did not enjoy after effects 10 
No longer part of social life 4 The pros of taking did not outweigh the cons 11 
Concern about health/health reasons 5 Other (specify) _________________ 12 
Pregnancy 6 Don’t know X 
Less available supply 7 Refused Y 
 
 
ASK ALL WHO HAVE USED COCAINE (Yes at Q75) IN LAST 12 MONTHS 
OTHERS GO TO Q183 
 
SHOW CARD 178 Given by family/friend 1 
Q178 How did you get the 
cocaine on the last 
occasion you used it? 
Just call me out the 
number from the 
card 
CODE ONE ONLY 
Given by a contact I did not know personally 2 
 Given by a stranger 3 
 Shared amongst group of friends 4 
 Bought from a friend 5 
 Bought from a contact I did not know personally 6 
 Bought from a stranger 7 
 Other (specify)_______________ 8 
  Refused Y 
  Don’t know X 
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ASK ALL WHO HAVE USED COCAINE (Yes at Q75) IN THE LAST 12 MONTHS 
OTHERS GO TO Q183 
 
 
SHOW CARD 179 Street/park 1 
Q179 In which of the 
following places did 
you obtain the cocaine 
on the last occasion 
you used it? 
Just call me out the 
number from the 
card 
CODE ONE ONLY 
Disco/bar/club 2 
 Office/workplace 3 
 School/college 4 
 House of a dealer 5 
 House of a friend 6 
 Ordered by phone for collection/delivery  7 
 Internet 8 
 Other (specify)__________________ 9 
 Don’t know X 
  Refused Y 
 
ASK ALL WHO HAVE USED COCAINE (Yes at Q75) IN LAST 12 MONTHS 
OTHERS GO TO Q183 
 
SHOW CARD 180 
Q180 How easy or difficult is it to 
obtain cocaine in a 24 hour 
period? 
Just call me out the number 
from the card 
Very easy 1 
 Fairly easy 2 
 Neither easy nor difficult 3 
 Fairly difficult 4 
 Very difficult 5 
 Don’t know X 
  Refused Y 
 
Question 181 and 182 removed 
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ASK ALL 
 
SHOW CARD 183 
READ OUT: All the substances on this SHOW CARD are only sold in headshops or via the 
internet 
 
Q183 Have you taken any of the substances 
presented on this show card in the last 12 
months?  
 
Show card, if Yes to any listed on card code 
Yes and Continue. 
Yes 1 CONTINUE 
 No 2 
GO TO Q193 
Don’t know X 
Refused Y 
 
 
Q184 What is/are the name of the 
substances that you took? 
 
SHOW CARD 183 AGAIN 
 
MULTICODE 
Herbal smoking mixtures/incense e.g. 
Smoke, Spice, Sence 
1 
CONTINUE 
 Party Pills or Herbal Highs 2 
 Bathsalts, Plantfeeders or Other 
Powders 
3 
 Kratom (Krypton) 
 
4 
 Salvia, Magic mint, Divine mint or 
Sally D 
5 
 Other, please specify 6 
 Don’t know  
GO TO Q193 
 Refused  
 
 
Removed precode for legal weed and separate precodes for spice and smoke 
 
SHOW CARD 185 
Q185 Where did you get the 
substance(s)? 
 
INTERVIEWER: PUT ANY 
MENTIONS OF HEMPSHOP, 
BUZZSHOP, GROWSHOP 
AND SMARTSHOP INTO 
CODE 3 
 
I got them from a friend or someone I know 1 
 I bought them off the internet 2 
 I bought them in a headshop 3 
 I bought them in a shop other than a headshop 4 
 I bought them in a market 5 
 I bought them from a dealer 6 
 Other, please specify 7 
 Don’t know X 
 Refused Y 
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ASK ALL WHO HAVE CONSUMED ALCOHOL  (CODES 1-7 AT 11B) IN THE LAST 12 
MONTHS, OTHERS GO TO Q195 
 
I am just going to ask a few questions about alcohol 
 
 Q193   During the last 12 months, have you 
INTERVIEWER NOTE: WE ARE ASKING THIS QUESTION OF EVERYONE WHO DRANK 
ALCOHOL IN THE LAST 12 MONTHS 
 
 Yes No Don’t know Refused 
Had feelings of guilt or remorse after 
drinking 
1 2 X Y 
Had a friend or family member tell you 
about things you said or did while drinking 
that you did not remember 
1 2 X Y 
Failed to do what was normally expected 
from you because of drinking  
 
(SHOW CARD 193C) 
 
Missed days and poor performance at work 
or school/college; or, 
Suspended or expelled from school/college; 
or,  
Neglected children and/or other family 
members 
 
1 2 X Y 
Needed a first drink in the morning to get 
yourself going after a heavy drinking 
session 
1 2 X Y 
Needed to drink more than before to get the 
same effect 
1 2 X Y 
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ASK ALL  WHO HAVE CONSUMED ALCOHOL (CODES 1-7 AT Q11B) IN THE LAST 12 
MONTHS  
OTHERS GO TO Q195 
 
 
Q194 During the last 12 months, have you 
 
 Yes No Don’t know Refused 
Got into a physical fight when you had 
been drinking 
1 2 X Y 
Been in an accident when you had 
been drinking 
1 2 X Y 
Ever felt that you should cut down on 
your drinking 
1 2 X Y 
Regretted something you said or did 
after drinking 
1 2 X Y 
Felt that your drinking harmed your 
friendships or social life 
1 2 X Y 
Felt that your drinking harmed your 
home life or marriage 
1 2 X Y 
Felt that your drinking harmed your 
work or studies 
1 2 X Y 
Felt that your drinking harmed your 
health  
1 2 X Y 
 
 
 
Ask everyone 
I am just going to read out some consequences you may have experienced as a result of 
someone else’s drinking 
 
Q195   During the last 12 months have you ……….? 
 
 Yes No Don’t know Refused 
Had family problems or relationship 
difficulties 
1 2 X Y 
Been a passenger with a driver who 
had too much to drink 
1 2 X Y 
Been hit or assaulted by someone 
who had been drinking 
1 2 X Y 
Had financial trouble because of 
someone else’s drinking 
1 2 X Y 
Had property vandalized by someone 
who had been drinking 
1 2 X Y 
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THANK RESPONDENT 
 
 
WHEN COLLECTING DEMOGRAPHICS AND TAKING CONTACT DETAILS STATE: 
 
Your name, address and telephone number are taken for quality control purposes ONLY, i.e. 
you may get a phone call or a letter from ……… to check that the interviewer has carried out 
your interview according to instructions” 
 
REPEAT CONFIDENTIALITY REASSURANCE IF CONCERNED ABOUT CONFIDENTIALITY
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O.U.O  Job No:  
 
CLASSIFICATION 
 
C1a  Can you please tell me your date 
of birth? 
Record exact date, month and 
year. Add refused and don’t know 
code 
 
C.1b 
What was your age last birthday? 
STATE EXACT AGE 
AND CODE: 
  
15– 16 1 31 - 34 5 
17 - 19 2 35 - 40 6 
20 - 24 3 41 – 54 7 
25 - 30 4 55 - 64 8 
  Refused Y 
  Don’t 
know 
X 
SHOW CARD C2 
C.2 Which of these describes you? 
Single (never 
married) 
1 Divorced 5 
Married  2 Widowed 6 
Co-habiting 3 Refused Y 
Separated 4 Don’t know X 
    
C.3 Please circle 
one 
Male 1 
 of the 
following: 
Female 2 
 
 
SHOW CARD C4 
C.4 To which one of the following groups do 
you consider you belong?  Just call me 
out the number from this card if you 
prefer. CODE ONE ONLY.  
White  
Irish  1 
Irish Traveller  2 
British   3 
Roma  4 
Any other White 
background 
(specify)________ 
5 
Black or 
Black Irish 
African  6 
Any other black 
background 
(specify_______) 
7 
Asian or 
Asian Irish 
Chinese 8 
Any other Asian 
background 
(specify________) 
9 
Other 
including 
mixed 
background   
Specify_______________ 10 
Do not wish to answer this question Y 
Don’t know X 
 
C.5a Is your home owned or rented?  
PROBE 
Owned outright 1 
Owned with a mortgage 2 
Rented from a private landlord 3 
Rented from a local authority 4 
Rented from a housing association 5 
Part owned/Part rented 6 
Other (Specify) ____________ 7 
Don’t know X 
Refused Y 
 
C.5b How many children, including children 
aged 16-18 in full time education, are 
dependent on you? 
0 1 2 3 4 5 6 7 8 9+ 
Refused Y Don’t know X 
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C.5c What is the age of your youngest 
dependent child? STATE EXACT 
AGE 
   
Refused Y Don’t know X 
 
C.5d 
In this household, do you care for an  
 adult who requires substantial 
assistance with the activities of daily 
life? 
Yes 1 No 2 
Refused Y Don’t 
know 
X 
 
SHOW CARD C6 
C.6a Which of these best describes 
you? Just call me out the number 
from this card if you prefer. 
In 
Paid 
Job 
Self-employed 1 
Working full-time 30 hrs+/week 2 
Working part time  3 
No 
Paid 
Job 
Seeking work for the first time 4 
Unemployed (having lost/given 
up job) 
5 
Home (domestic) duties 6 
Unable to work due to 
permanent illness/disability 
7 
Not working (seeking work) 8 
Not working (not seeking work) 9 
On Government 
training/education scheme 
10 
On Government employment 
scheme (CE, job options etc) 
11 
Retired  12 
Student 13 
Other (Specify) 
____________________ 
14 
 Refused Y 
 Don’t know X 
 
C.6b 
IF NOT IN PAID JOB:  Have you 
ever had a paid job? 
Yes 1 No 2 
Refused Y Don’t 
know 
X 
 
ASK ALL 
SHOW CARD C6C 
C.6c Which, if any, of the following 
benefits/allowances are you 
currently in receipt of? 
Jobseeker’s Benefit (Unemployment 
benefit) 
1 
Jobseeker’s Allowance (Unemployment 
assistance) 
2 
One parent family payment 3 
Illness Benefit (Disability benefit) 4 
Disability allowance 5 
Invalidity pension 6 
Carer’s allowance 7 
Family income supplement 8 
Widow/widowers pension 9 
Other(Specify)___________ 10 
None of these 11 
Don’t know X 
Refused Y 
 
 
C.7 Which member of your household would you 
say is the CHIEF INCOME EARNER (CIE) 
that is the person with the largest income, 
whether from employment, pensions, state 
benefits, investments or any other sources?  
(If equal income is claimed for two people, 
classify the elder as the C.I.E.) 
Self A Go to C.9 
Other (WRITE IN) 
 
B Go to C.8 
Don’t know X Go to C.8 
Refused Y Go to C.8 
 
C.8 Is ............ related to you? 
Yes A  
No B  
Refused Y  
Don’t know X  
 
ASK ALL 
C.9 Employment Status of C.I.E: Does the 
C.I.E. have a paid job full-time or part-time? 
Yes A 
Go to C.11 
No B Go to C.10 
Refused Y Go to C.10 
Don’t know X Go to C.10 
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SHOW CARD C10 
C.10 Looking at this card, please tell me the 
statement that best describes the 
C.I.E.  Just read out the letter of one 
that best applies. 
A-Retired, gets 
pension from previous 
job 
A 
Go to C.11 B-Unemployed less 
than 2 mths 
B 
C-Sick, still receiving 
pay or statutory pay 
from job 
C 
D-Widowed, receiving 
pension from 
spouse’s previous job 
D 
Go to C11 - 
Ask 
occupation 
details of 
spouse  
E-
Divorced/separated, 
receiving 
maintenance  
E 
F-Full-time student F Go to C.12 
Code SG - C1 
G-Not working, 
private means 
G Go to C.12 - 
Assess SG 
H-Unemployed - 
longer than 2mths 
H 
Go to C. 12 
Code SG -  
E  
I-Sick - only receiving 
Income Support or 
Invalidity Benefit 
I 
J-Receiving State 
Pension only 
J 
Refused Y Go to C.11 
Don’t know X Go to C.11 
 
C.11 Employment Status of C.I.E.: 
• What type of firm/organisation 
does/did (C.I.E.) work for? 
      WRITE IN: 
_________________________ 
Refused Y Don’t know X 
 
• What job does/did ......... do? 
      WRITE IN: 
_________________________ 
Refused Y Don’t know X 
 
 
• Does/Did ....... have any 
position/rank/grade in the organisation 
(ie., responsible for the work of other 
people)? 
Yes 
A 
No 
B 
Refused 
Y 
Don’t 
know 
X 
 
PROMPT AS APPROPRIATE (Foreman, 
Sergeant, Office Manager, Executive, 
Officer etc.) 
IF YES,WRITE IN: 
_____________________ 
Refused Y Don’t know X 
 
AND ASK: How many people is/was ...... 
responsible for? 
 
Refused Y Don’t know X 
 
• Does ..... have any qualifications? 
Yes 
A 
No 
B 
Refused 
Y 
Don’t know 
X 
 
PROMPT AS APPROPRIATE: 
Apprenticeship, professional 
qualifications, University degree) 
WRITE IN: 
__________________________ 
Refused Y Don’t know X 
 
• IF FARMER ASK:  How many 
acres/hectares does/did CIE farm? 
 
Refused Y Don’t know X 
 
C.12 Assess Social Grade: 
A 1 D 5 
B 2 E 6 
C1 3 Refused Y 
C2 
4 Don’t 
know 
X 
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SHOW CARD C13 AND READ OUT 
C.13 A person has a disability if 
he/she has a physical or mental 
impairment which has a substantial and 
long-term adverse effect on his/her 
ability to carry out normal day to day 
activities.  On the basis of this 
definition, do you regard yourself as 
being disabled? 
Yes 1 No 2 
DK X Refused Y 
 
 
SHOW CARD C14 
C.14 What is the highest level of 
education that you have 
completed, was it ...?   
No formal education 1 
Primary education 2 
Lower secondary 
(Junior/Intermediate/Group Certificate, 
‘O’ levels/GCSEs, NCVA Foundation 
Certificate, basic Skills Training 
Certificate or equivalent) 
4 
Upper secondary 
Leaving certificate, (including Applied 
and Vocational Programmes), ‘A’ 
Levels NCVA       Level 1 Certificate or 
equivalent) 
5 
Third level 
Non degree qualification 
(National Certificate, Diploma 
NCEA/Institute of Technology or 
equivalent) 
 
6 
Primary degree (Third level bachelor 
degree) 
7 
Professional qualification (of degree 
status at least) 
8 
Both a degree and a professional 
qualification 
9 
Postgraduate certificate or diplomas 10 
Postgraduate degree or masters 11 
Doctorate (PhD) 12 
Refused Y 
Don’t know X 
 
 
C.15 Have you ceased your full time 
education? 
Yes 1 
No 2 
Refused Y 
Don’t know X 
 
C.15a If Yes – At what age? 
  
Refused Y 
Don’t know X 
 
C.16 Interviewer to complete 
Carlow 1 Clare 18 
Dublin City 2 Kerry 19 
South Dublin 3 Limerick City 20 
Dublin Fingal 4 Limerick 
County 
21 
Dun Laoghaire 5 Tipperary NR 22 
Kildare 6 Tipperary SR 23 
Kilkenny 7 Waterford City 24 
Laois 8 Waterford 
County 
25 
Longford 9 Galway City 26 
Louth 10 Galway County 27 
Meath 11 Leitrim 28 
Offaly 12 Mayo 29 
Westmeath 13 Roscommon 30 
Wexford 14 Sligo 31 
Wicklow 15 Cavan 32 
Cork City 16 Donegal 33 
Cork County 17 Monaghan 34 
 
C.17 REMOVED  
 
I certify that this interview has been 
Carried out strictly in accordance with 
your instructions and within the Code of 
Conduct of the MRS. 
Intv. Sign:  
Intv. No:    
Date of 
Interview 
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IF AGED 15-17 SAY TO PARENT/RESPONSIBLE ADULT: 
 
Under the rules of the Market Research Society we are not allowed to ask children any 
questions without an adult’s permission.  May I have your permission to interview 
your child about lifestyles, such as alcohol, tobacco and drugs?  I will explain that 
he/she does not have to answer any question that he/she doesn’t want to. 
 
IF NECESSARY:  We need to interview 15 -17 year olds because it is important to 
understand changes to lifestyles over time 
 
REASSURE AS NECESSARY WITH REGARDS TO CONFIDENTIALITY, FOR 
RESEARCH PURPOSES ONLY ETC. 
 
HAND STANDARD LETTER TO PARENT OR RESPONSIBLE ADULT. 
 
PERMISSION & SIGNATURE MUST BE OBTAINED FROM A RESPONSIBLE ADULT 
BEFORE INTERVIEWING ANYONE AGED 15 
 
NAME AND SIGNATURE OF ADULT GIVING AUTHORITY FOR INTERVIEW: 
 
 
PRINT NAME:  
SIGNATURE:  
RELATIONSHIP TO 
CHILD: 
 
 
Interviewer record: 
Parent present during interview 1 
Parent not present during interview 2 
 
OFFICE USE ONLY 
Intervr. 
Check
ed 
Supervis
or 
Checked 
Supervis
or 
Accomp. 
Back- 
checked 
   Tel 1 
   Visit 2 
   Post 3 
   Date: 
 
Initials
: 
 
REMOVE NAME, ADDRESS AND TEL NUMBER FROM SCRIPT 
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Appendix F Showcards 
 
10-000957 
 
 
NACD 
 
POPULATION STUDY 
 
 
 
SHOWCARDS 
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10-000957            SHOWCARD ‘11C’ 
 
A
 s
ta
nd
ar
d 
dr
in
k 
is
 
 
A
 b
ot
tle
 o
f a
lc
op
op
s 
(2
75
 m
l l
on
g 
ne
ck
 
st
an
da
rd
 b
ot
tle
) 
 
 
A
 s
m
al
l g
la
ss
  
of
 w
in
e 
(1
00
 m
l) 
 
 
A
 s
in
gl
e 
m
ea
su
re
  
of
 s
pi
rit
s,
 fo
r 
ex
am
pl
e 
w
hi
sk
ey
, 
vo
dk
a,
 g
in
 
 
 
A
 h
al
f p
in
t o
r 
a 
gl
as
s 
 
of
 b
ee
r,
 la
ge
r 
or
 c
id
er
 
 
A
 s
m
al
l c
an
  
or
 s
m
al
l b
ot
tle
  
of
 b
ee
r,
 la
ge
r 
or
 c
id
er
 (
33
0m
l) 
 
Technical Report – General Population Survey on Drug Prevalence 2010/2011 
 
10-000957 November 2011 
10-000957            SHOWCARD ‘11D’ 
  
o
r 
6 
pr
e-
m
ix
ed
 
sp
iri
t d
rin
ks
 
(a
lc
op
op
s)
 
 
o
r 
on
e 
bo
ttl
e 
 
o
f 
w
in
e 
 
 
o
r 
7 
pu
b 
m
ea
su
re
s 
 
o
f 
sp
iri
ts
 
 
4 
pi
nt
s 
o
f 
b
e
e
r/
 
ci
d
e
r 
or
 m
or
e 
 
Technical Report – General Population Survey on Drug Prevalence 2010/2011 
 
10-000957 November 2011 
 
10-000957 SHOW CARD ‘11D2’ 
      
 
 
 
1 Daily 
2 4/5 times a week 
3 2/3 times a week 
4 Once a week 
5 2/3 times a month 
6 Once a month 
7 Less often than once a month 
8 Never 
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10-000957 SHOW CARD ‘16’ 
      
 
 
  
Sedatives Benzos 
Sleeping pills Roches 
Rohypnol ® Librium ® 
Roofies Valium ®, (Diazepam) 
Row rows Normison ®, (Duck eggs), 
Temazepam 
Dalmane ®, Flurazepam Ativan ® 
Mogadon ®, (Moggies), 
Nitrazepam 
Halcion ®, Triazolam 
Phenobarbitone Xanax ® 
Tranquillisers Stilnoct ®, Zolpidem 
Tranks Zimovane ®, Zopiclone 
Downers  
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10-000957 SHOW CARD ‘23’ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 Oral (tablets or syrup) 
2 Injection with a needle 
3 Other (please tell me which) 
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10-000957 SHOW CARD ‘24’ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 I got them on a prescription 
2 I got them from someone I know 
3 
I bought them without a prescription 
in a chemist 
4 I bought them over the internet 
5 Other (please tell me how) 
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10-000957 SHOW CARD ‘25’ 
 
 
 
 
 
 
 
 
 
 
 
 
Anti depressants Lustral ® 
Prozac ® Molipaxin ® 
Seroxat ® Zispin ® 
Prothiaden ® 
Olanzapine 
(Zyprexa ®) 
Effexor ® 
 
 
Technical Report – General Population Survey on Drug Prevalence 2010/2011 
 
10-000957 November 2011 
10-000957 SHOW CARD ‘32’ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 Oral (tablets or syrup) 
2 Injection with a needle 
3 Other (please tell me which) 
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10-000957 SHOW CARD ‘33’ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 I got them on a prescription 
2 I got them from someone I know 
3 
I bought them without a prescription 
in a chemist 
4 I bought them over the internet 
5 Other (please tell me how) 
 
 
 
Technical Report – General Population Survey on Drug Prevalence 2010/2011 
 
10-000957 November 2011 
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Cannabis Blow 
Marijuana Weed 
Dope Draw 
Grass Puff 
Pot Whacky Backy 
Hash(ish) Skunk 
Ganja Resin 
Shit  
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1 Never 
2 Once or twice 
3 3 to 5 times 
4 6 to 9 times 
5 10 to 19 times 
6 20 times or more 
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1 Grass 
2 Weed 
3 Skunk 
4 Hash Oil 
5 Herb 
6 Hash 
7 Resin 
8 Other (please tell me which) 
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1 Joint 
2 Pipe 
3 Bong 
4 Eat 
5 Other (please tell me which) 
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10-000957 SHOW CARD ‘45’ 
 
 
 
 
 
 
 
 
 
Ecstasy Mitsubishi 
Pills Shamrocks 
E MDMA 
XTC Yokes 
Doves 
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1 Never 
2 Once or twice 
3 3 to 5 times 
4 6 to 9 times 
5 10 to 19 times 
6 20 times or more 
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Amphetamines Ice 
Speed Crystal 
Billy Bennies 
Whizz Uppers 
Base Dexies 
Sulphate Purple hearts 
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10-000957 SHOW CARD ‘57’ 
 
 
 
 
 
 
 
 
 
1 Never 
2 Once or twice 
3 3 to 5 times 
4 6 to 9 times 
5 10 to 19 times 
6 20 times or more 
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10-000957 SHOW CARD ‘62’ 
 
 
 
 
 
 
 
 
 
 
 
Crack Stones 
Rock Freebase 
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10-000957 SHOW CARD ‘66’ 
 
 
 
 
 
 
 
 
 
 
 
 
1 Never 
2 Once or twice 
3 3 to 5 times 
4 6 to 9 times 
5 10 to 19 times 
6 20 times or more 
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10-000957 SHOW CARD ‘70’ 
 
 
 
 
 
 
 
 
 
 
 
 
Cocaine Snow 
Charlie Nose candy 
Coke Blow 
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10-000957 SHOW CARD ‘74’ 
 
 
 
 
 
 
 
 
 
 
 
 
1 Never 
2 Once or twice 
3 3 to 5 times 
4 6 to 9 times 
5 10 to 19 times 
6 20 times or more 
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10-000957 SHOW CARD ‘78’ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 Doing a line / Snort 
2 Injection with a needle 
3 Smoke 
4 Other (please tell me which) 
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10-000957 SHOW CARD ‘79’ 
 
 
 
 
 
 
 
 
 
 
 
 
Heroin Junk 
Smack Skag 
Gear Brown 
H Horse 
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1 Never 
2 Once or twice 
3 3 to 5 times 
4 6 to 9 times 
5 10 to 19 times 
6 20 times or more 
 
Technical Report – General Population Survey on Drug Prevalence 2010/2011 
 
10-000957 November 2011 
10-000957 SHOW CARD ‘87’ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 Smoke 
2 Injection with a needle 
3 “Chasing the dragon” 
4 Other (please tell me which) 
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10-000957 SHOW CARD ‘88’ 
 
 
 
 
 
 
 
 
 
 
 
 
 
LSD Trips 
Acid Tabs 
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10-000957 SHOW CARD ‘92’ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 Never 
2 Once or twice 
3 3 to 5 times 
4 6 to 9 times 
5 10 to 19 times 
6 20 times or more 
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10-000957 SHOW CARD ‘96’ 
 
 
 
 
 
 
 
 
 
 
 
 
Solvents Petrol 
Glues Nail varnish remover 
Dry-cleaning fluids 
Correction fluids  
e.g. Tipp-Ex ® 
Aerosols Gas lighter fuel 
Paint stripper 
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10-000957 SHOW CARD ‘100’ 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 Never 
2 Once or twice 
3 3 to 5 times 
4 6 to 9 times 
5 10 to 19 times 
6 20 times or more 
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10-000957 SHOW CARD ‘104’ 
 
 
 
 
 
 
 
 
 
Poppers Liquid gold 
Amyl Nitrite Locker room 
Rush 
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10-000957 SHOW CARD ‘108’ 
 
 
 
 
 
 
 
 
 
1 Never 
2 Once or twice 
3 3 to 5 times 
4 6 to 9 times 
5 10 to 19 times 
6 20 times or more 
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10-000957 SHOW CARD ‘112’ 
 
 
 
 
 
 
 
 
 
 
Magic 
Mushrooms 
Mushies 
Psilocybin 
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10-000957 SHOW CARD ‘116’ 
 
 
 
 
 
 
 
 
 
 
 
 
1 Never 
2 Once or twice 
3 3 to 5 times 
4 6 to 9 times 
5 10 to 19 times 
6 20 times or more 
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1 I picked them myself 
2 I got them from someone I know 
3 I bought them off the internet 
4 I bought them in a shop / market 
5 Other (please tell me how) 
Technical Report – General Population Survey on Drug Prevalence 2010/2011 
 
10-000957 November 2011 
10-000957 SHOW CARD ‘121’ 
 
 
 
 
 
 
 
 
 
Methadone Brown (phy) 
Physeptone ® Green (phy) 
Phy 
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10-000957 SHOW CARD ‘128’ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 I got them on a prescription 
2 I got them from someone I know 
3 
I bought them without a prescription 
in a chemist 
4 I bought them over the internet 
5 Other (please tell me how) 
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10-000957 SHOW CARD ‘138’ 
 
 
 
 
Opiates (excluding heroin & methadone) 
Temgesic ® 
Codeine  
(examples on the next show card) 
Kapake ® 
Morphine 
Opium 
DF118 ® (DF’s) 
Diffs 
Dikes 
Peach 
Fentanyl 
(Durogesic ® & Sublimaze ® & Actiq ®) 
Oxycodone  
(Oxycontin ® & Oxynorm ®)  
MST ® (MST’s) 
Buprenorphine (Subutex ®) 
Diconal ® 
Pethidine 
Napps 
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10-000957 SHOW CARD ‘138’ CODEINE 
 
DF 118 30 Tablets 
FEMINAX TABLETS 
KAPAKE 
MAXILIEF EFFERVESCENT TABLETS PARACETAMOL 
MIGRALEVE 
MIGRALEVE PINK 
MIGRALEVE YELLOW 
NUROFEN PLUS 
NUROFEN PLUS IBUPROFEN / CODEINE PHOSP 
NUROFEN PLUS TABLETS 
PANADEINE TABLETS 
PARACETAMOL / CAFFEINE / CODEINE AND 
DOXYLAMINE 
PARACODIN 0.2 Syrup 
PARACODIN 
PARAMOL 
SOLPADEINE CAPSULES (Capsules Hard) 
SOLPADEINE SOLUBLE  Tablets 
SOLPADEINE SOLUBLE TABLETS, Tablets Effervescent 
SOLPADEINE TABLETS 
SOLPADOL Tablets Effervescent 
SOLPADOL CAPLETS 
SYNDOL Tablets 
TYLEX  Capsules Hard 
TYLEX Tablets Effervescent 
UNIFLU PLUS WITH VITAMIN C TABLETS 500 Tablets 
VEGANIN PLUS 
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10-000957 SHOW CARD ‘145’ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 I got them on a prescription 
2 I got them from someone I know 
3 
I bought them without a prescription 
in a chemist 
4 I bought them over the internet 
5 Other (please tell me how) 
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10-000957 SHOW CARD ‘146’ 
  
 
Anabolic Steroids 
 
(There are more than 100 kinds of anabolic steroids which are used in body 
building as well as in gender reassignment and the treatment of certain sexual 
dysfunctions.  This does not include steroids taken for the treatment of 
respiratory ailments e.g. Asthma, Arthritis and other inflammatory conditions) 
Dianabol 
Deca-Durabolin ®, Durabolin ®, Nandrolone 
Stanozolol 
DHEA 
Winstrol ® 
British Dragon, Primobol ® (Primo) 
Clenbuterol 
Methandranone 
Stanolone 
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10-000957 SHOW CARD ‘153’ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 I got them on a prescription 
2 I got them from someone I know 
3 
I bought them without a prescription 
in a chemist 
4 I bought them over the internet 
5 Other (please tell me how) 
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10-000957 SHOW CARD ‘154’ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 More as a criminal 
2 More as a patient 
3 Neither a criminal nor a patient 
4 Both a criminal and a patient 
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10-000957 SHOW CARD ‘155’ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 Fully agree 
2 Largely agree 
3 Neither 
4 Largely disagree 
5 Fully disagree 
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10-000957 SHOW CARD ‘156’ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 Do not disapprove 
2 Disapprove 
3 Strongly disapprove 
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10-000957 SHOW CARD ‘157’ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 No risk 
2 Slight risk 
3 Moderate risk 
4 Great risk 
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10-000957 SHOW CARD ‘162’ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 Yes – tried to and stopped 
2 Yes -  tried to but not stopped 
3 No 
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10-000957 SHOW CARD ‘163’ 
 
 
 
 
 
1 Cost / could no longer afford it 
2 Persuaded by friends / family 
3 Impact on job / friends / family 
4 No longer part of social life 
5 Concern about health / health reasons 
6 Pregnancy 
7 Less available supply 
8 Gave up smoking cigarettes 
9 Put on rehabilitation programme 
10 Did not want to take anymore 
11 Did not enjoy after effects 
12 The pros of taking did not outweigh the cons 
13 Other (please tell me) 
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1 Given by family / friend 
2 Given by a contact I did not know personally 
3 Given by a stranger 
4 Shared amongst group of friends 
5 Bought from a friend 
6 Bought from a contact I did not know personally 
7 Bought from a stranger 
8 Other (please tell me) 
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10-000957 (173) SHOW CARD ‘163b’ 
 
 
 
 
 
 
 
 
1 Street / park 
2 Disco / bar / club 
3 Office / workplace 
4 School / college 
5 House of a dealer 
6 House of a friend 
7 Ordered by phone for collection / delivery 
8 Internet 
9 Other (please tell me) 
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10-000957 (174) SHOW CARD ‘163c’ 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 Very easy 
2 Fairly easy 
3 Neither easy nor difficult 
4 Fairly difficult 
5 Very difficult 
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10-000957  (191)       SHOWCARD ‘164a’ 
 
 
 
 
 
 
 
 
1 No 
2 Yes, once 
3 Yes, more than once 
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10-000957  (191.1)    SHOWCARD ‘164b’ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Examples of significant problems are: 
Missed days and poor performance at work or school / 
college; 
Suspended or expelled from school; 
Neglected children and or other family members 
 
 
 
1 No 
2 Yes, once 
3 Yes, more than once 
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10-000957  (191.4)      SHOWCARD ‘164c’ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Examples of committing an offence are: 
Possession of cannabis for use, sale or supply 
Theft to obtain the substance 
Driving under its influence 
 
 
 
1 No 
2 Yes, once 
3 Yes, more than once 
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10-000957 (192)        SHOWCARD ‘165’ 
 
 
 
 
 
 
 
 
1 No, never 
2 Yes, in the last 12 months 
3 Yes, but more than 12 months ago 
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10-000957 (192.2)        SHOWCARD ‘165a’ 
 
When you used less or none at all,  
did you experience any of the following? 
 
Trouble sleeping Anxiety 
Sweating Irritability 
Trembling Depression 
Rapid heartbeat 
 
 
 
1 No, never 
2 Yes, in the last 12 months 
3 Yes, but more than 12 months ago 
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10-000957 (192.7)        SHOWCARD ‘165b’ 
 
 
 
 
 
 
Eye and mouth 
dryness 
Hoarseness 
Nausea Persistent cough 
 
 
 
 
 
 
1 No, never 
2 Yes, in the last 12 months 
3 Yes, but more than 12 months ago 
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10-000957 (192.8)        SHOWCARD ‘165c’ 
 
 
 
Apathy (not caring about anything) 
Depression 
Paranoia (suspicion of other people, feelings 
that people are thinking and talking about you) 
Thinking and seeing things differently 
Heightened sense of awareness 
 
 
 
 
1 No, never 
2 Yes, in the last 12 months 
3 Yes, but more than 12 months ago 
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10-000957 SHOW CARD ‘166’ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 Yes – tried to and stopped 
2 Yes -  tried to but not stopped 
3 No 
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10-000957 SHOW CARD ‘167’ 
 
 
 
 
1 Cost / could no longer afford it 
2 Persuaded by friends / family 
3 Impact on job / friends / family 
4 No longer part of social life 
5 Concern about health / health reasons 
6 Pregnancy 
7 Less available supply 
8 Put on rehabilitation programme 
9 Did not want to take anymore 
10 Did not enjoy after effects 
11 The pros of taking did not outweigh the cons 
12 Other (please tell me) 
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10-000957        SHOW CARD ‘175’ 
 
 
 
 
 
 
 
 
 
 
1 Given by family / friend 
2 
Given by a contact I did not know 
personally 
3 Given by a stranger 
4 Shared amongst group of friends 
5 Bought from a friend 
6 
Bought from a contact I did not know 
personally 
7 Bought from a stranger 
8 Other (please tell me how) 
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10-000957 SHOW CARD ‘176’ 
 
 
 
 
 
 
 
 
1 Street / park 
2 Disco / bar / club 
3 Office / workplace 
4 School / college 
5 House of a dealer 
6 House of a friend 
7 
Ordered by phone for collection / 
delivery 
8 Internet 
9 Other (please tell me) 
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10-000957 SHOW CARD ‘177’ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 Very easy 
2 Fairly easy 
3 Neither easy nor difficult 
4 Fairly difficult 
5 Very difficult 
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10-000957 (170) SHOW CARD ‘177a’ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 Yes – tried to and stopped 
2 Yes -  tried to but not stopped 
3 No 
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10-000957 (171) SHOW CARD ‘177b’ 
 
 
 
1 Cost / could no longer afford it 
2 Persuaded by friends / family 
3 Impact on job / friends / family 
4 No longer part of social life 
5 Concern about health / health reasons 
6 Pregnancy 
7 Less available supply 
8 Put on rehabilitation programme 
9 Did not want to take anymore 
10 Did not enjoy after effects 
11 The pros of taking did not outweigh the cons 
12 Other (please tell me) 
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10-000957      SHOWCARD ‘178’ 
 
 
 
1 Given by family / friend 
2 
Given by a contact I did not know 
personally 
3 Given by a stranger 
4 Shared amongst group of friends 
5 Bought from a friend 
6 
Bought from a contact I did not know 
personally 
7 Bought from a stranger 
8 Other (please tell me how) 
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10-000957 SHOW CARD ‘179’ 
 
 
 
 
 
 
 
 
1 Street / park 
2 Disco / bar / club 
3 Office / workplace 
4 School / college 
5 House of a dealer 
6 House of a friend 
7 
Ordered by phone for collection / 
delivery 
8 Internet 
9 Other (please tell me which) 
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10-000957 SHOW CARD ‘180’ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 Very easy 
2 Fairly easy 
3 Neither easy nor difficult 
4 Fairly difficult 
5 Very difficult 
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10-000957          SHOWCARD ‘183’ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 
Herbal smoking mixtures / incense e.g. 
Smoke, Spice, Sence 
2 Party Pills or Herbal Highs 
3 Bathsalts, Plantfeeders or Other Powders 
4 Kratom (Krypton) 
5 Salvia, Magic mint, Divine mint or Sally D 
6 Other (please tell me which) 
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10-000957           SHOWCARD ‘185’ 
 
 
 
 
 
 
1 I got them from a friend or someone I know 
2 I bought them off the internet 
3 I bought them in a headshop 
4 I bought them in a shop other than a headshop 
5 I bought them in a market 
6 I bought them from a dealer 
7 Other, please specify 
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10-000957          SHOWCARD ‘193.C’ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Missed days and poor performance at work or 
school / college; or, 
Suspended or expelled from school / college; or, 
Neglected children and / or other family members 
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10-000957      SHOWCARD ‘C2’ 
 
 
 
 
 
 
 
 
 
1 Single (never married) 
2 Married 
3 Co-habiting 
4 Separated 
5 Divorced 
6 Widowed 
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10-000957      SHOW CARD ‘C4’ 
 
White 
Irish 1 
Irish Traveller 2 
British 3 
Roma 4 
Any other White background 
(specify)_______________ 
5 
Black or Black 
Irish 
African 6 
Any other black background 
(specify)_______________ 
7 
Asian or Asian 
Irish 
Chinese 8 
Any other Asian background 
(specify) _______________ 
9 
Other 
including 
mixed 
background 
Specify_________________ 10 
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10-000957      SHOW CARD ‘C6’ 
 
 In Paid Job 
1 Self employed 
2 Working full-time 30hrs+ / week 
3 Working part time 
 No Paid Job 
4 Seeking work for the first time 
5 Unemployed (having lost or given up job) 
6 Home (domestic) duties 
7 Unable to work due to permanent illness / disability 
8 Not working (seeking work) 
9 Not working (not seeking work) 
10 On Government training / education scheme 
11 On Government employment scheme (CE, job options etc) 
12 Retired 
13 Student 
14 Other (please tell me which) 
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10-000957      SHOW CARD ‘C6c’ 
 
1 Jobseeker’s Benefit  
(Unemployment benefit) 
2 Jobseeker’s Allowance  
(Unemployment assistance) 
3 One parent family payment 
4 Illness Benefit  
(Disability benefit) 
5 Disability allowance 
6 Invalidity pension 
7 Carer’s allowance 
8 Family income supplement 
9 Widow / widowers pension 
10 Other (please tell me which) 
Technical Report – General Population Survey on Drug Prevalence 2010/2011 
 
10-000957 November 2011 
10-000957      SHOW CARD ‘C10’ 
 
A Retired, gets pension from previous job 
B Unemployed, less than 2 months 
C Sick, still receiving pay or statutory pay from job 
D 
Widowed, receiving pension from spouse’s previous 
job 
E Divorced / separated, receiving maintenance 
F Full-time student 
G Not working, private means 
H Unemployed longer than 2 months 
I 
Sick – only receiving Income Support or Invalidity 
Benefit 
J Receiving State Pension only 
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A person has a disability if he / she has a physical 
or mental impairment which has a substantial and 
long-term adverse effect on his / her ability to 
carry out normal day to day activities.   
 
On the basis of this definition, do you regard 
yourself as being disabled? 
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10-000957      SHOW CARD ‘C14’ 
 
1 No formal education 
2 Primary education 
3 
Lower secondary 
(Junior / Intermediate / Group Certificate, ‘O’ levels / 
GCSEs, NCVA Foundation Certificate, basic Skills 
Training Certificate or equivalent) 
4 
Upper secondary 
Leaving certificate, (including Applied and 
Vocational Programmes), ‘A’ Levels NCVA Level 1 
Certificate or equivalent) 
5 
Third level 
Non degree qualification (National Certificate, 
Diploma NCEA / Institute of Technology or 
equivalent) 
6 Primary degree (Third level bachelor degree) 
7 Professional qualification (of degree status at least) 
8 Both a degree and a professional qualification 
9 Postgraduate certificate or diplomas 
10 Postgraduate degree or masters 
11 Doctorate (PhD) 
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Appendix G Contact sheet 
 
DRUGS PREVALANCE SURVEY 
CONTACT SHEET – 10-000957 
 
 
 
 
 
Q.C1 
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WEEKDAY 
(1-7) 
EXACT 
TIME DATE  COMMENTS - record outcome of each call 
E-Progress 
Updated P 
Interviewer 
Initial 
1 
      
2 
      
3 
      
4 
      
5 
      
6 
      
7 
      
8 
      
      
   
TOTAL NUMBER OF CALLS (WRITE IN BOX)    
 You must record at least 5 attempts in total to make appointment/complete interview before abandoning address. 
For 15-24 year old selected respondents a further 2 calls must be made before abandoning. 
 At least one call must be an evening and one at a weekend plus one further evening or weekend call. 
CONTACT CODES:  WEEKDAY  MON = 1   TUES = 2    WED = 3   THURS = 4   FRI = 5   SAT = 6   SUN = 7 
 
 
 
 
Serial 
Number  
Check Letter  Point Number  
 
 
Issue 1 
Interviewer  
Issue 2 
Interviewer  
Issue 3 
Interviewer  
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*  HOUSE/ HOUSEHOLD SELECTION 
 
QC2A. House/Apartment & Household Selection Grid 
 
Record number of properties / 
households sharing address 1 2 3 4 5 6 7 8 9 
Choose property / household 1 1 2 1 4 6 2 5 4 
 
 
*  RESPONDENT SELECTION * 
 
 
Q.C2
B 
I’d like to interview one of the people aged 15 - 64 who live in this household, and in 
order to choose fairly, I’d like to ask a few questions.  Can you tell me how many 
people (aged between 15 and 64) currently live here as part of this household? 
  One only 01 COMPLETE INTERVIEW 
  Two or more 02 COMPLETE DETAILS BELOW 
  None 03 GO TO Q.C5 
 
 
 
 
Q.C
3 
We have a special way of selecting which person to interview and in order 
to choose fairly, can you please tell me the first name or initial of each 
member of the household (aged between 15 & 64), and the date and month 
they have their birthday. 
LIST NAMES/INITIALS BELOW  
PERSO
N NO. 
NAME OR 
INITIAL 
DATE 
&MONTH 
OF BIRTH 
INCLUDE: 
1   People normally living here away for up to 6 
months 
2   People away at work for whom this is main 
address 
3   Boarders and lodgers 
4    
5   EXCLUDE 
6   People 18+ living elsewhere for study/work 
7   Spouses separated and no longer resident 
8   People away for 6 months or more 
9    
10    
 
 
INTERVIEWER:  CIRCLE PERSON NUMBER WHO HAD BIRTHDAY LAST – YOU MUST 
ATTEMPT TO INTERVIEW THIS PERSON.  NO SUBSTITUTIONS ARE ALLOWED ONCE 
SELECTED.  MAKE APPOINTMENT IF NECESSARY. 
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• ONLY ASK AGE OF SELECTED RESPONDENT - WRITE IN HERE  
•  
• IF SELECTED RESPONDENT IS AGED 15 OBTAIN PARENTAL 
PERMISSION 
 
 
 
Q.C4 RECORD RESPONDENT’S FULL NAME & TELEPHONE NUMBER, 
(INCLUDING STD). 
 
TITLE:  FULL NAME:  
 
TELEPHONE (INC STD 
CODE): 
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*  DWELLING INFORMATION  * 
 
Q.C5 
Code property type of printed address: 
 
House/bungalow – detached 01 
House/bungalow – semi-detached 02 
House/bungalow – mid terrace 03 
House/bungalow – end terrace 04 
Purpose built flat/maisonette(s)/ apartment(s) - building less than six 
floors 
05 
Purpose built flat/maisonette(s)/ apartment(s)  - building six or more 
floors 
06 
Conversion flat/maisonette(s)/Shared House 07 
Hostel or bed and breakfast 08 
Other (WRITE IN) 09 
  
 
Technical Report – General Population Survey on Drug Prevalence 2010/2011 
 
10-000957 November 2011 
Q.C6 
FINAL OUTCOME  
Successful interview 01 
R
EF
U
SE
D
 Refused before respondent selection  02 
Refused after respondent selection 03 
Entry to block/scheme refused by warden etc 04 
N
O
 C
O
N
TA
C
T Unable to access block/scheme/gated apartments 05 
Occupied, no contact at address after  5+ calls 06 
No contact with selected resident, 4+ calls 07 
Occupier in but not answering door after 5+ calls 08 
Unsure if occupied, no contact after 5+ calls 09 
PR
O
PE
R
TY
 
IN
EL
IG
IB
LE
 Property vacant 10 
Property derelict 11 
Property demolished 12 
Non-residential property 13 
Property not found 14 
O
TH
ER
 
Too ill to participate 
WRITE IN DESCRIPTION 15 
Away during fieldwork  
WRITE IN DATE BACK 
16 
Household Not Eligible 
WRITE IN REASON 
17 
Mother tongue required  
WRITE IN LANGUAGE 
18 
Other  
WRITE IN 
19 
Withdrawn by Head Office 20 
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Q.C7 
REFUSAL INFORMATION 
R
EA
SO
N
 F
O
R
 R
EF
U
SA
L 
 (M
U
LT
IC
O
D
E 
O
K
) 
Never does surveys 01 
Interview takes too long 02 
Taken part in too many surveys  03 
Interview is too intrusive 04 
Too busy at this time 05 
Always too busy 06 
Worried about misuse of information  07 
Worried about confidentiality 08 
Worried about safety/security 09 
Survey is a waste of money 10 
Not interested in helping government 11 
Not interested in subject matter 12 
“Nothing in it for me” 13 
Other (WRITE IN) 14 
 
 
 
R
E
-
C
O
N
T
A
C
T
 
Do not recontact 
respondent likely to take offence or be potentially dangerous if further efforts made 
to persuade them to take part 
15 
ES
TI
M
A
TE
D
 
C
O
N
TA
C
T 
D
ET
A
IL
S 
Estimated Age  
WRITE IN 
 
Sex of person refusing:  
Male 01 
Female 02 
 
 To which one of the following groups do you consider 
contact belongs? 
                                                                                                 
White  Irish 1 
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Irish Traveller 2 
British 3 
Roma 4 
Any other White background (specify)________ 5 
Black or 
Black Irish 
African 6 
 
Any other black background (specify)________ 
7 
Asian or  
Asian Irish 
Chinese 8 
 
Any other Asian background (specify)________ 
9 
Other 
including 
mixed 
background  
Specify________ 10 
Remember to return all contact sheets to the office (productives and                                                       
failures) as soon as possible. 
 
Check all relevant sections have been coded. 
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Appendix H NACD letter to survey respondents 
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Appendix I Letter to households 
 
 
Population Survey on behalf of 
Department of Community, Equality and Gaeltacht Affairs and  
the National Advisory Committee on Drugs (NACD) in the Republic of Ireland 
 
Ipsos MORI is a market research company which has been commissioned by the above 
organisations to conduct a study on lifestyles.  
 
The survey will investigate people’s views on a wide range of issues including their attitudes 
and behaviour in relation to tobacco, alcohol and other drugs. The information will help the 
Department and the National Advisory Committee on Drugs (NACD) give advice in relation to 
policy and services in these areas. I have attached a more detailed information leaflet.  
 
The company are interviewing 5,000 people between the ages of 15 and 64 across Ireland. 
All of the addresses chosen to take part in the survey have been selected at random from 
all residential addresses in Ireland to which An Post delivers mail.  Within each household 
there is a further random procedure to select who in the household should be interviewed. 
The selection of the individual household member would take place when the interviewer 
calls. As your address was one of those selected, we would be very grateful if the selected 
household member would volunteer to take part in the survey. 
 
There is no need to respond to this letter, as one of our interviewers will call at your home 
during the next month and, if it is convenient, we hope you will be able to spare 
approximately ten to twenty five minutes to answer some questions.  The interviewer will 
carry an identification card which should be presented to you. The interview will be 
conducted using a laptop computer so the interviewer will need to carry out the interview 
inside your home. This laptop is encrypted and password protected. Your name and address 
will not be recorded on the laptop but your household will be identified by a survey number 
which will be used for administrative purposes. All of the information collected will be treated 
in strict confidence and will be processed solely for the purposes of this survey. 
 
The company conforms with the principles of the Data Protection Act.  The information you 
provide will not be disclosed to anyone outside the research team. The research team 
includes the market research company, the NACD and the Health Research Board. The 
results of the research will be published in 2011.  The research data will remain 
confidential at all times and it will not be possible to identify you or any other member 
of your household from the published information. 
 
As it is important to have the views of the widest possible range of people, I hope you will 
agree to take part in the survey.  
 
Thank you, in anticipation, for your help. 
 
Yours sincerely 
 
 
 
 
 
Ipsos MORI 
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Population Survey on behalf of 
Department of Community, Equality and Gaeltacht Affairs and  
the National Advisory Committee on Drugs (NACD) in the Republic of Ireland 
 
You are invited to take part in our research study.  Before you decide it is important for you to 
understand why this research is being done and what it will involve.  Please take time to read 
the following information carefully and ask us if there is anything that is not clear or if you 
would like more information.  Take time to decide whether or not you wish to take part. 
 
What is this research about?   
This research is being carried out by the market research company (Ipsos MORI) on behalf 
of the National Advisory Committee on Drugs (NACD). The aim of this research is to gain a 
better understanding about the number of people who have taken tobacco, alcohol or other 
drugs, how they are used and what is their effect on their family, friends and community. This 
will allow us to identify gaps in policy and services for drug users or others affected by drug 
use.      
 
What will my responsibilities be if I take part? 
A researcher from Ipsos MORI will ask a series of questions about your tobacco, alcohol and 
drug use and attitudes towards these drugs. The interview will take about 20 minutes and 
your answers to the interview will be recorded on an encrypted and password protected 
computer.   
 
What if I decide not to take part? 
Your participation in the study is entirely voluntary.  If you decide to take part but then 
change your mind you are free to withdraw at any time without having to give a reason and 
any information that you have given will not be used.  You are also entitled to refuse to 
answer specific questions.      
 
What will happen to the information I give? 
Anything that you tell the interviewer will be strictly confidential. The data will be stored on an 
encrypted password protected computer. The information you provide will not be disclosed to 
anyone outside the research team. The research team includes the market research 
company, the NACD and the Health Research Board. Only Ipsos MORI will have access to 
the data.  The NACD and the Health Research Board will only have access to the 
anonymised data. The results of the research will be published in 2011. The research data 
will remain confidential at all times and it will not be possible to identify you or any other 
member of your household from the published information. 
 
If I have any questions or problems who can I call? 
If you have any questions or problems regarding this research you can contact the Ipsos 
MORI director, Ms Orla Deasy on 04890 500 800 or NACD director Ms Susan Scally at 01-
6473242 or Mr. Eddie Arthurs, Office of the Minister for Drugs at 01-647 3018 
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Appendix J Letter to An Garda Síochána  
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Appendix K Parental permission form 
 
10-000957 
 
 
 
 
Ipsos MORI 
Temple House 
Temple Road 
Blackrock 
Co Dublin 
  
 
Population Survey on behalf of 
Department of the Community, Equality and Gaeltacht Affairs and 
the National Advisory Committee on Drugs in the Republic of Ireland 
 
 
Your child __________  aged _____________ has been selected randomly from the people aged 15-64 in 
your household to participate in a study about lifestyles including topics on alcohol, tobacco and drugs. 
Your household’s address was earlier selected randomly from all residential addresses to which An Post 
delivers mail. 
 
We are interviewing 5,000 people between the ages of 15 and 64 and their answers to the study will all 
be grouped together so that no individual’s responses will be identified. 
 
We need to interview people as young as 15 years old because it is important to understand changes to 
lifestyles over time. Under the rules of the Market Research Society we are not allowed to ask children 
under 16 any questions without an adult’s permission. He/she will not have to answer any questions 
he/she doesn’t want to.   
 
Your child’s name, address and telephone number will not be passed to anyone outside our company so 
neither you nor your child will be contacted by anyone outside the company as a result of participation in 
the study. All the details collected are purely for the purpose of market research and the information is 
used purely for statistical purposes. The only contact that may be made would be if a supervisor or 
member of staff wrote to, telephoned or called you or your child to check only that the interview was 
carried out to instructions. 
 
You may if you wish be present at your child’s interview, although he/she may be more comfortable if you 
are out of hearing. 
 
If you give consent to your child taking part in this important study please sign both copies. 
One is for you to keep and one will be sent into the office for our records. 
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Appendix L Frequently asked questions 
Population Survey on behalf of Department of Community, Equality 
and Gaeltacht Affairs and the National Advisory Committee on 
Drugs (NACD) in the Republic of Ireland 
 
You are invited to take part in our research study.  Before you decide it is important 
for you to understand why this research is being done and what it will involve.  
Please take time to read the following information carefully and ask us if there is 
anything that is not clear or if you would like more information.  Take time to decide 
whether or not you wish to take part. 
 
What is this research about?   
This research is being carried out by the market research company (Ipsos MORI) on 
behalf of the National Advisory Committee on Drugs (NACD). The aim of this 
research is to gain a better understanding about the number of people who have 
taken tobacco, alcohol or other drugs, how they are used and what is their effect on 
their family, friends and community. This will allow us to identify gaps in policy and 
services for drug users or others affected by drug use.      
 
What will my responsibilities be if I take part? 
A researcher from Ipsos MORI will ask a series of questions about your tobacco, 
alcohol and drug use and attitudes towards these drugs. The interview will take about 
20 minutes and your answers to the interview will be recorded on an encrypted and 
password protected computer.   
 
What if I decide not to take part? 
Your participation in the study is entirely voluntary.  If you decide to take part but then 
change your mind you are free to withdraw at any time without having to give a 
reason and any information that you have given will not be used.  You are also 
entitled to refuse to answer specific questions.      
 
What will happen to the information I give? 
Anything that you tell the interviewer will be strictly confidential. The data will be 
stored on an encrypted password protected computer. The information you provide 
will not be disclosed to anyone outside the research team. The research team 
includes the market research company, the NACD and the Health Research Board. 
Only Ipsos MORI will have access to the data.  The NACD and the Health Research 
Board will only have access to the anonymised data. The results of the research will 
be published in 2011. The research data will remain confidential at all times and it will 
not be possible to identify you or any other member of your household from the 
published information. 
 
If I have any questions or problems who can I call? 
If you have any questions or problems regarding this research you can contact the 
Ipsos MORI director, Ms Orla Deasy on 04890 500 800 or NACD director Ms Susan 
Scally at 01-6473242 or Mr. Eddie Arthurs, Office of the Minister for Drugs at 01-647 
3018 
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Appendix M Interviewer instructions 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Interviewer Instructions 
 
POPULATION STUDY 
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10-000957 
1. Background to the Study 
 
 
The European Union has an ongoing Action Plan on drugs to establish and monitor 
the prevalence of drug use in the general population of the EU member states. 
 
To enable the EU to take this forward all member countries carry out population studies 
using a common methodology and basic questionnaire. 
This, the third study of its type in Ireland will provide data about the frequency of drug use 
(both legal and illegal) among the general population of Ireland.   
  
A similar study was carried out by us in 2006/2007 for the National Advisory Committee on 
Drugs (NACD).  Four years before that we carried out the first ever such study in Ireland and 
Northern Ireland for NACD and the Drug and Alcohol Information and Research (DAIRU).  
These bodies represent an all-Ireland front in providing data and advice to various 
government departments about the prevalence of drug use and other related aspects. 
 
NACD has commissioned Ipsos MORI in the Republic of Ireland to interview 5,000 adults 
aged between 15 and 64, using a CAPI methodology.   
 
We will, as far as possible, carry out the interviewing across the same time period as the 
previous study, October to April with a break for Christmas and the New Year. 
 
 
NACD was established in 2000 to provide advice to the Government on problem drug use in 
Ireland in relation to prevalence, prevention, consequences and treatment based on its 
analysis of reliable and relevant information.  The research we will undertake will provide 
robust trend information on drug use on Ireland.  Information on the use of substances such 
as tobacco, alcohol and drugs for lifetime use, last year and last month will be examined 
together with opinions on drug matters. 
 
NACD has published four bulletins from the previous survey which can be downloaded form 
the website www.nacd.ie 
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2. Sampling 
 
 
 
 
In this study the people to be interviewed are to be adults aged 15-64 whose normal place 
of residence is the Republic of Ireland.  The people can be of any nationality, so long as 
they are living in the Republic of Ireland at the time the study is being worked.  There are no 
exclusions; in other words anyone in the population in that age group could be selected for 
interview. 
 
We will interview a minimum of 5,000 people across the Republic of Ireland by means of a 
random selection method.  
 
To arrive at the addresses where interviewers will call we have ranked sampling points in 
order of the social deprivation index so that all types of areas will be represented.  We then 
select sampling points using a random selection procedure to ensure that the points chosen 
will give a full representation of the different types of areas in the country.    In each of the 
sampling points or areas we have then selected main and reserve addresses, again 
randomly.  
 
 Addresses have been chosen from each of the Regional Drugs Task Force (RDTF) areas in 
the Republic of Ireland. The number of addresses chosen is proportionate to the populations 
in each RDTF, so for example, as there are more people living in the Southern RDTF area 
than in any of the other boards, it follows that we have more addresses here to obtain more 
interviews.   
The number of interviews to be achieved in each of the RDTF areas is as follows: 
 
 
ERHA * 1,750 
Southern RDTF (Southern Health Board 640 
South Eastern RDTF (South Eastern HB) 460 
Western RDTF (Western HB) 450 
North Eastern RDTF (North Eastern HB) 450 
Mid Western RDTF (Mid Western HB) 450 
Midland RDTF (Midlands HB) 400 
North Western RDTF (North Western HB) 400 
Total 5,000 
 
 
* ERHA is the combined group of RDTFs Northern Area RDTF, South Western RDTF, East 
Coast RDTF, each equivalent to the former local health board areas, prior to 2005 
 
 
 
 
 
 
When using random sampling to select individuals for interview the results obtained are very 
accurate so long as very precise instructions are followed accurately, in order that the 
correct person is chosen for interview. 
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Interviewing will be conducted over the next few months.  It is important that we spread the 
interviews across the time period so that any changes in the behaviour of our respondents 
during holiday periods, for example, is not over represented. 
 
Our nationally representative sample of addresses has been selected from the An 
Post/Ordnance Survey Geo-Directory. The Geo Directory is comprised of all addresses to 
which An Post delivers mail.  The files are updated regularly from information collected from 
each postal round, so provide the most comprehensive and up to date sample frame 
available in the Republic of Ireland. 
 
The sample we have selected excludes large users and organisations so the vast majority of 
addresses issued to each interviewer will be private residential addresses. 
 
Each assignment will contain a specific number of addresses which should all be 
approached and an attempt made to interview the selected individual at each address, 
providing there is someone aged 15-64 living there. 
 
Overall we need to achieve a high response rate although we appreciate that some areas will 
prove more fruitful than others. 
 
All selected addresses with unique addresses will be written to on NACD headed paper in 
advance of fieldwork, to advise the occupiers that an interviewer will be calling with the view 
to take an interview with a person aged between 15 and 64 from the household.  Interviewers 
will have copies of the letter to hand out in case the contact at the door does not recall 
seeing the letter.    It may be that in some instances the letter may not have been delivered 
or the contact has not seen it so be prepared to give a copy to the contact you make and 
allow them time to peruse it.  In the case of non unique addresses the interviewer will have 
the original letter to hand deliver at the first call as well as a copy.  
 
The reason that we send letters in advance of interviewers calling is to prepare the way for 
interviewers gaining access to the home and being able to sit down with their laptop 
computer.   
There is also a letter from the Project Director, Orla Deasy, written on Ipsos MORI headed 
paper and again you will have copies and originals for non-unique addresses. 
 
We will be working across 385 different sampling points over the fieldwork period.  Each 
sample point will have 31 main addresses with six or seven held in reserve to cover 
ineligibles.  Working across this number of sample points will give us a wide coverage of the 
country. 
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3. When to Interview 
 
 
 
Each address has to be visited a minimum of five times before it can be deemed to be non 
effective.  Where a 15 -24 year old is the selected person then a further two calls must be 
made.   
 
The reason for this approach is to ensure that each address has the best possible chance 
of providing an interview.   
 
It is essential therefore to space out your calls across different days and times of day so as to 
allow people living at an address the best chance of being contacted. 
 
Ideally you should not begin work before mid-afternoon (c. 3.30pm) which will maximise your 
chances of finding someone at home. 
 
Once you have made contact with a responsible adult in the household you will follow a 
strict procedure to select the correct individual in the household to interview. 
 
You will keep a record of the number of calls and times of these calls on the Contact Record 
Sheet, explained in Chapter 4 and will update us after each day’s work by means of “i-
Progress”.  We will then be able to monitor and inform NACD on achievement, not only on 
completed interviews but also on number of calls made, and eventual outcomes.  
 
Until you have established contact you should make your calls before 9.00pm and from 
Monday to Sunday.  Calls later than 9:00 pm can only be made by prior appointment and a 
first call on a Sunday should be made after mid-day. 
 
You must not make subsequent calls at the same time of day, as it is likely that if the 
household is empty at 5.00pm on a Tuesday it will be on a Wednesday and Thursday too! 
 
If you establish that a young person (that is aged between 15 and 24) is the selected 
respondent you must make an additional two evening and/or weekend calls before you can 
send back the contact sheet as non effective. We also have a music voucher for this age 
group to encourage participation. 
 
Although it will be necessary to keep trying to make contact at some addresses at different 
times of day and on different days it is worth knowing that on the last survey over 50% of all 
the successful interviews were carried out on the first or second call! 
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4. The Contact Record Sheet/Address List 
 
 
 
In this study you will be given particular addresses in a relatively small geographical area.  
These are printed on to “Contact Sheets” and how you record the information you will collect 
when making your calls is crucial to the overall success and reporting on this study. 
 
It is sensible to plan your route before going out on the first day so that you can make your 
initial calls as quickly and easily as possible.  You may wish to consult a street map or 
ordnance survey map showing town-lands to help you plan your route. If you don’t know the 
area you have been given you may wish to drive round in daylight on your first day. 
 
 
When you receive each assignment, please check the addresses in case you know anyone 
living at any of them.  We do not want you to attempt to interview anyone you know.  If you 
find such an address, please code “19” as the final outcome on the contact sheet and write in 
“Known to me”.  Inform your RC at once and return the contact sheet to the office; don’t wait 
until you have completed the assignment.  
This also applies if, when you make contact at any given address, you discover that you 
know the person/people living there.  We will organise that another interviewer contacts this 
household. 
 
Make sure that you inform us/ update i-Progress at the same time. 
 
 
As far as we can know, the addresses you will have been given are those of private 
households.  (There may be the occasional commercial property such as a small shop but 
this should be the exception.) 
 
A private household is where a group of people (not always related) live together and whose 
food and household expenses are managed as one unit. 
 
However, sometimes more than one household is found at a single address. 
 
This could be: 
 
(1) A house has been converted into two or more flats; 
(2) Two families sharing a dwelling such as a young married couple living 
with parents but with separate catering and housekeeping 
arrangements – each is a separate household. 
(3) A group of students or other non-related individuals living together at 
one address.   Those sharing occupancy can be siblings but it is likely 
in this situation that each is his or her own household unit.  These 
individuals form separate households, if they don’t cater as one unit. 
(4) Several households in town-lands with the same address 
 
If you come across a multi-household dwelling or multi household addresses you must first 
randomly select the household before randomly selecting an individual within that 
household.  You do this by using a random table selection grid. This is known as a KISH 
Grid.  This is part of your contact sheet 
 
There are different kinds on multi households,   The KISH grid provided will enable you to 
record the number of households (in the case of a flat conversion or two or more 
households at the one address) or enable you to record the number of people who share 
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the one address but are each their own heads of household, i.e. a group of students living 
together who don’t have communal budgeting/catering.   Once you have recorded the 
households/individual heads of household you follow the instruction on the Kish Grid as to 
which household/ head of household to select.  
 
The same principle applies if you are selecting one property out of several properties sharing 
the same address.   
 
Each contact sheet has a unique address code which you transfer to the questionnaire when 
you begin to interview the selected individual.  You must take the greatest care to transfer 
this number accurately as the computer is set up to take all the numbers in the range (that is 
all the individual addresses that have been selected). 
 
The numbers in this unique address code represent the RDTF, the sample point and 
the addresses within that sample point.  
 
Because you will need to introduce yourself and the study to the person you initially make 
contact with; the full introduction is written at the end of these instructions, as well as on the 
actual CAPI script. 
 
When you do make contact with a responsible adult in the (private) household, you will 
explain who you are and what you are doing.  Practise and learn your introduction at home, 
show your ID card and look at the person, rather than reading out the introduction.  You may 
be asked why you are at the particular address and you can explain it was chosen at 
random, from the An Post/Ordnance Survey Geo-Directory.   
This is important to do if the person is concerned about how their address was obtained. 
 
If the person who answered the door to you seems reluctant to talk, back off before you get 
an outright refusal.  Offer a copy of the letter from the client and The Frequently Asked 
Questions Leaflet and say you’ll call at another time when you’re next in the area.  You can 
catch people at a bad time for them and if you don’t try to pressure them you may be 
successful next time you call.  Try as far as possible to avoid getting a refusal at this stage.   
Better to postpone carrying out the selection procedure than to never have the chance of 
doing so. 
 
The next call may find them more receptive. 
 
 
If contact at the door is amenable now proceed with the selection of correct individual within 
the household using the last birthday rule. 
 
Ask: 
 
 “How many people aged between 15-64 live here?” 
 
(a) If the answer is none then no interview can be taken here. 
 
(b) If the answer is one, me! – take the interview there and then if you can.  33% 
of households are single adult households! 
 
(c) If the answer is one but he/she isn’t in then you should try to ascertain the 
best time to call and interview that person. 
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(d) If the answer is two or more then you need to record their details on the 
contact sheet and select the one who has celebrated their birthday most 
recently.   
 
This is the “last birthday rule” and is used to select individuals within a household in a 
random manner.  You must select and interview only the “selected” person.  To do 
otherwise introduces bias into the sample and affects the reliability of the data. 
 
It doesn’t matter in which order your contact gives you the names of all those 
aged between 15-64.  Ask what was the day and month of (all) their 
birthdays.  Choose the individual who had the most recent birthday.  This has 
nothing to do with the age of respondents, only when they had their 
birthdays.  We don’t need dates of birth, only the birthdays, i.e. not 10th June 
1962 only 10th June. 
  
You only need to determine only the age of the selected individual which 
you write on to the contact sheet as this will be transferred to the 
questionnaire. 
 
If there are twins in the household and their birthday is the most recent one 
then interview the twin born second. 
 
If two (or more) people in any household share the same birthday, select the 
younger person as your respondent. 
If a member of the household has their birthday on the day that you make 
contact and carry out the selection procedure, select this person as the 
respondent who will complete the interview. 
 
If your selected respondent isn’t at home then you try to establish a good time 
to call back. 
 
If the last birthday has changed since you first made contact at the address you still 
proceed with the person who was selected at the time of the first contact. 
 
 
Each time you make a call you record the result using abbreviations you understand like 
NAH for not at home or NR for no reply as well as the day and time the call was made by 
using the codes provided for time of day and day of the week.  Also write on the comments 
line any information which will be useful to you when planning future calls in the area.  
 
 For example, your initial contact has told you that her teenage son (your selected 
respondent) comes in to eat his dinner at 7.00pm and usually is out of the house for the 
evening by 8.00pm.  You’ll need to catch him about 7.30!  Write this to remind you when 
you’re planning your route for your next round of calls. 
You may wish to leave a calling card if you have not succeeded in making contact after two 
visits or an appointment card to remind selected respondents of when they have agreed to 
carry out the interview.  If you have made an appointment then you must keep it. 
Record codes at C5 and C6 after your final call.  If you are refused please record the refusal 
information, not forgetting to estimate the age and ethnicity of the person who refused you. 
 
Rules for interviewing those aged 15 -17 
 
If your selected individual in the household is aged 15, 16 or 17 you need to obtain written 
parental permission before you can conduct an interview.  As the interview is conducted 
using CAPI there is a special letter for the parent/guardian of such a child to sign.   
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It would be best to give this letter to the parent to peruse before trying to set up the interview 
with the child. If the parent agrees to the interview with their child then please ensure that the 
parent signs both copies of the letter and keeps one for his/her own records and that you 
send one copy back to the office, fully completed with unique address code, parent and 
child’s name and parent’s signature. 
 
Obviously with this study it would not be ideal to have the parent present during the interview 
so try to explain the subject matter in general terms. Explain that we do want to interview 15 -
17 year olds if they have been selected.  
 
If you appear very matter-of-fact about everything, the odds are that the parent will allow you 
to conduct the interview alone (or at least out of their hearing) with those under the age of 18.  
If the parent wants to sit in you must accede.   It is a parent’s right not only to know the type 
of questions that you are going to ask but to actually sit in on the interview if they wish.  
 
Proceed with the interview as instructed and record on the questionnaire script whether or 
not the parent of the 15 -17 year old was present during the interview. 
 
If permission is not granted you cannot take an interview with a child aged 15-17 and 
you will record this in the final outcome box on the contact sheet.  No substitute can be 
taken if the parent refuses permission.  Please note that if the parent gives permission for 
you to approach the child to interview you still need to get the child’s consent.  If he or she 
doesn’t wish to do the interview then you must accept that. 
 
If after five calls to the address on different days/different times of day you have not got an 
interview you may record the final outcome as a non-contact on the contact sheet and return 
to the office.  It may be that you could not make any contact with anyone in the household or 
it may be that you could never get to see the selected respondent.  If the selected 
respondent is aged 15-24 we would like you to keep trying at least twice more to get the 
interview.  This age group is always hard to get at home.  
 
However, you may feel that you still have a chance of getting the interview.   In that case 
keep the contact sheet and try again when you are close by the area, perhaps working on 
another point of this study.  So long as you have updated us using i-Progress and your 
supervisor knows that you are holding on to that contact sheet this is fine. 
 
Sometimes you may not be able to carry out an interview with the selected respondent 
because they don’t speak adequate English.  If this happens we will try to find an interpreter 
to conduct the interview.  Try to establish the language spoken and tell the Field Office.  We 
will write to the household in their own language and ask them to contact us to arrange an 
interview if they wish. 
 
In the case of a blind respondent or one who has difficulty in reading the show cards you 
must read out the cards to such a person.  People cannot be excluded because they can’t 
read.  Equally if a person is deaf then you will have a list of questions to show to them so that 
they will have the opportunity to participate in the survey. 
 
You must complete the contact sheets accurately and conscientiously with full details.  
We may need to reallocate the work to another interviewer or supervisor if response rate in 
the area is too low and a complete history of previous calls will be useful.  In any event you 
will need a record of calls and time of call for the eprogress questionnaire. 
 
From the contact sheets we will calculate the study response rate and construct a profile of 
non-productive or invalid addresses and refusals for the report to our client. 
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Included in this will be information about the type of property lived in and in the case of 
refusals the type of person who refused.  Please fill this section in accurately. 
 
If any address is non-residential, eg, a small shop or office, make no attempt to take an 
interview.   Do check however that there isn’t living accommodation above or attached to the 
business premises with the same address.  If completely non-residential, code this in the 
Final Outcome Box. 
 
Should you have an area with a high number of ineligible addresses (over 65s only or 
commercial addresses like small shops, vacant or demolished properties) we can issue you 
with reserve addresses to supplement the addresses which cannot yield interviews.  If there 
are too many such “ineligible” addresses then we may issue a reserve point. 
 
 
If you feel that you need to have reserve addresses you must request to have these in 
writing to the office or by telephone to Marianne who will put your request in writing.  
Reserve addresses will not be issued to you because of refusals or non-contacts, only 
for ineligible properties. 
 
 
 
In the majority of cases you will be able to complete a successful interview so don’t forget to 
record the name and telephone number of the selected respondent on your contact 
sheet this will help you to set up an appointment. 
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5. Questionnaire Downloading and Using i-Progress 
 
 
 
As we are working on CAPI not only will you download your completed interviews after each 
day’s work you will inform us of progress by completing an i-Progress questionnaire for each 
call made to an address.  Your RC will also contact you at regular intervals to see how your 
work is going.  Please keep your paperwork organised so that you can always give her an 
up-to-date report.  Note the column on your contact sheet for you to record that you have 
completed the i-progress report. 
 
The basic information that we will get from the General Survey Management System will 
cover: 
 
• Total number of successful interviews conducted to date; 
• Total number of definite non-productives to date; 
• Total number of invalid addresses to date; 
• Number of addresses still being worked on. 
 
 
We will only get meaningful information if you use eprogress regularly and download all 
questionnaires after each day’s work. 
 
 Complete all your i-Progress questionnaires before downloading and everything will be sent 
at the one time. 
 
Dial in at a sensible time so that you are less likely to get the engaged tone.  Remember that 
early evening is the time that most of Ipsos’s interviewers will be trying to do the same thing.  
 
 Remember to clear any messages waiting on your answer service before beginning to 
download.  If you do not do or a call tries to come in as you are attempting the download, it 
will not be successful. 
 
 Check that you have indeed downloaded your work and eprogress before switching off your 
machine.    If you get an error message then you will need to try again. 
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6. The Interview 
 
 
 
We will have written to Garda Headquarters to advise them that this study is taking place 
before fieldwork begins.  You should contact the local Garda station in the area you are to 
work in to tell them when you will be working, car registration (if asked for) etc.  This can be 
in person but is acceptable by phone.   
 
You should conduct the interview in a one-to-one setting.  This is desirable for most surveys: 
in this study it is essential. 
 
The purpose of the interview is to determine the respondent’s use of tobacco, alcohol, drugs 
sometimes used as medicines and illegal drugs.  While the use of illegal drugs these days is 
not necessarily seen as something to be embarrassed about or kept quiet by those who use 
them, nevertheless, many people would not freely talk about their use of these types of drugs 
in front of members of their family. 
 
For the majority of respondents the interview will take around 20-25 minutes.  However try 
where possible to be invited into the home so that you can sit down with your laptop.  The 
letter that will be sent in advance explains that you will be using a laptop computer to carry 
out the interview.   If invited into a living room with other members of the household present, 
decline and say something like – “I don’t want to disturb them, can we do the interview in the 
hall or the kitchen or somewhere we can be private?”   
Make sure you can plug in your laptop so that you do not run the risk of your laptop battery 
dieing.  However if you have to use  battery to interview then be sure to charge it up again as 
soon as possible and certainly before going out the next day. 
 
Reassure respondents at the beginning of the interview about confidentiality.  Their names 
and individual address will not be linked to their answers.  Indeed the only reason for taking 
their names and telephone numbers (remember you are at the address) is to check that you, 
the interviewer, have carried out your work accurately.  Explain as you usually do about 
backchecking and give whatever reassurance is needed as to their complete anonymity. 
 
Point out if you need to that their name doesn’t go on the questionnaire and that the answers 
of all the people interviewed on this study (5,000 in total) are input to computers like yours 
using numbers and that the results of all the 5,000 are produced as statistics, tables of 
figures etc. 
 
You must ask all the questions using the exact wording, and show the cards which are 
designed not only to speed up the answering process but to ensure that all respondents are 
presented with the same choices. You must not (as in all surveys) betray any emotion or 
reaction to any of the answers given to your questions. 
  
You must appear interested in what your respondent says in order to encourage him/her to 
keep answering but please do not engage in discussion or pass any opinion about the 
topic of the study or answers you have been given. 
 
If it helps secure an interview or in response to the enquiry “What’s it for?” you may tell your 
respondent (or contact) that although everyone has an opinion about the prevalence of drug 
use in Ireland, this study is to provide real information.  You may advise them of the earlier 
studies and direct them to the NACD website.   
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You will have an actual published bulletin which you can show to respondents so that they 
can understand how the results are collated and used.  Do not leave this with anyone as 
you will have only one copy of the actual bulletin.  You have copies of FAQ sheet which 
may answer respondents’ queries and copies of the letters.  
 
 
You can explain if you need to that the results of this study will be published.   The 
information gathered from this study will be used by various government departments to plan 
resources needed for education, rehabilitation etc.   
 
Any contact or respondent can contact NACD at any time for reassurances about their 
participation or indeed any worries they may have.   If you sense someone has a concern 
either about drug use or the interview they have given you leave them a copy of the client 
letter and point out that they can ring the director or any of her colleagues at any time. 
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7. The Questionnaire (and Show Cards) 
 
 
 
This is straightforward and clearly set out and flows well. 
 
Remember to read out the entire preamble on the information screens.   Information screens 
are marked “pause.” 
 
One of the joys of carrying out an interview using CAPI is that you don’t have to think about 
routing or what to ask next.  Ask the questions as written and use the show cards where 
instructed.  Their use will minimize the risk of embarrassment at potentially sensitive 
questions and answers, as respondents can call you out a number rather than have to tell 
you something that may be embarrassing. 
 
Each section is laid out in similar fashion, as is the type of question.  The exact words must 
be used.  
  
Do not abbreviate questions or leave any out.  
 
Do not assume that you know the answer to a particular question because of a previous 
answer.   
 
You will find that the questions will begin to flow rhythmically after the first couple of sections.  
 
Where exact ages or number of days is required to be recorded and a respondent may not 
be sure, get them to give you their best estimate. 
 
For example, if you are talking to a smoker in his mid forties and he cannot remember 
whether he was 14 or 15 when he first smoked tobacco products ask him just to give you the 
one he thinks.  He needs to make the decision, not you! Try hard to get a figure. 
 
Don’t knows are not very useful to anyone so we really don’t want too many of them.  Don’t 
offer the “Don’t know” or “Refused” options to your respondents and only use them if they 
really cannot or will not give you an answer to the question.  These options are present at 
every question but must only be used in exceptional circumstances. 
 
You will introduce the show cards at Q 11c.  This is a coloured card depicting measures of a 
standard drink by type of alcohol.  Allow your respondent time to understand this card before 
asking the relevant question. 
At Q 11d you have two cards to show, one a picture card to help respondents understand the 
question and one to help them choose the time frame. 
 
When using the subsequent cards, where applicable, ask the respondent just to call you out 
the number that applies to the answer.  Be certain that they are giving you the code 
against the answer by checking the answer you are given a couple of times.  For 
example say “Is that code 2 or two times?” 
 
Control the use of the show-cards and allow the respondent to look only at the card relevant 
to the question.  The card numbers match the question numbers. 
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Show Card 16:  Ask Q 16 – “Have you ever heard of any of these?” – showing the relevant 
card at the same time.  If ‘yes’ you will ask the questions in this section.  If none are heard of 
then code ‘no’ and you will be routed to the next section. 
 
Using the appropriate show cards and reading out the questions as they appear, continue in 
this way for all sections. 
 
Be careful to enter the number which relates to the answer the respondent has given 
you.  It is an easy thing to enter the number 2 (for no) instead of the number 1 (for yes) 
and so miss asking the correct questions in that section. 
 
Encourage the respondent to look at the show card that introduces each section as you ask 
the subsequent questions in each section.   
 
Use the link between the sections, enabling you to progress from legal drugs, tobacco, 
alcohol and drugs sometimes used as medicines to illegal drugs. 
 
Note that questions may not appear sequentially and some questions have been 
removed. 
 
Read out the preamble before Q 154 as the questionnaire moves away from collecting facts 
to collecting opinions.   
Please do not get drawn into a discussion with a respondent at these questions or indeed at 
any others.   
 
Note the wording of Q155; Not disapproving is not the same as approving and it may be 
helpful to emphasise the not disapprove slightly when reading out the question. 
 
Q.157 Note that this question is about risk, not whether or not they disapprove.  You may 
remind them of this by reading out the question again and emphasise the words “risk 
harming themselves”. 
 
Q160  This is asked of all who ever took cannabis and depending on their pattern of usage 
they will either be asked a series of questions or go to the next section. 
Q164 is asked of all ecstasy users in the same way. 
Q168 is asked of cocaine users in the same way. 
Q183 is asked of all and is to do with substances that can be bought over the internet or in 
head shops. 
Q 193 is asked of all who have consumed alcohol in the past 12 month 
 
Should a respondent give you two or more answers to a question which has been set up as a 
single code it will not be possible to enter two codes.  You will need to ask your respondent 
to choose the most appropriate answer from those answers he or she has already given you. 
 
At any point in the questionnaire, if you sense that your respondent is uneasy about any of 
the questions or answers that you are recording, please take the time to reassure him/her 
about confidentiality.   This reassurance should always be offered before you begin collecting 
the classification data. 
 
If at any time during the interview a respondent is distressed or upset by realising that he or 
she may have a problem with drink or drugs you can show them the copy of the letter that 
Susan Scally, the Director of NACD has written to the chair person of each of the Regional 
and Local Task Forces across the country.  If they wish to have the number of their local 
RDTF, please do write down the contact name and telephone number of the one that is 
closest to them. 
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Please remember than you are not trained to counsel or support anyone in this matter, so 
only if it is very obvious that someone is asking for help do you offer it.   
Technical Report – General Population Survey on Drug Prevalence 2010/2011 
 
10-000957 November 2011 
 
8. Classification Section 
 
 
 
Having completed the interview you do not want respondents to feel concerned or nervous 
about giving you personal information about themselves or the household so please ask the 
classification questions in as relaxed a fashion as you have asked the rest of the 
questionnaire. 
Some of the questions on this classification section you are well used to, others may be new 
to you.  Use show cards throughout the classification section where directed. 
 
C1a asks for the respondent’s date of birth.  This should match the age that the respondent 
has already given you and if it does not the script will ask you which is correct. 
C4. This question regarding the ethnicity of the respondent is worded as the last census so 
you should not have any problems with it.  Ask the respondent to call you out the number 
from the card. 
 
Please collect as much information as you can about the occupation of the Chief Income 
Earner in order to be able to arrive at the correct social grading.     
 
Please familiarise yourself with all of the questions, and be sure to code up answers 
accurately.  Ask the recontact question don’t assume that because a respondent has given 
you an interview, they would be happy to be contacted again about this subject. 
 
If you have any comments about the interview record these in the comments box at the end 
and don’t forget, you need to move on until you reach the “New” screen before an interview 
is complete and saved on your laptop.  If you don’t want to record comments in front of the 
respondent then stop and save your interview so that you can complete when you leave.    
Please remember that your interview isn’t “saved”, i.e. safe until you have reached the NEW 
screen again. 
 
Do remember to leave a completed thank you letter with each respondent. It is useful for 
respondents to have a contact number if they have any queries or concerns after you leave. 
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9. The Interviewer’s Role 
 
 
 
This is all important.  Please always remember that this important work could not be 
undertaken without skills such as yours. 
 
The quality of the information collected (and reported on) depends on your interviewing 
ability, people skills, accuracy and powers of persuasion. 
 
Follow the procedures of selection correctly.  If you don’t, the validity of the sample and the 
accuracy of the results could be affected.  The sample is only representative if: 
 
1. You select the correct person; 
2. You never interview a substitute, no matter how difficult it is to make contact 
with the selected person. 
3. You make every effort to contact and take an interview at every address; 
4. You use all your skill to persuade a reluctant respondent to take part. 
 
You can tell people how important this study is and that the results will be published next 
year.  Assure them that there are no right or wrong answers and that their answers are 
of value to the final outcome of the study.  Again if you feel it will help, stress the fact that 
all information given is treated in the strictest confidence.  
 
Show them your copy of the bulletin so they understand how their answers will be 
used. 
 
If you are told by your contact or your selected respondent that he/she is too busy assure 
them that you will come back at a more convenient time.  Do your best to make them feel 
that their participation is important and that it isn’t any trouble for you to call back.  
Sometimes this sort of courtesy will swing the balance in your favour and you will get the 
interview there and then. 
 
In other words, do your utmost to make contact and secure an interview with the correct 
respondent. 
 
Unlike quota studies you cannot just keep moving on until you find someone who meets your 
quota requirements. 
 
Pre-selected or random studies like this one give much more accurate results, which is why 
this methodology is being used. 
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10. Materials Check List 
 
 
 
• These Instructions 
• Set of questions to show to deaf respondents  
• 31 Contact Sheets Main Sample 
• Tally sheet for all addresses 
• Show Cards in plastic pockets containing coloured drinks cards and classification 
cards 
• Letters to Households 
• Parental Permission Letters ( 2 copies of each) 
• Music voucher for 15-24 year olds 
• Appointment Cards  
• Calling Cards 
• Copy of Director’s letter to Garda Headquarters 
• Form for local Garda Station (Call in person)  
• Client letter explaining survey 
• Bulletin  
• Copy of NACD Director’s letter to RDTF 
• List of RDTF contact names , addresses etc.  
• FAQ sheets 
• Thank You letters 
• Pay Claims (You may submit a pay claim when you have finished a point or claim    
fortnightly.) 
• Return Envelopes for pay claim and the return of contact sheets. 
 
 
 
If you have any queries about the survey get in touch with your RC in the first instance If you 
have queries about the interviewing software or hardware please get in touch with CAPI Help 
Desk. 
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Appendix N Sampling points 
ClusterID Location countyname HB clusterLetters 
101 CARLOW - CARLOW RURAL CARLOW SEHB Main 
102 CARLOW - FENNAGH CARLOW SEHB Main 
103 CARLOW - SLIGUFF CARLOW SEHB Main 
104 DUBLIN CO - ARRAN QUAY B DUBLIN ERHA Main 
105 DUBLIN CO - ARRAN QUAY C DUBLIN ERHA Main 
106 DUBLIN CO - ASHTOWN B DUBLIN ERHA Main 
107 DUBLIN CO - AYRFIELD DUBLIN ERHA Main 
108 DUBLIN CO - BALLYBOUGH A DUBLIN ERHA Main 
109 DUBLIN CO - BALLYMUN B DUBLIN ERHA Main 
110 DUBLIN CO - BALLYMUN D DUBLIN ERHA Main 
111 DUBLIN CO - BOTANIC A DUBLIN ERHA Main 
112 DUBLIN CO - BOTANIC C DUBLIN ERHA Main 
113 DUBLIN CO - CABRA EAST A DUBLIN ERHA Main 
114 DUBLIN CO - CABRA WEST D DUBLIN ERHA Main 
115 DUBLIN CO - CLONTARF EAST 
C 
DUBLIN ERHA Main 
116 DUBLIN CO - CLONTARF WEST 
B 
DUBLIN ERHA Main 
117 DUBLIN CO - DRUMCONDRA 
SOUTH C 
DUBLIN ERHA Main 
118 DUBLIN CO - FINGLAS NORTH 
A 
DUBLIN ERHA Main 
119 DUBLIN CO - FINGLAS SOUTH 
A 
DUBLIN ERHA Main 
120 DUBLIN CO - FINGLAS SOUTH 
B 
DUBLIN ERHA Main 
121 DUBLIN CO - GRACE PARK DUBLIN ERHA Main 
122 DUBLIN CO - GRANGE A DUBLIN ERHA Main 
123 DUBLIN CO - GRANGE B DUBLIN ERHA Main 
124 DUBLIN CO - KILMORE B DUBLIN ERHA Main 
125 DUBLIN CO - NORTH DOCK C DUBLIN ERHA Main 
126 DUBLIN CO - PHOENIX PARK DUBLIN ERHA Main 
127 DUBLIN CO - PRIORSWOOD C DUBLIN ERHA Main 
128 DUBLIN CO - PRIORSWOOD E DUBLIN ERHA Main 
129 DUBLIN CO - RAHENY-
GREENDALE 
DUBLIN ERHA Main 
130 DUBLIN CO - ROTUNDA B DUBLIN ERHA Main 
131 DUBLIN CO - WHITEHALL C DUBLIN ERHA Main 
132 DUBLIN CO - CRUMLIN B DUBLIN ERHA Main 
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ClusterID Location countyname HB clusterLetters 
133 DUBLIN CO - CRUMLIN E DUBLIN ERHA Main 
134 DUBLIN CO - KILMAINHAM C DUBLIN ERHA Main 
135 DUBLIN CO - KIMMAGE D DUBLIN ERHA Main 
136 DUBLIN CO - KYLEMORE DUBLIN ERHA Main 
137 DUBLIN CO - MANSION HOUSE 
A 
DUBLIN ERHA Main 
138 DUBLIN CO - MERCHANTS 
QUAY B 
DUBLIN ERHA Main 
139 DUBLIN CO - MERCHANTS 
QUAY C 
DUBLIN ERHA Main 
140 DUBLIN CO - PEMBROKE EAST 
E 
DUBLIN ERHA Main 
141 DUBLIN CO - PEMBROKE 
WEST B 
DUBLIN ERHA Main 
142 DUBLIN CO - PEMBROKE 
WEST C 
DUBLIN ERHA Main 
143 DUBLIN CO - RATHFARNHAM DUBLIN ERHA Main 
144 DUBLIN CO - RATHMINES 
WEST D 
DUBLIN ERHA Main 
145 DUBLIN CO - RATHMINES 
WEST F 
DUBLIN ERHA Main 
146 DUBLIN CO - ROYAL 
EXCHANGE A 
DUBLIN ERHA Main 
147 DUBLIN CO - SAINT KEVIN'S DUBLIN ERHA Main 
148 DUBLIN CO - TERENURE B DUBLIN ERHA Main 
149 DUBLIN CO - USHERS E DUBLIN ERHA Main 
150 DUBLIN CO - WALKINSTOWN B DUBLIN ERHA Main 
151 DUBLIN CO - WOOD QUAY B DUBLIN ERHA Main 
152 DUBLIN CO - BALLINTEER-
BROADFORD 
DUBLIN ERHA Main 
153 DUBLIN CO - BALLINTEER-
MARLEY 
DUBLIN ERHA Main 
154 DUBLIN CO - BALLINTEER-
MEADOWBROADS 
DUBLIN ERHA Main 
155 DUBLIN CO - BALLYBRACK DUBLIN ERHA Main 
156 DUBLIN CO - BLACKROCK-
NEWPARK 
DUBLIN ERHA Main 
157 DUBLIN CO - BLACKROCK-
TEMPLEHILL 
DUBLIN ERHA Main 
158 DUBLIN CO - CHURCHTOWN-
WOODLAWN 
DUBLIN ERHA Main 
159 DUBLIN CO - CLONSKEAGH-
ROEBUCK 
DUBLIN ERHA Main 
160 DUBLIN CO - CLONSKEAGH-
WINDY ARBOUR 
DUBLIN ERHA Main 
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ClusterID Location countyname HB clusterLetters 
161 DUBLIN CO - DUNDRUM-
BALALLY 
DUBLIN ERHA Main 
162 DUBLIN CO - DUN LAOGHAIRE-
MOUNT TOWN 
DUBLIN ERHA Main 
163 DUBLIN CO - DUN LAOGHAIRE-
SANDYCOVE 
DUBLIN ERHA Main 
164 DUBLIN CO - DUN LAOGHAIRE-
WEST CENTRAL 
DUBLIN ERHA Main 
165 DUBLIN CO - GLENCULLEN DUBLIN ERHA Main 
166 DUBLIN CO - SHANKILL-
RATHSILLAGH 
DUBLIN ERHA Main 
167 DUBLIN CO - SHANKILL-
SHANGANAGH 
DUBLIN ERHA Main 
168 DUBLIN CO - STILLORGAN-
PRIORY 
DUBLIN ERHA Main 
169 DUBLIN CO - BALBRIGGAN 
RURAL 
DUBLIN ERHA Main 
170 DUBLIN CO - BALBRIGGAN 
URBAN 
DUBLIN ERHA Main 
171 DUBLIN CO - BALDOYLE DUBLIN ERHA Main 
172 DUBLIN CO - 
BLANCHARDSTOWN-
BLAKESTOWN 
DUBLIN ERHA Main 
173 DUBLIN CO - 
BLANCHARDSTOWN-
COOLMINE 
DUBLIN ERHA Main 
174 DUBLIN CO - 
BLANCHARDSTOWN-CORDUFF 
DUBLIN ERHA Main 
175 DUBLIN CO - CASTLEKNOCK-
KNOCKMAROON 
DUBLIN ERHA Main 
176 DUBLIN CO - DONABATE DUBLIN ERHA Main 
177 DUBLIN CO - DUBBER DUBLIN ERHA Main 
178 DUBLIN CO - HOWTH DUBLIN ERHA Main 
179 DUBLIN CO - KINSALEY DUBLIN ERHA Main 
180 DUBLIN CO - LUSK DUBLIN ERHA Main 
181 DUBLIN CO - MALAHIDE WEST DUBLIN ERHA Main 
182 DUBLIN CO - RUSH DUBLIN ERHA Main 
183 DUBLIN CO - SKERRIES DUBLIN ERHA Main 
184 DUBLIN CO - SUTTON DUBLIN ERHA Main 
185 DUBLIN CO - SWORDS-
FORREST 
DUBLIN ERHA Main 
186 DUBLIN CO - SWORDS-
GLASMORE 
DUBLIN ERHA Main 
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187 DUBLIN CO - SWORDS-
LISSENHALL 
DUBLIN ERHA Main 
188 DUBLIN CO - SWORDS-
SEATOWN 
DUBLIN ERHA Main 
189 DUBLIN CO - TURNAPIN DUBLIN ERHA Main 
190 DUBLIN CO - BALLYBODEN DUBLIN ERHA Main 
191 DUBLIN CO - CLONDALKIN-
BALLYMOUNT 
DUBLIN ERHA Main 
192 DUBLIN CO - CLONDALKIN-
DUNAWLEY 
DUBLIN ERHA Main 
193 DUBLIN CO - CLONDALKIN-
MONASTERY 
DUBLIN ERHA Main 
194 DUBLIN CO - CLONDALKIN-
MOORFIELD 
DUBLIN ERHA Main 
195 DUBLIN CO - CLONDALKIN-
ROWLAGH 
DUBLIN ERHA Main 
196 DUBLIN CO - CLONDALKIN 
VILLAGE 
DUBLIN ERHA Main 
197 DUBLIN CO - FIRHOUSE-
BALLYCULLEN 
DUBLIN ERHA Main 
198 DUBLIN CO - FIRHOUSE 
VILLAGE 
DUBLIN ERHA Main 
199 DUBLIN CO - LUCAN-ESKER DUBLIN ERHA Main 
200 DUBLIN CO - LUCAN HEIGHTS DUBLIN ERHA Main 
201 DUBLIN CO - NEWCASTLE DUBLIN ERHA Main 
202 DUBLIN CO - RATHCOOLE DUBLIN ERHA Main 
203 DUBLIN CO - RATHFARNHAM-
HERMITAGE 
DUBLIN ERHA Main 
204 DUBLIN CO - RATHFARNHAM-
ST. ENDA'S 
DUBLIN ERHA Main 
205 DUBLIN CO - TALLAGHT-
FETTERCAIRN 
DUBLIN ERHA Main 
206 DUBLIN CO - TALLAGHT-
JOBSTOWN 
DUBLIN ERHA Main 
207 DUBLIN CO - TALLAGHT-
SPRINGFIELD 
DUBLIN ERHA Main 
208 DUBLIN CO - TALLAGHT-
TYMON 
DUBLIN ERHA Main 
209 DUBLIN CO - TEMPLEOGUE-
LIMEKILN 
DUBLIN ERHA Main 
210 DUBLIN CO - TERENURE-
GREENTREES 
DUBLIN ERHA Main 
211 KILDARE - ATHY EAST URBAN KILDARE ERHA Main 
212 KILDARE - NAAS URBAN KILDARE ERHA Main 
213 KILDARE - CARRIGEEN KILDARE ERHA Main 
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214 KILDARE - CASTLEDERMOT KILDARE ERHA Main 
215 KILDARE - MONASTEREVIN KILDARE ERHA Main 
216 KILDARE - CELBRIDGE KILDARE ERHA Main 
217 KILDARE - CLONCURRY KILDARE ERHA Main 
218 KILDARE - KILCOCK KILDARE ERHA Main 
219 KILDARE - LEIXLIP KILDARE ERHA Main 
220 KILDARE - MAYNOOTH KILDARE ERHA Main 
221 KILDARE - THOMASTOWN KILDARE ERHA Main 
222 KILDARE - BODENSTOWN KILDARE ERHA Main 
223 KILDARE - DONORE KILDARE ERHA Main 
224 KILDARE - DROICHEAD NUA 
URBAN 
KILDARE ERHA Main 
225 KILDARE - KILDARE KILDARE ERHA Main 
226 KILDARE - 
MORRISTOWNBILLER 
KILDARE ERHA Main 
227 KILKENNY - KILKENNY NO.1 
URBAN 
KILKENNY SEHB Main 
228 KILKENNY - CLOGH KILKENNY SEHB Main 
229 KILKENNY - CLARA KILKENNY SEHB Main 
230 KILKENNY - DUNBELL KILKENNY SEHB Main 
231 KILKENNY - KILKENNY RURAL KILKENNY SEHB Main 
232 KILKENNY - TUBBRIDBRITTAIN KILKENNY SEHB Main 
233 KILKENNY - FARNOGE KILKENNY SEHB Main 
234 LAOIS - ABBEYLEIX LAOIS MHB Main 
235 LAOIS - RATHDOWNEY LAOIS MHB Main 
236 LAOIS - BALLYLYNAN LAOIS MHB Main 
237 LAOIS - MARYMOUNT LAOIS MHB Main 
238 LAOIS - MOUNTMELLICK 
URBAN 
LAOIS MHB Main 
239 LAOIS - O'MORESFOREST LAOIS MHB Main 
240 LAOIS - PORTLAOIGHISE 
RURAL 
LAOIS MHB Main 
241 LAOIS - ROSENALLIS LAOIS MHB Main 
242 LONGFORD - LONGFORD NO.1 
URBAN 
LONGFORD MHB Main 
243 LONGFORD - COLUMBKILLE LONGFORD MHB Main 
244 LONGFORD - CALDRAGH LONGFORD MHB Main 
245 LONGFORD - LONGFORD 
RURAL 
LONGFORD MHB Main 
246 LONGFORD - RATHCLINE LONGFORD MHB Main 
247 LOUTH - FAIR GATE LOUTH NEHB Main 
248 LOUTH - WEST GATE LOUTH NEHB Main 
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250 LOUTH - ARDEE RURAL LOUTH NEHB Main 
251 LOUTH - ARDEE URBAN LOUTH NEHB Main 
252 LOUTH - COLLON LOUTH NEHB Main 
253 LOUTH - DRUMMULLAGH LOUTH NEHB Main 
254 LOUTH - DUNDALK RURAL LOUTH NEHB Main 
255 LOUTH - HAGGARDSTOWN LOUTH NEHB Main 
256 LOUTH - LOUTH LOUTH NEHB Main 
257 LOUTH - ST. PETER'S LOUTH NEHB Main 
258 MEATH - CULMULLIN MEATH NEHB Main 
259 MEATH - DUNBOYNE MEATH NEHB Main 
260 MEATH - KILBREW MEATH NEHB Main 
261 MEATH - MOYNALTY MEATH NEHB Main 
262 MEATH - DULEEK MEATH NEHB Main 
263 MEATH - JULIANSTOWN MEATH NEHB Main 
264 MEATH - ST. MARY'S MEATH NEHB Main 
265 MEATH - BECTIVE MEATH NEHB Main 
266 MEATH - KENTSTOWN MEATH NEHB Main 
267 MEATH - NAVAN RURAL MEATH NEHB Main 
268 MEATH - KILLALLON MEATH NEHB Main 
269 MEATH - OLDCASTLE MEATH NEHB Main 
270 MEATH - KILCOOLY MEATH NEHB Main 
271 MEATH - TRIM RURAL MEATH NEHB Main 
272 OFFALY - TULLAMORE URBAN OFFALY MHB Main 
273 OFFALY - KILCOLMAN OFFALY MHB Main 
274 OFFALY - KILCORMAC OFFALY MHB Main 
275 OFFALY - SHANNONHARBOUR OFFALY MHB Main 
276 OFFALY - EDENDERRY URBAN OFFALY MHB Main 
277 OFFALY - MOUNTBRISCOE OFFALY MHB Main 
278 OFFALY - SCREGGAN OFFALY MHB Main 
279 OFFALY - SILVERBROOK OFFALY MHB Main 
280 WESTMEATH - ATHLONE EAST 
URBAN 
WESTMEAT MHB Main 
281 WESTMEATH - AUBURN WESTMEAT MHB Main 
282 WESTMEATH - MOATE WESTMEAT MHB Main 
283 WESTMEATH - DELVIN WESTMEAT MHB Main 
284 WESTMEATH - KILBEGGAN WESTMEAT MHB Main 
285 WESTMEATH - KINNEGAD WESTMEAT MHB Main 
286 WESTMEATH - MULLINGAR 
RURAL 
WESTMEAT MHB Main 
287 WESTMEATH - MULLINGAR 
NORTH URBAN 
WESTMEAT MHB Main 
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288 WESTMEATH - MULLINGAR 
SOUTH URBAN 
WESTMEAT MHB Main 
289 WESTMEATH - TULLAGHAN WESTMEAT MHB Main 
290 WEXFORD - ENNISCORTHY 
URBAN 
WEXFORD SEHB Main 
291 WEXFORD - WEXFORD NO. 2 
URBAN 
WEXFORD SEHB Main 
292 WEXFORD - ENNISCORTHY 
RURAL 
WEXFORD SEHB Main 
293 WEXFORD - KILBORA WEXFORD SEHB Main 
294 WEXFORD - GOREY RURAL WEXFORD SEHB Main 
295 WEXFORD - ADAMSTOWN WEXFORD SEHB Main 
296 WEXFORD - CARRICKBYRNE WEXFORD SEHB Main 
297 WEXFORD - CARRICK WEXFORD SEHB Main 
298 WEXFORD - FORTH WEXFORD SEHB Main 
299 WEXFORD - WEXFORD RURAL WEXFORD SEHB Main 
300 WICKLOW - ARKLOW NO.1 
URBAN 
WICKLOW ERHA Main 
301 WICKLOW - BRAY NO. 2 WICKLOW ERHA Main 
302 WICKLOW - BRAY NO. 3 WICKLOW ERHA Main 
303 WICKLOW - WICKLOW URBAN WICKLOW ERHA Main 
304 WICKLOW - BLESSINGTON WICKLOW ERHA Main 
305 WICKLOW - DELGANY WICKLOW ERHA Main 
306 WICKLOW - GREYSTONES WICKLOW ERHA Main 
307 WICKLOW - KILMACANOGE WICKLOW ERHA Main 
308 WICKLOW - BALLINACLASH WICKLOW ERHA Main 
309 WICKLOW - BALLINDERRY WICKLOW ERHA Main 
310 WICKLOW - WICKLOW RURAL WICKLOW ERHA Main 
311 WICKLOW - BALLYBEG WICKLOW ERHA Main 
312 CLARE - ENNIS NO. 4 URBAN CLARE MWHB Main 
313 CLARE - LISDOONVARNA CLARE MWHB Main 
314 CLARE - RUAN CLARE MWHB Main 
315 CLARE - CLENAGH CLARE MWHB Main 
316 CLARE - CRUSHEEN CLARE MWHB Main 
317 CLARE - ENNIS RURAL CLARE MWHB Main 
318 CLARE - TEMPLEMALEY CLARE MWHB Main 
319 CLARE - ENNISTIMON CLARE MWHB Main 
320 CLARE - KILCHREEST CLARE MWHB Main 
321 CLARE - KILLEELY CLARE MWHB Main 
322 CLARE - KILTENANLEA CLARE MWHB Main 
323 CORK Co. Boro. - 
BISHOPSTOWN C 
CORK SHB Main 
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324 CORK Co. Boro. - 
BROWNINGSTOWN 
CORK SHB Main 
325 CORK Co. Boro. - 
CHURCHFIELD 
CORK SHB Main 
326 CORK Co. Boro. - FAIR HILL C CORK SHB Main 
327 CORK Co. Boro. - GILLABBEY B CORK SHB Main 
328 CORK Co. Boro. - 
GREENMOUNT 
CORK SHB Main 
329 CORK Co. Boro. - MAHON C CORK SHB Main 
330 CORK Co. Boro. - THE GLEN A CORK SHB Main 
331 CORK Co. Boro. - THE GLEN B CORK SHB Main 
332 CORK Co. Boro. - TIVOLI B CORK SHB Main 
333 CORK Co. Boro. - COBH URBAN CORK SHB Main 
334 CORK Co. Boro. - MALLOW 
NORTH URBAN 
CORK SHB Main 
335 CORK Co. Boro. - YOUGHAL 
URBAN 
CORK SHB Main 
336 CORK Co. Boro. - BANDON CORK SHB Main 
337 CORK Co. Boro. - BANTRY 
URBAN 
CORK SHB Main 
338 CORK Co. Boro. - KEALKILL CORK SHB Main 
339 CORK Co. Boro. - MEALAGH CORK SHB Main 
340 CORK Co. Boro. - 
KILCATHERINE 
CORK SHB Main 
341 CORK Co. Boro. - 
BALLINCOLLIG 
CORK SHB Main 
342 CORK Co. Boro. - CARRIGALINE CORK SHB Main 
343 CORK Co. Boro. - COBH RURAL CORK SHB Main 
344 CORK Co. Boro. - DOUGLAS CORK SHB Main 
345 CORK Co. Boro. - LEHENAGH CORK SHB Main 
346 CORK Co. Boro. - 
RATHCOONEY 
CORK SHB Main 
347 CORK Co. Boro. - RIVERSTOWN CORK SHB Main 
348 CORK Co. Boro. - 
WHITECHURCH 
CORK SHB Main 
349 CORK Co. Boro. - 
WATERGRASSHILL 
CORK SHB Main 
350 CORK Co. Boro. - ALLOW CORK SHB Main 
351 CORK Co. Boro. - NEWTOWN CORK SHB Main 
352 CORK Co. Boro. - LISCLEARY CORK SHB Main 
353 CORK Co. Boro. – 
SLIEVEREAGH 
 
 
CORK SHB Main 
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354 CORK Co. Boro. - 
BALLYNAMONA 
CORK SHB Main 
355 CORK Co. Boro. - DROMORE CORK SHB Main 
356 CORK Co. Boro. - RATHLUIRC CORK SHB Main 
357 CORK Co. Boro. - BALLYCOTTIN CORK SHB Main 
358 CORK Co. Boro. - DRISHANE CORK SHB Main 
359 CORK Co. Boro. - 
MITCHELSTOWN 
CORK SHB Main 
360 CORK Co. Boro. - GOLEEN CORK SHB Main 
361 KERRY - KILLARNEY URBAN KERRY SHB Main 
362 KERRY - TRALEE URBAN KERRY SHB Main 
363 KERRY - VALENCIA KERRY SHB Main 
364 KERRY - CASTLEGREGORY KERRY SHB Main 
365 KERRY - KENMARE KERRY SHB Main 
366 KERRY - MUCKROSS KERRY SHB Main 
367 KERRY - BALLYCONRY KERRY SHB Main 
368 KERRY - ARABELA KERRY SHB Main 
369 KERRY - CASTLEISLAND KERRY SHB Main 
370 KERRY - MILLBROOK KERRY SHB Main 
371 KERRY - TRALEE RURAL KERRY SHB Main 
372 LIMERICK Co. Boro. - 
BALLYNANTY 
LIMERICK MWHB Main 
373 LIMERICK Co. Boro. - CASTLE C LIMERICK MWHB Main 
374 LIMERICK Co. Boro. - DOCK C LIMERICK MWHB Main 
375 LIMERICK Co. Boro. - JOHN'S C LIMERICK MWHB Main 
376 LIMERICK Co. Boro. - ST. 
LAURENCE 
LIMERICK MWHB Main 
377 LIMERICK Co. Boro. - 
BALLINGARRY 
LIMERICK MWHB Main 
378 LIMERICK Co. Boro. - 
KILFERGUS 
LIMERICK MWHB Main 
379 LIMERICK Co. Boro. - 
ARDPATRICK 
LIMERICK MWHB Main 
380 LIMERICK Co. Boro. - BRUFF LIMERICK MWHB Main 
381 LIMERICK Co. Boro. - DARRAGH LIMERICK MWHB Main 
382 LIMERICK Co. Boro. - 
KNOCKAINY 
LIMERICK MWHB Main 
383 LIMERICK Co. Boro. - 
BALLYCUMMIN 
LIMERICK MWHB Main 
384 LIMERICK Co. Boro. – 
BALLYSIMON 
 
 
LIMERICK MWHB Main 
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385 LIMERICK Co. Boro. - CULLANE LIMERICK MWHB Main 
386 LIMERICK Co. Boro. - 
DROMCOLLIHER 
LIMERICK MWHB Main 
387 LIMERICK Co. Boro. - 
NEWCASTLE RURAL 
LIMERICK MWHB Main 
388 LIMERICK Co. Boro. - 
NEWCASTLE URBAN 
LIMERICK MWHB Main 
389 NORTH TIPP - THURLES 
URBAN 
TIPPERAR MWHB Main 
390 NORTH TIPP - BALLINA TIPPERAR MWHB Main 
391 NORTH TIPP - 
CARRIGATOGHER 
TIPPERAR MWHB Main 
392 NORTH TIPP - NENAGH RURAL TIPPERAR MWHB Main 
393 NORTH TIPP - ROSCREA TIPPERAR MWHB Main 
394 NORTH TIPP - HOLYCROSS TIPPERAR MWHB Main 
395 SOUTH TIPP - CARRICKBEG 
URBAN 
TIPPERAR SEHB Main 
396 SOUTH TIPP - CLONMEL WEST 
URBAN 
TIPPERAR SEHB Main 
397 SOUTH TIPP - 
KNOCKGRAFFON 
TIPPERAR SEHB Main 
398 SOUTH TIPP - MAGORBAN TIPPERAR SEHB Main 
399 SOUTH TIPP - 
PEPPARDSTOWN 
TIPPERAR SEHB Main 
400 SOUTH TIPP - BUOLICK TIPPERAR SEHB Main 
401 WATERFORD Co. - 
BALLYTRUCKLE 
WATERFOR SEHB Main 
402 WATERFORD Co. - CENTRE A WATERFOR SEHB Main 
403 WATERFORD Co. - 
FARRANSHONEEN 
WATERFOR SEHB Main 
404 WATERFORD Co. - MOUNT 
SION 
WATERFOR SEHB Main 
405 WATERFORD Co. - CLONEA WATERFOR SEHB Main 
406 WATERFORD Co. - 
MOUNTKENNEDY 
WATERFOR SEHB Main 
407 WATERFORD Co. - TRAMORE WATERFOR SEHB Main 
408 WATERFORD Co. - 
WOODSTOWN 
WATERFOR SEHB Main 
409 WATERFORD Co. - ARDMORE WATERFOR SEHB Main 
410 GALWAY Co. - BALLYBAAN GALWAY WHB Main 
411 GALWAY Co. - BARNA GALWAY WHB Main 
412 GALWAY Co. - CLADDAGH GALWAY WHB Main 
413 GALWAY Co. - MENLOUGH GALWAY WHB Main 
414 GALWAY Co. - RAHOON GALWAY WHB Main 
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415 GALWAY Co. - SHANTALLA GALWAY WHB Main 
416 GALWAY Co. - TAYLORS HILL GALWAY WHB Main 
417 GALWAY Co. - 
LAURENCETOWN 
GALWAY WHB Main 
418 GALWAY Co. - ANNAGHDOWN GALWAY WHB Main 
419 GALWAY Co. - BARNA GALWAY WHB Main 
420 GALWAY Co. - DEERPARK GALWAY WHB Main 
421 GALWAY Co. - KILCUMMIN GALWAY WHB Main 
422 GALWAY Co. - KILLANNIN GALWAY WHB Main 
423 GALWAY Co. - LACKAGHBEG GALWAY WHB Main 
424 GALWAY Co. - GLENNAMADDY GALWAY WHB Main 
425 GALWAY Co. - ARDAMULLIVAN GALWAY WHB Main 
426 GALWAY Co. - GORT GALWAY WHB Main 
427 GALWAY Co. - ATHENRY GALWAY WHB Main 
428 GALWAY Co. - 
LETTERBRICKAUN 
GALWAY WHB Main 
429 GALWAY Co. - WORMHOLE GALWAY WHB Main 
430 LEITRIM - CLOVERHILL LEITRIM NWHB Main 
431 LEITRIM - KINLOUGH LEITRIM NWHB Main 
432 LEITRIM - CARRIGALLEN EAST LEITRIM NWHB Main 
433 LEITRIM - KEELDRA LEITRIM NWHB Main 
434 MAYO - BALLYSAKEERY MAYO WHB Main 
435 MAYO - BALLINROBE MAYO WHB Main 
436 MAYO - CONG MAYO WHB Main 
437 MAYO - HOLLYMOUNT MAYO WHB Main 
438 MAYO - BELMULLET MAYO WHB Main 
439 MAYO - BEKAN MAYO WHB Main 
440 MAYO - KILMOVEE MAYO WHB Main 
441 MAYO - SWINEFORD MAYO WHB Main 
442 MAYO - DOOEGA MAYO WHB Main 
443 MAYO - KILMEENA MAYO WHB Main 
444 ROSCOMMON - ATHLONE 
WEST RURAL 
ROSCOMMO WHB Main 
445 ROSCOMMON - ARTAGH 
NORTH 
ROSCOMMO WHB Main 
446 ROSCOMMON - ANNAGHMORE ROSCOMMO WHB Main 
447 ROSCOMMON - FUERTY ROSCOMMO WHB Main 
448 ROSCOMMON - ROOSKY ROSCOMMO WHB Main 
449 SLIGO - SLIGO NORTH SLIGO NWHB Main 
450 SLIGO - SLIGO WEST SLIGO NWHB Main 
451 SLIGO - TOOMOUR SLIGO NWHB Main 
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452 SLIGO - BALLYMOTE SLIGO NWHB Main 
453 SLIGO - CARNEY SLIGO NWHB Main 
454 SLIGO - CARRICKBANAGHER SLIGO NWHB Main 
455 SLIGO - CLOONOGHILL SLIGO NWHB Main 
456 SLIGO - CLOONACOOL SLIGO NWHB Main 
457 CAVAN - KINGSCOURT CAVAN NEHB Main 
458 CAVAN - CARN CAVAN NEHB Main 
459 CAVAN - BALLYJAMESDUFF CAVAN NEHB Main 
460 CAVAN - COOTEHILL URBAN CAVAN NEHB Main 
461 CAVAN - LARAH SOUTH CAVAN NEHB Main 
462 CAVAN - REDHILL CAVAN NEHB Main 
463 DONEGAL - BUNCRANA 
URBAN 
DONEGAL NWHB Main 
464 DONEGAL - BUNDORAN 
URBAN 
DONEGAL NWHB Main 
465 DONEGAL - LETTERKENNY 
URBAN 
DONEGAL NWHB Main 
466 DONEGAL - DONEGAL DONEGAL NWHB Main 
467 DONEGAL - INVER DONEGAL NWHB Main 
468 DONEGAL - DUNFANAGHY DONEGAL NWHB Main 
469 DONEGAL - GORTAHORK DONEGAL NWHB Main 
470 DONEGAL - 
MAGHERACLOGHER 
DONEGAL NWHB Main 
471 DONEGAL - BALLYLIFFIN DONEGAL NWHB Main 
472 DONEGAL - DESERTEGNY DONEGAL NWHB Main 
473 DONEGAL - KILLEA DONEGAL NWHB Main 
474 DONEGAL - LETTERKENNY 
RURAL 
DONEGAL NWHB Main 
475 DONEGAL - BALLYARR DONEGAL NWHB Main 
476 DONEGAL - CARRICKART DONEGAL NWHB Main 
477 DONEGAL - CLONLEIGH 
NORTH 
DONEGAL NWHB Main 
478 DONEGAL - DOOISH DONEGAL NWHB Main 
479 DONEGAL - KILLYGORDON DONEGAL NWHB Main 
480 DONEGAL - KNOCK DONEGAL NWHB Main 
481 DONEGAL - STRANORLAR DONEGAL NWHB Main 
482 MONAGHAN - ANNAYALLA MONAGHAN NEHB Main 
483 MONAGHAN - CREMARTIN MONAGHAN NEHB Main 
484 MONAGHAN - MULLYASH MONAGHAN NEHB Main 
485 MONAGHAN - BELLANODE MONAGHAN NEHB Main 
486 MONAGHAN - ENAGH MONAGHAN NEHB Main 
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487 DUBLIN CO - BEAUMONT C DUBLIN ERHA Reserve 
488 DUBLIN CO - CHAPELIZOD DUBLIN ERHA Reserve 
489 DUBLIN CO - KILMAINHAM A DUBLIN ERHA Reserve 
490 DUBLIN CO - MERCHANTS 
QUAY D 
DUBLIN ERHA Reserve 
491 DUBLIN CO - FOXROCK-
DEANSGRANGE 
DUBLIN ERHA Reserve 
492 DUBLIN CO - KILLINEY SOUTH DUBLIN ERHA Reserve 
493 DUBLIN CO - RATHFARNHAM-
BUTTERFIELD 
DUBLIN ERHA Reserve 
494 KILDARE - KILCULLEN KILDARE ERHA Reserve 
495 LONGFORD - SONNAGH LONGFORD MHB Reserve 
496 MEATH - CEANANNAS MÓR 
RURAL 
MEATH NEHB Reserve 
497 WESTMEATH - ATHLONE EAST 
RURAL 
WESTMEAT MHB Reserve 
498 WEXFORD - GOREY URBAN WEXFORD SEHB Reserve 
499 WICKLOW - KILBALLYOWEN WICKLOW ERHA Reserve 
500 CORK Co. Boro. - 
MONTENOTTE B 
CORK SHB Reserve 
501 CORK Co. Boro. - KINSALE 
URBAN 
CORK SHB Reserve 
502 CORK Co. Boro. - BLARNEY CORK SHB Reserve 
503 KERRY - LISLAUGHTIN KERRY SHB Reserve 
504 LIMERICK Co. Boro. - 
COOLRAINE 
LIMERICK MWHB Reserve 
505 NORTH TIPP - NENAGH EAST 
URBAN 
TIPPERAR MWHB Reserve 
506 SOUTH TIPP - INISHLOUNAGHT TIPPERAR SEHB Reserve 
507 GALWAY Co. - MERVUE GALWAY WHB Reserve 
508 MAYO - AGHAGOWER SOUTH MAYO WHB Reserve 
509 CAVAN - VIRGINIA CAVAN NEHB Reserve 
510 DONEGAL - GORTNAVERN DONEGAL NWHB Reserve 
511 DONEGAL - GLEN DONEGAL NWHB Reserve 
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Data is weighted using 2010 population estimates based on 2006 Census, and the 2010 
population estimates use Regional Authority to denote region.  Regional Authority and the 
Health Board/RDTF equivalent is shown below.  Results are reported by Health Board/RDTF 
to enable comparisons with previous years. 
 
Regional Authority Health Board/RDTF 
Equivalent  
Border North East HB/RDTF minus 
Meath and North West 
HB/RDTF (ERHA) 
Dublin Eastern Regional Health 
Authority/RDTF 
Mid-East Eastern Regional Health 
Authority/RDTF plus Meath 
Midland Midlands HB/RDTF 
Mid-West Mid West HB/RDTF 
South-East South East HB/RDTF 
South-West Southern HB/RDTF 
West West HB/RDTF 
 
 
 
 
 
 
Contact NACD
National Advisory Committee on Drugs 
Hawkins House 
Hawkins St 
Dublin 2
Tel: 00 353 1 635 4283 
Email: nacd@nacd.ie 
Web: www.nacd.ie
Ipsos MORI
Block 3 
Blackrock Business Park 
Carysfort Avenue 
Blackrock 
Co. Dublin
Tel: 00 353 1 438 9049 
Web: www.ipsos-mori.com
